



Phase II Study of Pazopanib (GW786034) given Preoperatively
in Stage I–II NSCLC: A Proof-of-concept Study
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S. Swann6, M. Lane7, L. H. Ottesen8, D. Yankelovitz9, 1New York-Presby-
terian Hospital/Weill Medical Collge of Cornell University, New York, NY,
2M.D. Anderson Cancer Center, Houston, TX, 3Christiana Care Helen F.
Graham Cancer Center, Newark, DE, 4New York Hospital, Flushing, NY,
5Vall d’Hebron University Hospital, Barcelona, Spain, 6GlaxoSmithKline,
New York, NY, 7New York-Presbyterian Hospital/Weill Cornell Medical
College, New York, NY, 8GlaxoSmithKline, London, NY, 9New York-Presby-
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Purpose/Objective(s): Pazopanib is an oral angiogenesis inhibitor targeting
VEGFR, PDGFR and c-kit. The objective of this single-arm trial was to
determine the clinical/biological activity and safety of pazopanib given
preoperatively in early stage NSCLC patients (pts).
Materials/Methods: After biopsy and before surgery, pts received pazo-
panib 800 mg QD for 2–6 weeks followed by a 7-day washout period prior
to surgery. The primary endpoint was tumor volume change assessed by
sequence-blinded central evaluation of high resolution CT images before and
after treatment. Secondary endpoints included safety, exploratory analysis of
pre- and post-treatment plasma biomarkers and transcriptional profiling of
pre- and post-treatment tumor biopsies. Plasma analysis allowed correlation
of cytokines/angiogenic factors (C/AFs) with tumor volume change. Levels
of 52 C/AFs were measured by suspension bead multiplex assays or ELISA.
Tumor RNA was subject to microarray analysis on Affymetrix chips.
Results: Thirty-five pts were included. Median age: 64 (49–81); 63%
females; 60% adenocarcinoma, 11% squamous cell and 29% other NSCLC;
stage IA: 20 pts; stage IB: 13 pts; stage II: 2 pts. Median duration of therapy:
16 days (3–29). 30 pts (86%) had a reduction in tumor volume (changes
ranged from 86% to 17%). Relevant adverse events included grade 4
post-operative pulmonary embolism in 1 pt, grade 3 ALT increase in 2 pts
and hypertension in 1 pt. Three pts discontinued study drug due to AEs. 33
patients had paired samples for C/AF analysis. Pazopanib treatment was
associated with reduction of sVEGFR-2. A significant correlation between
baseline levels of 11 C/AFs and tumor reduction was observed. Multivariate
classification analysis identified HGF and IL-12 as predictive of response in
81% of cases. 26 patients had paired tumor tissue for RNA analysis:
significant changes in gene expression levels were observed. Multivariate
classification analysis is ongoing.
Conclusions: Pazopanib has clear activity in early stage NSCLC with a
favorable tolerability profile. The exploratory analysis identified possible
predictive markers for pazopanib treatment. Further clinical development in
lung cancer is planned.
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Molecular Staging of NSCLC Using Tumor Specific Autoanti-
bodies
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Introduction: Recently, serum autoantibody profiling has been actively
explored as a means to provide novel biomarker candidates to aid in the
detection and staging of non-small cell lung cancer (NSCLC). Herein, we
appraise a serum repository collected in our clinics at RUMC from patients
being considered for curative resection for novel auto-antibodies that show
promise for either accurately discerning disease progression or locoregional
lymph node involvement.
Methods: Proteomic methods were used to detect novel autoantibodies for
NSCLC that included the 1D and 2D western blotting followed by MALDI
TOF/TOF mass spectrometric (MS) identification of the relevant proteins.
Serum from NSCLC patients was divided into 2 groups based on the
presence (T1–2N1–2M0; n  13) or absence (T1–2N0M0; n  31) of lymph
node metastases. The control serum group consisted of age- and sex-matched
patients with no lung disease (n  34) was compared to the lymph node
negative group for diagnostic marker identification. Lysates from lung
adenocarcinoma (A549, Calu3, and H1975), squamous cell carcinoma
(H226) and a control (NL-20) cell lines were resolved by 1- or 2-D gel
electrophoresis and blotted onto nitrocellulose as a source of autoantigens.
Results: The 1D banding profiles of auto-antibodies varied within 32 kDa to
98 kDa regions in our patient groups, indicating differences between patient
groups based on either the presence of disease or nodal status. Most notable
of these were two bands (in the A549 cell line), one at 57 kDa and the other
at 37 kDa, which were very prominent in the NSCLC lymph node positive
group, but undetectable in our control serum group. The MS analysis of the
spots identified a´-enolase, Peptidyl-prolyl cis-trans isomerase A (PPIase A),
Tropomyosin alpha-3 chain, ATP-synthase subunit beta, Cofilin-1 as the
autoantigens.
Conclusions: Proteomic methods were used to reveal several tumor-specific
auto-antibodies that show promise for improving our ability to stage and
diagnose NSCLC patients. Our current efforts are focused on completing the
identification of the statistically-relevant differences in auto-antigens re-
vealed from this study via mass spectrometry.
Author Disclosure Block:
K.P. Patel, None; D. DeCresce, None; M.J. Liptay, None; L. Faber, None;
A. Kim, None; J.S. Coon, None; P. Bonomi, None; J.A. Borgia, None.
3
A Phase II Study of Cetuximab (C225) in Combination with
Chemoradiation (CRT) in Patients (PTS) with Stage IIIA/B
Non-small Cell Lung Cancer (NSCLC): A Report of the 2 Year
and Median Survival (MS) for the RTOG 0324 Trial
G. R. Blumenschein1, R. Paulus2, W. Curran3, F. Robert4, F. Fossella1,
M. Werner-Wasik5, P. Doescher6, H. Choy7, R. Komaki1, 1The University of
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Philadelphia, PA, 3Winship Cancer Institute Emory University School of
Medicine, Atlanta, GA, 4University of Alabama at Birmingham, Birmingham,
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Purpose/Objective(s): C225 is a chimerized monoclonal antibody that
targets the epidermal growth factor receptor (EGFR). NSCLC commonly
expresses the EGFR, which is associated with aggressive tumor behavior and
poor clinical outcome. Preclinical model systems demonstrate radiosensiti-
zation following molecular inhibition of EGFR signaling.
Materials/Methods: We report a phase II trial testing the combination of
C225 with CRT in unresectable stage III NSCLC with a planned sample size
of 84 PTS. Eligibility criteria included Zubrod performance status (PS)  1,
weight loss  5% over past 3 months, FEV1 1.2 L, adequate hematologic,
hepatic, and renal function. PTS received an initial dose of C225 (400
mg/m2) on day 1 of wk 1, then wkly doses of C225 (250 mg/m2) until
completion of therapy (wks 2 - 17). During wk 2, PTS started CRT (63 Gy/35
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fractions) with wkly carboplatin (C) AUC 2 and paclitaxel (P) 45 mg/m2 
6 doses followed by C (AUC 6) and P (200 mg/m2)  2 cycles (wks 12–17).
Interim monitoring for severe (grade 3) or excessive non-hematologic
toxicities occurred after PTS had been treated and followed for at least 90
days after RT. Primary endpoints include safety and compliance of concur-
rent C225 and CRT.
Results: 93 PTS were enrolled with 87 evaluable PTS. PTS characteristics:
57% male, median age 64 years (range 42–85), 47% PS 0, 46% stage IIIA.
Median follow-up is 21.6 months (M). Response rate is 62% (n  54), MS
is 22.7 M, and 24 M overall survival (OS) is 49.3%(# at risk  40). Adverse
events related to treatment include 20% (n  17) of PTS with grade (G) 4
hematologic toxicities, 8% (n 7 PTS) G 3 esophagitis, and 7% (n 6 PTS)
G 3–4 pneumonitis. There were 5 G 5 events.
Conclusions: The combination of C225 with CRT is feasible and active with
MS and OS better than any previously reported by the RTOG. These results
warrant confirmation in a randomized trial. Complete compliance, toxicity,
and updated survival data will be reported. Supported by RTOG U10
CA21661, CCOP U10 CA37422, and Stat U10 CA32115 grants from the
NCI.
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Phase II Trial of Cisplatin (C), Etoposide (E), and Radiation
(RT) Followed by Gemcitabine (G) Vs G and Docetaxel (D) in
Stage III A/B Unresectable Non-small Cell Lung Cancer
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Purpose/Objective(s): SWOG 9504 demonstrated highly promising sur-
vival rates for D consolidation after E  C and radiation therapy in pts with
locally advanced (LA) NSCLC. However, a recent phase III HOG trial
suggested no benefit from single-agent D consolidation compared with
observation alone (Hanna ASCO 2007 #7512). The current study was
developed to assess the feasibility and efficacy of consolidation with either
G alone or G  D after the same chemoradiation schedule as SWOG 9504.
Materials/Methods: The treatment schema included concurrent C 50 mg/m2
Day 1, 8 E 50 mg/m2 Day 1–5 for two 28-day cycles RT 61–62 Gy over
7 weeks after which pts were randomized to consolidation with either G 1000
mg/m2 Day 1, 8 (Arm A) or G 1000 mg/m2 Day 1, 8  D 75 mg/m2 Day 1
(Arm B) every 21 days for 3 cycles. Eighty-three pts were registered; 64
were randomized to consolidation.
Results: 83 pts were registered and 81 received induction chemotherapy. 64
pts were randomized, 32 to Arm A and 32 to Arm B. Median age was 59.5
yrs in Arm A and 84% in Arm A and 81% in Arm B were male. Number of
pts with ECOG PS 0:1 was 11:21 in Arm A and 13:19 in Arm B. Common
Grade 3 or 4 events for Arms A and B included neutropenia (28.1% vs.
56.3%) febrile neutropenia (0% vs 6.3%), thrombocytopenia (6.3 vs. 18.8%),
anemia (3.1% vs. 18.8%), dyspnea (3.1% vs. 9.4%), pneumonia (3.1% vs.
6.3%), and fatigue (6.3% vs. 15.6%). Grade 2 alopecia was 3.1% in both
treatment arms. Median progression-free survival was 8.2 months (95% CI
5.1, 9.3) for Arm A and 16.2 months (95% CI  10.4, NE) for Arm B.
Median overall survival was 19.9 months (95% CI  12.6, NE) for Arm A
and NE for Arm B (95% CI  21.0, NE).
Conclusions: G or GD following chemoradiation in locally advanced
NSCLC is well tolerated. Long-term PFS and overall survival data are
premature; however, the estimated median PFS is nearly twice as long in the
doublet arm. The doublet, as expected, resulted in more toxicity, particularly
myelosuppression and fatigue.
Author Disclosure Block:
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Analysis of V20 and Radiation Pneumonitis on SWOG0023: A
Phase III Trial of Concurrent Chemoradiation and Docetaxel
Consolidation Followed by Gefitinib or Placebo in Stage III
Non-small Cell Lung Cancer
L. E. Gaspar1, M. W. Redman2, K. Chansky2, K. Kelly3, K. S. Albain4, Y. C.
Ung5, J. R. Jett6, D. R. Gandara7, 1University of Colorado Denver, Aurora,
CO, 2Fred Hutchinson Cancer Research Center, Seattle, WA, 3University of
Kansas, Kansas City, KS, 4Loyola University Chicago, Chicago, IL, 5Sun-
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Background: An accepted risk factor for radiation (RT)-related pneumonitis
is % total lung volume receiving 20 Gy (V20). In this large phase III trial
a V20 of 35% was recommended but not mandated. Enrolled patients were
treated with concurrent cisplatin/etoposide (PE) plus 61 Gy thoracic RT,
docetaxel consolidation followed by randomization to gefitinib vs placebo
maintenance.
Purpose/Objective(s): This analysis was conducted to determine the inci-
dence, timing and severity of pneumonitis and correlate it with the V20 and
other patient and treatment-related factors.
Materials/Methods: Pneumonitis was defined by NCI CTC Version 2.0.
Logistic regression was used to assess associations with pneumonitis, linear
regression was used to assess correlations with larger V20, and Cox regres-
sion was used to assess associations between V20 and survival adjusting for
other prognostic factors.
Results: The study closed 4/15/05 having accrued 620 eligible pts. With a
median follow-up time of 27 months, median survival time was 23 months
for gefitinib (n  118) and 35 months for placebo (n  125; two-sided P 
.013). The toxic death rate was 2% with gefitinib compared with 0% for
placebo. As of January 2008, pneumonitis Gr 3 has been reported in 44 of
578 pts (8.3%) evaluable patients. Of 456 patients with V20 data available,
V20 exceeded 35% in 27% of patients. Larger V20 was significantly
associated with stage (IIIA vs IIIB), performance status (1 vs. 0), lower lobe
primary location, and larger tumor volume. There was strong evidence of a
relationship between V20 and Grade 3 pneumonitis (p  .01) and esoph-
agitis (p  .001). Median survival for patients with V20  35% vs V20 
35% was 24 vs 12 months, respectively(p.0001). Multivariate analysis
determined that V20 was an independent factor predicting the incidence of
pneumonitis and the median survival.
Conclusions: The incidence of significant pneumonitis observed in SWOG
0023 was highly correlated with V20 35%. Poor overall survival was
observed in patients with V2035%. Based on this data, SWOG lung studies
designed specifically for patients with large V20 are in development.
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Single Nucleotide Polymorphism Oo Tgf-1T869c and Tgf-1
Genotypes Predicted a Decreased Risk of Severe Radiation
Pneumonitis Ii Patients with Non-small Cell Lung Cancer
Treated wth Definitive Radiotherapy
X. Yuan1, Z. Liao2, Z. Liu3, X. Wei4, S. Tucker5, R. Komaki6, L. Milas7, Q.
Wei3, 1Department of Oncology, Tongji Hospital, Huazhong University of
Science and Technology, Wuhan, China, 2Departments of Radiation Oncol-
ogy, The university of Texas M. D. Anderson Cancer Center, Houston, TX,
3Departments of Epidemiology, The university of Texas M. D. Anderson
Cancer Center, Houston, TX, 4The university of Texas M. D. Anderson
Cancer Center, Houston, TX, 5Departments of Bioinformatics and Compu-
tational Biology, The university of Texas M. D. Anderson Cancer Center,
Houston, TX, 6Departments of Radiation Oncology, The university of Texas
M. D. Anderson Cancer Center, Houston, TX, 7Departments of Experimental
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Purpose: To investigate the association between SNPs in the TGF-1 gene
and risk of radiation pneumonitis (RP) in patients with non-small cell lung
cancer (NSCLC) treated with definitive radiotherapy.
Methods and Materials: We used available blood samples of164 cases from
a large dataset of NSCLC patients established for a comprehensive study of
RP. These patients were treated with definitive radiation at The University of
Texas M.D Anderson Cancer Center between 3/1999 and 5/2005. DNA was
extracted from the whole blood. We genotyped three SNPs of the TGF-1
gene: rs1800469: C-509T, rs1800471: G915C, and rs1982073: T869C, as
determined by polymerase chain reaction.
Results: There were 90 males and 74 females with a mean age of 63 years
in this subgroup of patients. Radiation doses ranging from 60–70 Gy in
30–35 fractions were given to 95% (156/164) of patients, and platinum based
concurrent chemotherapy was given to 74% (121/164) of patients.Grade 3
RP was observed in 36 (22.0%) patients. In the univariate analysis, variant C
genotypes (CT  CC) of TGF-1 rs1982073: T869C were associated with
a decreased risk of RP (HR 0.45, 95% CI 0.23–0.86) and this protective
effect was virtually unchanged after adjustment for age, sex, and race (HR
0.47, 95% CI 0.24–0.91). A decreased risk of RP was also associated with
the combined variant genotypes of all three SNPs, either using the number of
variant alleles (HR  0.67, 95% CI  0.47–0.98) or genotypes (HR  0.42,
95% CI  0.22–0.81), even after adjustment for age, sex and race (HR 
0.69, 95% CI  0.48–0.99 and HR  0.44, 95% CI  0.23–0.84,
respectively).
Conclusions: Single nucleotide polymorphism of TGF-1 rs1982073:
T869C SNP and TGF-1 genotype were associated with a decreased risk of
Grades 3 RP in NSCLC patients who were treated with definitive radio-
therapy.
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Sequential Scheduling of Erlotinib with Chemotherapy as 1st-
line Therapy for Advanced NSCLC: Subgroup Analyses of a
Randomized Double-Blind Placebo-Controlled Phase II Trial
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Purpose: To determine whether sequential use of erlotinib with chemother-
apy improves outcomes as 1st-line therapy for advanced NSCLC.
Methods: Eligible patients (pts) had stage IIIB/IV NSCLC and performance
status 0/1. Erlotinib (E) 150mg/day or placebo (P) was given on d15–28 of
4-weekly chemotherapy cycles (up to 6 cycles) comprising gemcitabine (G)
1250mg/m2 (d1, 8) and either cisplatin (C) 75mg/m2 or carboplatin (C)
AUC5 (d1). E or P were continued after chemotherapy, until disease
progression or unacceptable toxicity. Clinical subgroups were pre-defined by
disease stage, smoking history, histology, gender, age and performance
status.
Results: 154 pts (median age 57 years) were enrolled from 7 Asia Pacific
countries (n76 GC-E; n78 GC-P). Baseline characteristics were balanced
between the two arms. There was a significant improvement in PFS (31.3
wks in GC-E vs 23.7 wks in GC-P, log-rank p0.0175; hazard ratio [HR] 
0.57, 95% CI 0.38–0.84), with a 43% reduction in the risk of progression or
death in favor of the GC-E arm. In pre-defined analyses, the PFS benefit for
GC-E over GC-P was apparent in all pt subgroups, such as current smokers
(HR  0.68); former smokers (HR  0.56); never smokers (HR  0.47);
adenocarcinoma (HR  0.55); non-adenocarcinoma (HR  0.79); female
(HR  0.60) and male (HR  0.63) although the sample sizes were
insufficient to detect significant differences in all cases. A difference of
12.4% in ORR (36.8% in GC-E vs 24.4% in GC-P; odds ratio  1.85) was
observed with a trend to significance (p0.0888). Median OS has not been
reached. Biomarker data are not yet available. The addition of E to GC was
generally well tolerated. Treatment-related grade 3/4 toxicities occurred in
38% of GC-E pts vs 35% of GC-P pts. Treatment-related skin toxicity was
more common in the GC-E arm (64% vs 33%), but was mostly grade 1–2 and
did not lead to discontinuation.
Conclusion: The sequential GC-E regimen significantly prolonged PFS;
benefit was observed in all clinical subgroups, including males, smokers, and
those with non-adenocarcinoma histology. Further investigation of this novel
approach in phase III is planned.
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FLEX: Cetuximab in Combination with Platinum-Based Che-
motherapy (CT) Improves Survival Versus CT Alone in the
1st-line Treatment of Patients (pts) with Advanced Non-small
Cell Lung Cancer (NSCLC)
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Objective: To demonstrate superior overall survival (OS) for the EGFR-
targeted antibody cetuximab (Erbitux) in combination with CT compared to
CT alone in the 1st-line treatment of advanced NSCLC.
Methods: Pts with EGFR-expressing advanced NSCLC were randomized
1:1 to cetuximab (400 mg/m2 initial dose, then 250 mg/m2/wk)  CT
(cisplatin 80 mg/m2 d1 and vinorelbine 25 mg/m2 d1, d8 q3w) or CT alone.
The primary endpoint was OS time.
Results: A total of 1125 pts (557 cetuximab  CT/ 568 CT alone) were
randomized: median age 59 (range 18–83) years; male: 70%; stage IV: 94%;
adenocarcinoma: 47%; squamous cell carcinoma: 34%; ECOG PS 2: 17%. A
planned survival analysis was performed after 868 events. OS was signifi-
cantly improved in the cetuximab  CT arm vs CT (median 11.3 vs 10.1
months; HR [95% CI]: 0.871 [0.762–0.996]; p  0.0441). Pre-specified
subgroup analyses demonstrated that the addition of cetuximab provided a
substantial benefit in Caucasians across all histologies. Pts in the cetux-
imab CT arm who developed an acne-like rash of any grade within the first
3 wks and who were still alive after the first cycle (n 290) had a longer OS
than those without acne-like rash (n  228) (median [95% CI]: 14.3 months
[12.1–15.7] vs 8.1 months [6.9–10.4]). The response rate was also signifi-
cantly improved in the cetuximab  CT arm vs CT (36.3% [95% CI:
32.3–40.4%] vs 29.2% [95% CI: 25.5–33.2%]; p  0.012). While PFS was
comparable in both arms, time to treatment failure was significantly im-
proved in the cetuximab  CT arm vs CT (4.2 vs 3.7 months; HR [95% CI]:
0.859 [0.761–0.971]; p  0.015). Treatment was generally well tolerated.
The most frequent grade 3/4 adverse events (cetuximab  CT vs CT) were:
neutropenia 52.7% vs 51.4%; febrile neutropenia 21.7% vs 15.5%; anemia
13.9% vs 16.7%, and acne-like rash 10.4% vs 0.2%.
Conclusions: The addition of cetuximab to standard CT significantly im-
proved OS versus CT alone. The safety profile of cetuximab  CT was
predictable and manageable. The FLEX study is the first to demonstrate a
survival benefit of a targeted agent in combination with platinum-based CT
across all histological subtypes in 1st-line NSCLC.
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S0536: SWOG Phase II trial of Carboplatin (C), Paclitaxel (P),
Cetuximab (CX) and Bevacizumab (B) Followed by Cetuximab
and Bevacizumab in Advanced Non-small Cell Lung Cancer
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Background: The combination of Bevacizumab (B) and chemotherapy
increases survival in patients (pts) with incurable NSCLC. Recently, Cetux-
imab (CX) has demonstrated improved survival (OS) when given in combi-
nation with platinum based chemotherapy. Given the strong rationale for
combining EGFR and VEGFR targeted agents, SWOG sought to investigate
the safety and efficacy of Carboplatin (CB), Paclitaxel (P), and CX with B in
this multi-center phase II trial. Eligibility included stage IIIB or IV incurable
non-squamous cell NSCLC, no prior chemotherapy or EGFR or VEGF-
related agents, PS 0–1, no brain metastases, no history of hemoptysis.
Treatment: CB AUC 6, P 200 mg/m2, B 15 mg/kg IV on day 1 every 3
weeks, and CX 400 mg/m2 on day 1 then 250 mg/m2 weekly for up to 6
cycles, followed by B 15 mg/kg every 3 weeks and CX 250 mg/m2 weekly
until progression. The primary endpoint was feasibility defined by the
frequency and severity of hemorrhagic toxicities. Secondary endpoints in-
cluded response rate, progression-free survival (PFS), OS and toxicity.
Results: 110 pts were enrolled with 104 evaluable (52 females) from August
2006 to September 2007. Baseline characteristics median age 64 years old
(42–78), PS 0 (43 pts) or 1 (60 pts) stage IIIB (9 pts) or IV (94 pts),
adenocarcinoma histology (81 pts), smoking history current/former (81 pts).
104 pts are evaluable for toxicity. There were 4 treatment-related deaths
including 2 pts due to lung hemorrhage, 1 pt unknown, and 1 pt due to
infection. Grade 4 adverse events have occurred in 40 pts. The estimated rate
of grade 4 or worse hemorrhage is 2% (95% CI: 0–7%). 95 pts have
measurable disease at baseline and 87 pts are assessable at this time. Partial
response (PR) by RECIST has been observed in 42 pts (48%; 37%–59%) and
stable disease (SD) in 22 pts (25%). Disease control rate (PR  SD) is 74%.
PFS is 7 m and OS is 14 m. 23 pts remain on treatment.
Conclusions: The combination of CB, P, B and CX demonstrates safety,
tolerability and efficacy in patients with advanced NSCLC and is the most
active lung cancer regimen studied to date in SWOG. Biomarker studies are
pending and a Phase III proposal is planned.
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Nonsquamous Histology: A Predictor of Efficacy for
Pemetrexed Treatment of Non-small Cell Lung Cancer
(NSCLC). An Analysis of Phase IIII Trials Using Treatment-by-
Histology Interactions
C. P. Belani1, T. Brodowicz2, P. Peterson3, W. John3, G. V. Scagliotti4,
1Pennsylvania State Hershey Cancer Inst, Hershey, PA, 2Medical University
Vienna, Vienna, Austria, 3Eli Lilly and Company, Indianapolis, IN, 4Univer-
sity of Torino, Orbassano, Italy
Purpose: A tailored approach to chemotherapeutic intervention based on
histology or tissue type may advance the treatment of NSCLC and other
malignancies to the next level. The treatment-by-histology interaction (THI)
analysis demonstrates that efficacy differs by histologic subtype. In addition,
THI predicts the relative efficacy of a specific treatment vs a comparator. A
retrospective analysis of the phase III study of pemetrexed (P) vs docetaxel
(D) in previously treated patients (pts) (N  571), showed statistically
significant THI. Subgroup analyses in this trial further showed that while the
efficacy of D was fairly consistent between histologic types, the efficacy of
P was superior in pts with nonsquamous histology.
Methods: A THI analysis was performed on two recently reported large
randomized trials evaluating the efficacy of P. In the first study, P was
compared with placebo in non-progressing pts (N663) completing 4 cycles
of platinum-based therapy and, in the second study, the combination of P 
cisplatin (PC) was compared with gemcitabine  C (GC) in chemonaive pts
(N  1725). THI was tested prospectively using Cox models of overall
survival (OS) and progression-free survival (PFS). Subgroup analyses were
used to explain any observed THIs and to evaluate the predictive value of
nonsquamous histology for the efficacy of P.
Results: A total of 73% of pts in both studies had nonsquamous histology.
THIs were statistically significant for PFS (p 0.036 and p 0.002) and for
OS (p  0.011 [preliminary] and p  0.002) in the P vs placebo and in the
PC vs GC studies, respectively. In both studies, nonsquamous patients
treated with P-based therapy experienced improved PFS and OS compared
with squamous patients treated with P-based therapy; conversely, in each
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trial’s comparator arm, PFS and OS results were similar between nonsqua-
mous and squamous patients.
Conclusions: Nonsquamous histology is predictive of improved efficacy of
pemetrexed in patients with NSCLC.
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Biomarker Status Correlates with Clinical Benefit: Phase 2
Study of Single-agent Erlotinib (E) or E Intercalated with
Carboplatin and Paclitaxel (ECP) in an EGFR Biomarker-
selected NSCLC Population
F. R. Hirsch1, R. Dziadziuszko1, D. R. Camidge1, F. Kabbinavar2, K.
Richardson3, F. Richardson4, B. Wacker4, W. A. Franklin1, M. Varella
Garcia1, P. A. Bunn1, et al., 1University of Colorado Cancer Center, Aurora,
CO, 2UCLA/Translational Oncology Research International, Los Angeles,
CA, 3Molecular Biology Experimental Design, Boulder, CO, 4OSI Pharma-
ceuticals, Inc., Boulder, CO
Purpose: To understand molecular determinants that predict for efficacy of
E, 1stline, advanced NSCLC pts were prospectively selected based on EGFR
status (IHC and/or FISH) for a randomized phase 2 study of E or ECP
[Camidge et al 2008].
Methods: Tumor tissue (fine needle aspirate, biopsy, resection) was evalu-
ated by IHC (EGFR), FISH (EGFR gene copy number), and DNA sequenc-
ing (EGFR and Kras gene mutations).
Results: Among 143 enrolled pts (72 E; 71 ECP), 52% female; 79% White
(9% Asian); 54% former smokers (28% never, 18% current); 74% adeno-
carcinoma histology. Most samples were EGFR IHC  (any staining; 92%),
53% EGFR FISH , and 45%  by both. 13% had activating EGFR
mutations (11 pts exon-19 del., 5 pts exon-21 L858R; 119 specimens
analyzed) and 21% had Kras mutations (21 pts codon-12, 8 pts codon-13;
135 specimens analyzed), consistent with prior reports of mutation preva-
lence in an unselected NSCLC pts. No pt had both EGFR and Kras
mutations; 2 pts had an L858R and T790M mutation. Biomarker status in
subgroups was consistent with previous reports and similar in the 2 arms.
EGFR-activating mutations were higher among females (16% vs 6% males),
adenocarcinoma histology (15% vs 0% others), Asians (38% vs 6% Whites),
and never smokers (28% vs 5% former and 4% current); Kras mutations were
higher in current smokers (39% vs 21% former and 7% never). In the E arm,
preliminary 6-mo PFS rate (the 1° endpoint) was significantly higher in pts
with EGFR activating mutations vs no mutations (89% vs 23%, HR  0.17,
P  0.003), and numerically higher in pts with EGFR FISH  vs FISH-
(42% vs 26%, HR0.61, P0.08) and with no Kras mutation vs with (40%
vs 12%, HR1.79, P0.10). In the ECP arm, 6-mo PFS was numerically
higher in pts with EGFR activating mutations (56% vs 32%, HR  0.60, P
 0.41) and without Kras mutations (32% vs 9%, HR  1.65, P  0.16).
Conclusions: Activating EGFR mutations correlate with increased 6 mo PFS
probability in 1st line therapy with E. EGFR FISH  and absence of Kras
mutation independently trend towards increased 6 mo PFS rate with E.
Activating EGFR mutations and absence of Kras mutations trend toward
increased 6 mo PFS rate in ECP arm.
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Longitudinal Analysis Of Serum Proteomic Profile In NSCLC
Patients Treated With Epidermal Growth Factor Receptor Ty-
rosine Kinase Inhibitors (EGFR Tkis)
A. Spreafico1, A. Bachi1, H. Roder2, A. Cattaneo1, J. Grigorieva2, C. Belli1,
C. Lazzari1, M. Tsypin2, E. Villa1, V. Gregorc1, 1San Raffaele University
Hospital, Milan, Italy, 2Biodesix, Steamboat Springs, CO
Background: Matrix-assisted laser desorption/ionization time-of-flight mass
spectrometry MALDI ToF MS is a simple strategy for analyzing patient sera.
Our previous study (JNCI, 2007) showed that spectra of unfractionated
pretreatment sera could identify NSCLC patients with improved survival
after following EGFR TKIs therapy. The proteomic classifier (VeriStratTM,
Biodesix, Inc), based on 8 distinct m/z features, resulted specific, in terms of
TTP and OS, for EGFR-TKIs and not for chemotherapy, but modifications of
the proteomic profile has not been explored yet. In the current study we
evaluated possible changes of the serum proteomic profile during treatment
and at the time of the treatment withdrawal (PD, toxicity, discontinuation for
any case) in unselected advanced NSCLC patients.
Methods: Sera from advanced NSCLC pts treated with gefitinib were
analyzed by MALDI ToF MS. Mass spectra were acquired in linear mode
using a Voyager DE-STR mass spectrometer. Four spectra were collected
from 150 positions within each MALDI spot, generating an average of 600
spectra for each specimen. Samples were randomly spotted in triplicate and
average of 3 spectra was collected for each sample. Spectra were externally
calibrated with a mixture of standard proteins.
Results: A total of 111 sera were analyzed. Samples were collected at
baseline, during, and at treatment withdrawal. Pts characteristics were:
male/female: 86/25; median age: 68; never/ever-smokers: 17/88; adeno/
squamous/other: 55/26/30. Seventy-five baseline Veristrat were classified
as 50 postive, 20 negative, and 5 undefined at treatment withdrawal. Thirty-
three baseline Veristrat- were classified as 4 positive, 28 negative, and 1
undefined at treatment withdrawal. Out of 111 patients 87% had a proteomic
profile concordant to clinical benefit, while 14 (13%) had proteomic profile
modifications (vs-, or viceversa) during treatment, and apparently no
correlation with clinical benefit was found. Moreover these 14 patients had
a surprising median survival of 32 months, and are currently under
studying.
Conclusions: This study is showing that proteomic profile is concordant to
clinical benefit.
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Carboplatin/paclitaxel With/without Sorafenib In Chemonaive
Patients With Stage IIIB-IV Non-small Cell Lung Cancer
(nsclc): Interim Analysis (ia) Results From a Randomized Phase
III Trial (escape)
N. H. Hanna1, J. von Pawel2, M. Reck3, G. Scagliotti4, 1Indiana University,
Indianapolis, IN, 2Asklepios-Fachkliniken Munchen-Gauting, Gauting, Ger-
many, 3Hospital Grosshansdorf, Grosshansdorf, Germany, 4University of
Turin, Torino, Italy
Background: Sorafenib is an oral multikinase inhibitor with anti-angiogenic
and antiproliferative activity and single-agent activity in phase I-II NSCLC
trials.
Methods: Eligible pts had unresectable stage IIIB/IV NSCLC, no prior
systemic treatment, ECOG PS 0–1. Pts were randomized to receive carbo-
platin AUC 6 d1  paclitaxel 200 mg/m2 d1 combined with either sorafenib
400 mg (PCS) or placebo (PCP) orally, bid d2–19, q3w. Daily sorafenib 400
mg bid or placebo was continued as maintenance therapy following up to 6
cycles of chemotherapy. Safety and efficacy was monitored by the DMC
throughout the study. The DMC recommended termination of the study for
futility based on findings from a formal planned IA of efficacy at 384 death
events.
Results: 926 patients were randomized to treatment with PCS (n  464) or
PCP (n  462). Overall demographics were balanced between arms and
included: 63% male; 59% ECOG PS 1; 90% Stage IV disease; median age,
62 years and 24% squamous cell (SC) histology (219 pts). Baseline demo-
graphics were similar between SC and non-SC subsets. Preliminary efficacy
results revealed median overall survival (ITT analysis) 10.7 months in the
PCS group vs 10.6 months in the PCP group [HR (PCS/PCP), 95% CI 
1.16,(0.95,1.43); P  0.93, 1-sided]. From safety data currently available,
the most common causes of death in the ITT group were: PD, 292 (31.5%);
other, 43 (4.6%); unknown, 11 (1.2%); study treatment toxicity, 9 (1.0%);
and pneumonia, 4 (0.4%). Greater mortality was observed in the subset of
patients with SC treated with PCS, compared with those treated with PCP.
Cause of death in SC subset was PD 63 (28.8%), other 11 (5.0%), unknown
5 (2.3%), study treatment toxicity 4 (1.8%) and respiratory failure 2 (0.9%).
Fatal pulmonary hemorrhage was reported in 13 pts (1.4%) overall, with 9
events in the SCC subset (5 in PCS group, 4 in PCP group).
Conclusions: Based on this planned IA, there was no clinical benefit from
the addition of sorafenib to standard PC chemotherapy in NSCLC. PCS-
treated patients with squamous-cell NSCLC (n  107) had a greater
mortality rate than those receiving PCP (n  112).
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EGFR Biomarker-selected Randomized Phase II Study of Erlo-
tinib (E) or Intercalated E With Carboplatin/Paclitaxel (C/P) in
Chemo-naive Advanced NSCLC
D. R. Camidge1, F. Kabbinavar2, R. Martins3, F. Schnell4, S. Witta5, T.
Eisen6, J. Rusk7, B. Wacker7, F. R. Hirsch1, P. A. Bunn1, et al., 1University
of Colorado Cancer Center, Aurora, CO, 2UCLA/Translational Oncology
Research International, Los Angeles, CA, 3Fred Hutchinson Cancer Re-
search Center, Seattle, WA, 4Central Georgia Cancer Center, Macon, GA,
5Rocky Mountain Cancer Centers, Denver, CO, 6Addenbrookes Hospital,
Cambridge, United Kingdom, 7OSI Pharmaceuticals, Inc, Boulder, CO
Purpose/Objective(s): The EGFR inhibitor E improves overall survival
(OS) and progression-free survival (PFS) in 2nd/3rdline NSCLC. However,
daily E in combination with chemotherapy (CT) in 1st line advanced NSCLC
did not improve outcomes in unselected pts. Pre-clinical data suggest interca-
lating E with CT may be superior to continuous dosing. This trial evaluated E
alone and E intercalated with C/P in an EGFR-selected 1st line NSCLC
population but was not designed to formally compare treatment arms.
Methods: CT-naı¨ve stage IIIB/IV NSCLC pts with EGFR tumors by FISH
or IHC were randomized 1:1 to E 150 mg/d or carboplatin AUC 6/paclitaxel
200mg/m2 Day 1 plus E 150 mg/d Days 2–15 q21 days (ECP). After 4
cycles, pts could continue daily E until PD. Stratification factors: # of 
EGFR tests (1 vs 2), performance status (0/1 vs 2), stage (IIIB vs IV), and
smoking status (current vs former vs never). 1° endpoint was 6-mo PFS rate;
2° endpoints were to obtain estimates of PFS, RR, and OS for testing in
future studies.
Results: Of 215 patients screened for EGFR status, 143 pts were randomized
(72 E; 71 ECP): median age 63 years (range 27–90); 52% female; 79% White
(9% Asian); 54% former smokers (28% never smokers, 18% current smok-
ers); 74% adenocarcinoma. Preliminary 6-mo PFS rate 33% in E cohort and
26% in ECP cohort. RR: E (10%); ECP (19%). DCR: E (42%); ECP (66%).
Efficacy (6 mo PFS rate) in patient subgroups in E: 37% vs 26% (F:M); 40%
vs 29% (non-smoker:ever-smoker); 37% vs 20% (adeno:other). In ECP 39%
vs 17% (F:M); 33% vs 24% (non-smoker:ever-smoker); 28% vs 22%
(adeno:other). All comparisons are non-significant. Biomarker data will be
presented at this meeting (Hirsch et al. 2008). Common AEs included skin
toxicity (rash): E 81%, (G3/4 12%); ECP 76% (G3/4 6%) and diarrhea: E
57% (G3/4 1%); ECP 60% G3/4 7%). G3/4 neutropenia occurred in 25% of
ECP pts (E 1%).
Conclusions: 1) Of 215 adv NSCLC pts screened, 82% were EGFR  by
either IHC or FISH. 2) Efficacy of single agent E or intercalated E with C/P
in biomarker-selected 1st line pts is associated with similar 6-month PFS
rates. Neither arm met its pre-specified statistical goal. 3) Final PFS, OS and
additional subset results will be presented.
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A Study of Genetic Abnormalities of the EGFR Pathway in
African American Patients with Non-small Cell Lung Cancer
A. Hamdan1, C. Jin1, R. S. Leidner1, R. Eisenberg1, P. Fu1, M.
Skokan2, F. Cappuzzo3, F. R. Hirsch2, M. Varella-Garcia2, B.
Halmos1, 1Departments of Medicine, Pathology and Biostatistics,
Case Western Reserve University, Cleveland, OH, 2Departments of
Medicine and Pathology, University of Colorado Cancer Center,
Aurora, CO, 3Instituto Clinico Humanitas IRCCS, Rozzano, Italy
Purpose/Objective(s): The role of epidermal growth factor receptor (EGFR)
has been well established in non-small-cell lung cancer (NSCLC). Previous
studies have shown an increased frequency of activating EGFR mutations in
Asian patients. In this study, we investigated the frequency of EGFR
abnormalities in African American patients where very limited information
exists.
Abstracts Journal of Thoracic Oncology • Vol. 3, No. 11, Supplement 4, 2008
Copyright © 2008 by the International Association for the Study of Lung CancerS268
Materials/Methods: Dual-color FISH assay using the EGFR/CEP7 probe
was performed on formalin-fixed, paraffin-embedded NSCLC sections of 54
African American patients. Tumors were classified as EGFR FISH negative
(4 signals in 40% of nuclei) and EGFR FISH positive (4 signals in
40% of nuclei or gene amplification). Results were compared to a historical
cohort of 102 Caucasian patients. Incidence of EGFR FISH positivity and
confidence intervals were estimated by Wilson’s approach. The association
between categorical variables, including race and EGFR status, was exam-
ined by Chi-square test. The effect of ethnicity was further estimated by
logistic regression after controlling for confounders (i.e. age, sex, and
histology).
Results: African-Americans had a significantly higher rate EGFR FISH
positive NSCLC than Caucasians, 50% (n  27, 95% CI: 0.37–0.63) vs.
32% (n  33, 95% CI: 0.24–0.42; p  0.031). In African-Americans, no
association was detected between EGFR FISH positive status and gender
(p  1.0), histology (p  0.77), or stage (p  0.56), but association was
detected in Caucasian females (p  0.04). After controlling for the effects of
age, sex and histology, ethnicity showed a trend toward EGFR FISH
positivity (p  0.071) with an odds ratio of 1.91.
Conclusions: Our findings suggest there may be differences in NSCLC
EGFR status among ethnicities, and that African-American patients are more
frequently EGFR FISH positive than Caucasians. These results corroborate
the need to investigate the contribution of ethnicity to the patterns of genetic
abnormalities in large NSCLC cohorts and to verify the usefulness of
incorporating ethnicity in clinical trials and treatment paradigms with EGFR-
targeted agents. EGFR and KRAS mutational analysis is ongoing. Results
will be presented at the meeting.
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Biomarker Analysis of Tumor Tissue from Completely Resected
NSCLC Patients Enrolled in an Adjuvant Trial (RADIANT)
F. Richardson1, K. Richardson1, G. Sennello1, D. Young1, A. Szczesna2, P.
Serwatowski3, R. Cerfolio4, J. Kim5, S. Park6, W. Eberhardt7, 1OSI Phar-
maceuticals Inc., Boulder, CO, 2Mazowieckie Centrum Leczenia Chorob
Pluc i Gruzlicy, Otwock, Poland, 3Specjalistyczny Szpital im. prof.Alfreda
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Seoul, Republic of Korea, 6Gachon Medical School Ghil Medical Center, In
Cheon, Republic of Korea, 7Universita¨tsklinikum Essen, Essen, Germany
Background: RADIANT is a phase III clinical trial comparing erlotinib 150
mg daily vs. placebo (2:1) in Stage IB to IIIA NSCLC patients with EGFR
tumors (IHC and/or FISH), following surgical resection with or without
adjuvant chemotherapy. Planned accrual is 945 patients. Correlative biomar-
ker studies on resected, primary tumor tissue, whole blood, and serum are
key components of the study.
Methods: Tumor tissue was evaluated by IHC for protein expression of
EGFR (PharmDx Kit, Dako with   1% positive tumor cells), e-cadherin
(E) (Cell Signal. Tech.), and vimentin (V) (Dako) using exploratory H-score
of O´ [(intensity) x (% positive cells)], by FISH for gene expression of EGFR
(Vysis, Abbott), and by Wave HS for EGFR and Kras mutations. Serum
integrity was evaluated using qPCR of CA repeat sequences and LC/MS
analysis (VeristratTM, Biodesix).
Results: Among 278 patient samples analyzed, 97% were EGFR IHC,
69% EGFR FISH, while 269 patient samples showed 12% activating
EGFR and 21% Kras mutations. Preliminary comparisons suggest: EGFR
mutation rate increased while Kras mutation rate decreased with tumor stage.
EGFR mutations occurred in 7/30 Asians (A) vs. 21/209 Caucasians (C) and
22/40 non-smokers (NS) vs. 10/230 smokers (S). Kras mutations occurred in
1/30 A vs. 54/209 C and 4/40 NS vs.52/230 S. In adenocarcinoma, 29/149
patients had EGFR and 49/149 patients had Kras mutations; in squamous cell
carcinoma, 0/102 patients had EGFR and 4/102 patients had Kras mutations.
No sample demonstrated both activating EGFR and Kras mutation. One
patient had both an EGFR T790M and a Kras mutation. Preliminary E and
V results on 278 samples indicate a population with high E and low V
expression. To date, sera (pre/post dose) from 215/278 patients (estimated
90% with sufficient integrity for circulating DNA and proteomic analyses),
and whole blood from 196/278 patients have been collected.
Conclusion: Early biomarker assessment in the RADIANT patient popula-
tion indicates successful sample collection and analysis and supports con-
tinued efforts to collect and analyze tissue samples. Ultimately, these
biomarker analyses may help determine who may benefit from treatment
with erlotinib in the adjuvant setting.
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The Prognostic Importance of PTEN and Other Gene Copy
Numbers in Resectable Non-small Cell Lung Cancer (NSCLC)
L. E. Morrison1, L. P. Faber2, K. Walters2, M. Liptay2, T. M. Ruffalo1, O.
Rouhy2, S. McCormack2, D. Escarzaga2, P. Bonomi2, J. Coon2, 1Abbott
Molecular, Des Plaines, IL, 2Rush University Medical Center, Chicago, IL
Purpose/Objective(s): Identification of high risk early stage NSCLC
patients would have important therapeutic implications. Recent reports
suggest that gene expression arrays can identify high risk early stage disease.
While fresh frozen tissue was required for these analyses, fluorescence in situ
hybridization (FISH) performed on paraffin embedded tissue has been shown
to detect genomic alterations, and can aid in diagnosing NSCLC as well as
predicting response to targeted therapy. Here we evaluate FISH as a prog-
nostic tool in the management of early stage NSCLC.
Materials/Methods: Formalin-fixed paraffin embedded tumors from 60
patients with stage 1b and 2 NSCLC were analyzed by FISH using probes
targeting the 8q24 (MYC), centromere 6 (cen6), 7p12 (EGFR), 5p15, 10q23
(PTEN), centromere 10 (cen10), 3q26 (PIK3CA), and centromere 3 (cen3)
loci. FISH signals were enumerated in40 cells per specimen to obtain copy
numbers for each locus. Various parameters based on genomic copy numbers
were used to classify patients into two groups, and times to recurrence (TTR)
were compared by contingency tables (2-sided Fischer’s exact test) and
Kaplan Meyer analysis (log rank test).
Results: Several FISH parameters were found to associate strongly with
prognosis when patients that recurred within 3 years of surgery (unfavorable
prognosis) were compared to patients that either did not recur or recurred
more than 3 years post surgery (favorable prognosis). Of single FISH
parameters, PTEN copy number measured relative to cen10 copy number
(PTEN/cen10) provided the most significant distinction between favorable
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and unfavorable prognoses. Of the 18 patients with 0.80 PTEN/cen10
(PTEN deletion), 12 (67%) experienced recurrence within 3 years of surgery,
compared to only 8 (19.5%) of the 41 patients with 0.80 PTEN/cen10
(p  0.0008). Median TTR in the former and latter groups were 13.0 and
83.1 months, respectively (p0.0001).
Conclusions: These data indicate that PTEN deletion, and other chromo-
somal alterations, may be of prognostic importance in early stage NSCLC,
and FISH performed on biopsy specimens or resected tumors may prove
valuable in decisions related to adjuvant therapy.
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Accelerated Hyperfractionated Radiation Therapy (AHF-RT)
Increased Survival Compared to Daily TRT (QD-TRT) for
Limited Small Cell Lung Cancer Patients Treated with Concur-
rent Chemotherapy
X. Wei, R. Komaki, P. K. Allen, B. S. Glisson, D. J. Stewart, Z. Liao, J. Y.
Chang, K. M. Bucci, M. McAleer, J. D. Cox, M.D. Anderson Cancer Center,
Houston, TX
Purpose/Objective(s): To analyze the treatment outcome and acute and late
toxicity in patients with limited small-cell lung cancer (L-SCLC) treated by
AHF-RT or QD-TRT with cisplatin-based chemotherapy (ChT).
Materials/Methods: A total of 299 pts with L-SCLC who were treated with
ChT/RT with no surgery between 1987 and 2004 were reviewed. Complete
responders received prophylactic cranial irradiation(PCI). Restaging and
determination of response was done approximately 2 mos after completion of
treatment to the primary. The data were analyzed using Kaplan-Meier
survival function. The Log Rank test was used to assess the quality of
survival function using a p-value of 0.05.
Results: The median follow-up was 20 mos (rang, 1 to 205 mos). Pleural
fluid was present in 14% of pts. 119 pts received QD-TRT ranging from 45
Gy/15Fx/3W to 70Gy/35 Fx. 180 pts received AHF-RT ranging from
45Gy/30Fx/3W to 64.8Gy/36Fx. PCI was given to 163 pts with 2.5Gy 
10Fx or 2.0Gy  15Fx (61 pts in QD group compared to 102 pts in the BID
group). Comparison between AHF-RT and QD-TRT in 5 yrs, the overall
survival(OS) rate was 37.3 % vs 23.0%, p0.06; OS:PtsPCI (%) was
45.9% vs 27.4%, p0.02; Disease free survival was 28.2% vs 29.0%,
p0.37; Local recurrent was 56.1% vs 52.2%, p0.81; distant metastasis-
free survival was 36.3% vs 36.5%, p0.52, Acute dysphagia was 20.6% vs
16.0%, p0.32; Pneumonitis was 2.2% vs 2.5%, p0.87; and Lung fibrosis
was 17.2% vs 10.1%, p0.09, respectively. Other factors influencing out-
come were pleural effusion at diagnosis, weight loss at diagnosis, PCI, LR
control, DM failure and L-SCLC diagnosis after 1994. Multivariate analysis
showed that factors influencing overall survival were PCI (p0.001), pleural
effusion (p0.02), LR control (p0.001) and DM failure (p0.001).
Conclusions: The overall survival was improved by concurrent chemother-
apy and AHF-RT in spite of slightly lower biological equivalent dose (BED)
by 1.5Gy/Fx/30Fx/3W compared to 50 Gy/5W, and application of PCI. It is
important to reduce normal tissue toxicities in the future when concurrent
chemoradiation therapy especially AHF-RT is applied.
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An Ongoing Phase 1 Adaptive Dose Escalation Study of
ABT-263 in Patients with Relapsed Small Cell Lung Cancer
(SCLC) and Other Solid Tumors
C. M. Rudin1, G. I. Shapiro2, D. Camidge3, D. Khaira4, M. Ribeiro de
Oliveira5, P. Bonomi6, D. Gandara7, H. Xiong8, A. Krivoshik8, L. Gandhi2,
1Johns Hopkins University, Baltimore, MD, 2Dana-Faber Cancer Institute
Harvard, Boston, MA, 3University of Colorado Cancer Center, Aurora, CO,
4Dedicated Phase 1, Phoenix, AZ, 5Northwest Medical Specialties, PLLC,
Tacoma, WA, 6Rush University Medical Center, Chicago, IL, 7UC Davis
Cancer Center, Sacramento, CA, 8Abbott Laboratories, Abbott Park, IL
Purpose/Objective(s): ABT-263, a novel BH3 mimetic, binds with high
affinity (Ki  1 nM) and inhibits multiple antiapoptotic Bcl-2 proteins.
ABT-263 displays potent mechanism-based activity (EC501 ı`M) against
human lymphoid and SCLC tumor cell lines. Preclinical toxicities include
reductions in spermatogenesis, circulating lymphocytes and circulating plate-
let survival, mediated by Bcl-w, Bcl-2 and Bcl-XL, respectively. ABT-263
also enhances effects of both chemotherapy and radiation in cells derived
from multiple tumor types.
Materials/Methods: Safety and PK profiles of ABT-263 at daily doses (14
of 21 days) were studied in an ongoing phase 1 trial of patients with relapsed
or refractory SCLC or other solid tumors. A continuous reassessment method
(CRM) based on toxicity data guided dose escalation.
Results: 35 patients (dose range: 10 to 475 mg) have enrolled to date.
ABT-263 Cmax and AUC increase dose-proportionally with an average time
to Cmax of 9 h and a terminal half-life of 14–20 h. PK properties were
time-invariant during the first 14 days and body weight or surface area do not
appear to affect the AUC of ABT-263. 3 drug-related grade 4 thrombocy-
topenia dose-limiting toxicities (DLTs) were observed, 1 at each of the 325,
425 and 475 mg doses; 1 DLT of fatal respiratory failure occurred at 10 mg.
Observed mechanism-based, dose-related thrombocytopenia was consistent
with preclinical models. 11 patients reported serious adverse events (SAEs);
2 SAEs were possibly related to study drug. Typically, platelet nadir
occurred early in the cycle with recovery during continued dosing. At 325
mg, the median, minimum and maximum platelet nadirs as a fraction of
baseline were 29%, 10% and 40%, respectively and at 425 mg were 20%, 9%
and 31%, respectively. Stable disease (SD) was noted in 7 patients: 1 patient
at 10 mg (SCLC), 2 patients at 130 mg (1 carcinoid & 1 SCLC), 2 patients
at 325 mg (1 NSCLC & 1 carcinoid), 2 patients at 425 mg (1 SCLC & 1
carcinoid).
Conclusions: ABT-263 is a novel, orally bioavailable small molecule Bcl-2
protein inhibitor. Mechanism-based transient decreases in circulating plate-
lets appear manageable, predictable and confirm on target activity in surro-
gate tissue.
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The Applicability of the Proposed IASLC Staging Revisions to
Small-cell Lung Cancer (SCLC) with Comparison to the Cur-
rent Ajcc 6Th TNM Edition
S. I. Ou, J. A. Zell, Chao Family Comprehensive Cancer Center, University
of California Irvine Medical Center, Orange, CA
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Purpose/Objective(s): We examined the impact of the proposed IASLC
TNM and stage grouping revisions on staging and survival outcome of small
cell lung cancer (SCLC).
Materials/Methods: 10,660 SCLC patients from the California Cancer
Registry (CCR) between 1991 to 2005 with complete TNM staging were
identified and re-classified according to the IASLC proposed TNM revisions
and new stage groupings. Surveillance Epidemiology and End Results
(SEER) extent of disease codes (EOD) were used to identify various T4 and
M descriptors. Cox proportional hazards regression was used to identify
prognostic factors.
Results: Survival was correlated with both N category and the current
UICC6 and IASLC proposed T descriptors. Patients without mediastinal
lymph node involvement (N 0–1) had superior survival than patients with
mediastinal lymph node involvement (N 2–3). IASLC stage groupings
results in better separation of survival curves among early stage SCLC than
the current UICC6 stage groupings by univariate and multivariate analysis.
Pleural effusion (IASLC M1a) in SCLC had survival similar to other IASLC
M1a categories-pericardial effusion and contralateral intra-pulmonary me-
tastasis by pairwise hazard ratio (HR) comparisons.
Conclusions: IASLC proposed TNM staging results in better separation of
stage-specific SCLC survival curves than the current UICC6 staging system.
The new IASLC M1a descriptors (pleural effusion, pericardial effusion, and
contralateral/bilateral intrapulmonary metastasis) adequately prognosticate
SCLC patients as having metastatic disease.
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Expression and Function of PAX5 Transcription Factor in
SCLC
R. P. Kanteti, V. Nallasura, S. Loganathan, S. Krishnaswamy, L. Faoro, R.
Jagadeeswaran, E. E. Vokes, R. Salgia, University of Chicago, Chicago, IL
PAX transcription factors play an indispensable role in a variety of devel-
opmental processes and are usually absent in the adult organism, however
several reports have indicated that they are frequently expressed in a variety
of cancers. Using cancer lines that represent aero-digestive malignancies and
pancreatic cancer, we discovered that PAX5 was selectively expressed in
small cell lung cancer (SCLC) but not in non-SCLC (NSCLC), mesotheli-
oma, pancreatic, esophageal and head and neck cancer cell lines. Related
PAX2, PAX8 and PAX9 proteins were however not detected in SCLC cells.
In comparison, the NSCLC cell lines expressed PAX8, PAX2 and PAX9
proteins were found to be sporadically expressed in various cell lines. The
intensity and frequency of PAX5 expression increased from pulmonary
carcinoid, to large cell neuroendocrine carcinoma to SCLC. Although we
failed to detect any PAX5 translocation, we however saw polypoidy in some
of the SCLC samples. Since SCLCs express relatively high levels of the
RTK, c-MET, we determined whether PAX5 transcription factor regulates
expression of c-MET. Using minimal promoter of c-MET linked luciferase
reporter and ChIP assays, we showed that PAX5 can directly activate c-MET
transcription. Using PAX5 knockdown SCLC cells, we also showed a
concomitant loss in c-MET expression. Apart from transcriptional regulation,
we also discovered colocalization of PAX5 with phospho-c-MET in the
nucleus and significant interaction between the two. Finally, the abrogation
of PAX5 expression in SCLC cells resulted in a significant loss in viability
that was especially enhanced when combined with SN38 (TOPO1 inhibitor)
and SU11274 (c-MET inhibitor) treatments. We therefore suggest that PAX5
can be used as a biomarker to distinguish SCLC from other lung cancer
tumors and also as target for cancer therapy.
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Skin Necrosis Following Stereotactic Body Radiation Therapy
for Stage I Non-small Cell Lung Cancer: Who’s at Risk?
B. S. Hoppe, B. Laser, A. Kowalski, S. Fontenla, E. Pena-Greenberg, E.
Yorke, M. Lovelock, M. Hunt, K. Rosenzweig, Memorial Sloan-Kettering
Cancer Center, New York, NY
Purpose: We examined the rate of acute skin toxicity within a prospectively
managed database of patients treated for stage I non small cell lung cancer
(NSCLC) using stereotactic body radiotherapy (SBRT) and investigated
factors that might predict skin toxicity.
Methods: From May 2006 through January 2008, 50 patients with stage I
NSCLC were treated at Memorial Sloan Kettering Cancer Center with 60 Gy
in 3 fractions or 44–48 Gy in 4 fractions. After setup in the custom
immobilization cradle, pretreatment image acquisition, registration, and
setup correction was performed by registering the GTV as visualized on the
cone beam CT with that on the planning scan. Patients were treated with
multiple coplanar beams (3 to 7, median 4) with a 6 MV linac using intensity
modulated radiotherapy and dynamic multileaf collimation. Patients were
advised to apply a moisturizer prophylactically to the irradiated skin. Tox-
icity grading was based on the CTCAE- V3.0. Factors associated with grade
2 or higher acute skin reactions were analyzed by Fisher’s exact test.
Results: After a minimum 3 months of followup, 19 patients (38%) devel-
oped grade 1; 4 patients (8%) had grade 2; 2 patients (4%) had grade 3; and
1 patient had grade 4 acute skin toxicity. Timing from SBRT to acute skin
reaction ranged from 3 to 6 weeks (median 4 weeks). 6 patients developed
a reaction on their back and one on her side. Factors associated with grade
2 or higher acute skin toxicity included using only 3 beams (p0.0007),
distance from the tumor to the posterior chest wall skin  5 cm (p0.006),
and maximum posterior skin dose  50% of the prescribed dose (p0.02).
Conclusions: SBRT can be associated with significant skin toxicity. One
must consider the skin dose when evaluating the treatment plan. Our current
SBRT technique utilizes posteriorly directed beams for posterior lesions, and
these beams traverse the couch and immobilization device, which can lead to an
underestimation of the actual posterior skin dose by as much as 40%. This may
explain why these reactions predominantly occur on patients’ backs. Further
investigations include modifying the immobilization device, using more non-
overlapping beams, and using non-coplanar beams to reduce skin toxicity.
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Impact of Tumor Size on Outcomes in Stereotactic Body Radio-
therapy for Lung Cancer
Y. Matsuo1, K. Shibuya1, Y. Nagata2, K. Takayama1, Y. Norihisa1, T.
Mizowaki1, M. Narabayashi1, M. Hiraoka1, 1Kyoto University, Kyoto, Japan,
2Hiroshima University, Hiroshima, Japan
Purpose/Objective: The purpose of this study was to investigate factors
which have an influence on clinical outcomes in stereotactic body radiother-
apy (SBRT) for lung cancer.
Materials/Methods: We retrospectively reviewed patients with pathologi-
cally confirmed lung cancer who underwent SBRT with 48 Gy in 4 fractions
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at the isocenter. Those factors were evaluated including age, sex, perfor-
mance status, pulmonary function, histology, tumor size, minimal dose and
D95 of PTV, and tumor markers (CEA, SCC, CYFRA, and NSE) with regard
to local failure and disease progression which means loco-regional failure
and/or distant metastasis.
Results: Between September 2003 and May 2007, 54 patients were accept-
able for analysis for this study. Forty-four patients were male, and 10 were
female. Mean age was 76 years old. Histology was squamous cell carcinoma
in 22 patients, adenocarcinoma in 26, large cell carcinoma in 1 and non-small
cell carcinoma in 5. Fifteen patients showed disease progression including 5
patients with local failure as the first site, with median follow-up of 20
months. No significant difference was observed in any of the factors except
tumor size between the local failure group and the local control group. Mean
tumor sizes were 25.1 mm in the local control group, and 32.2 mm in the
local failure group (P  0.014). Tumor size was the only significant factor
with regard to disease progression, as well. Mean tumor sizes was 23.3 mm
in disease free patients, and 31.6 mm in patients with disease progression
(P0.001). Local control rates and disease-free survival rates at 2 years after
SBRT were 100% and 90.9%, 93.3% and 57.5%, and 59.1% and 31.5% for
the patients with tumors within 20 mm, tumors between 20 mm and 30 mm,
and tumors more than 30 mm, respectively.
Conclusions: Tumor size was a significant factor which affects both local
failure and disease progression in SBRT for lung cancer. More intensive
treatment might be needed for SBRT for large tumors.
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Wedge Resection with Permanent I-125 Brachytherapy for
Early Stage Non-small Cell Lung Cancer (NSCLC) using a
Prefabricated Absorbable Mesh Technique
M. A. Manning, P. Burney, M. K. Mohamed, E. Carey, K. Bell, Moses Cone
Health System, Greensboro, NC
Purpose/Objective(s): Lobectomy is standard of care for stage I NSCLC,
but it reduces pulmonary reserve. Patients with pulmonary dysfunction may
tolerate curative wedge resection with an I-125 mesh implant. We report
results using this technique with and without a novel prefabricated mesh
device.
Materials/Methods: Between 7/06 and 5/08, 56 patients with clinical stage
I NSCLC had wedge resection and brachytherapy. All had PET-CT staging
and were ineligible for lobectomy. Median age was 72 (48–87) and median
FEV-1 was 1.3 liters (0.6–3.4 liters). At surgery, a significant proportion
were upstaged. Pathologic staging confirmed 60.7% to be stage IA and
23.2% stage IB. Others were IIA (3.6%), IIB (5.4%), IIIA (1.8%), IIIB
(1.8%), and IV (3.6%). All implants consisted of absorbable polyglactin
mesh containing a median of 40 (30–50) I-125 seeds with a median seed
activity of 0.536 mCi (0.47 - 0.63 mCi). Half of the patients received mesh
prepared intraoperatively, while the second half received patient-specific
prefabricated mesh (BrachyMESH - Oncura).
Results: The median hospital stay was 5 days. All were immediately
extubated. Common toxicities included air leak delaying chest tube removal,
leukocytosis, paroxysmal atrial fibrillation, and increased secretions. Two
required repeat chest tube placement for subsequent pneumothorax. Two
patients with severe pre-op pulmonary dysfunction (pre-op FEV-1 of 0.6 and
0.68 liters) experienced respiratory failure and expired following prolonged
hospital stays. With a median follow-up of 7 months (0–23 months), overall
survival is 87.5% and disease free survival is 89%. The local control was
96.4% with the intraoperative mesh and 100% with the prefabricated mesh.
Conclusions: Wedge resection with permanent I-125 mesh implant is a
generally well-tolerated procedure leading to acceptable early local control in
patients ineligible for lobectomy. This technique may not be suitable for
patients with pre-op FEV-1 0.7 liters; but, it provides accurate surgical
staging conferring a diagnostic advantage over non-invasive treatment mo-
dalities. The prefabricated device offers similar results to manually prepared
devices.
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The Cleveland Clinic Experience with two Stereotactic Body
Radiation (SBRT) Fractionation Schedules for Early Stage Non-
small Cell Lung Cancer (NSCLC): A Comparison of Outcomes
G. M. Videtic, K. Stephans, M. Burdick, C. Reddy, T. Djemil, Cleveland
Clinic, Cleveland, OH
Purpose/Objective(s): To report on two SBRT schemes used in medically
inoperable early-stage NSCLC employing the same treatment platform.
Materials/Methods: 94 treatments in 86 patients involved either 50 Gy in 5
fractions (n56) or 60 Gy in 3 fractions (n38) from 10/2003 to 8/2007.
The Novalis/BrainLab system was used for planning; treatment delivery
employed abdominal compression. We looked for associations between PET
SUV, age, KPS, gender, tumor stage, smoking history or dose schedule and
local control (LC), nodal failure (NF), distant metastases (DM), and overall
survival (OS), acute and delayed toxicities.
Results: Age, gender, KPS, smoking pack-years and status, tumor size,
pre-treatment hemoglobin, PET SUV and FEV1/DLCO were balanced be-
tween the groups. Median age was 73 years and median KPS 80. 69 lesions
were T1, 24 were T2. Median tumor size was 2.2 cm in the 50 Gy group and
2.35 cm in the 60 Gy group (p0.43). Median follow-up was 15.3 months.
Actuarial rates for OS as well as LC, NF, and DM were unaffected by
fractionation. For 50 Gy and 60 Gy: at one year, LC was 97.3% v 100%, NF
7.3% v 3.4%, DM rate 21.8% v 29.5%, and OS was 83.1 v 76.9%, with no
differences significant. In univariable analysis, PET SUV did not predict for
LC, NF, DM, or OS by dose. KPS above 80 was associated with more NF
and DM (p0.04, p0.005) but not with OS (p0.9116). Greater smoking
history and larger tumor size were multivariate predictors of lower OS
(p0.022, p0.009). There was one case (1.2%) of clinical grade 3 pneu-
monitis. No significant decline in FEV1 or DLCO at 6 months was noted by
fractionation schedule. 9 patients (10%) had late chest wall toxicity that was
more frequent with 60 Gy vs. 50 Gy (7 of 38 v 2 of 56, p0.028). Median
time to chest wall toxicity was 8.4 months in the 60 Gy group. A trend for
chest wall toxicity with greater tumor dimension was noted (2.8 cm in those
with toxicity v 2.2 cm in those without, p0.054).
Conclusions: Both fractionation schedules are associated with excellent LC
and OS. The incidence of late chest wall toxicity was significantly associated
with the 60 Gy schedule.
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Influence of Age on Choice of Therapy and Surgical Outcomes
in Patients with Non-small Call Lung
W. D. Bolton, A. Correa, W. Hofstetter, R. Mehran, K. Pisters, J. Roth, S.
Swisher, A. Vaporciyan, G. Walsh, D. Rice, MD Anderson Cancer Center,
Houston, TX
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Purpose/Objective(s): US census data predict expansion of the elderly
population until 2050 and non small lung cancer (NSCLC) incidence is
expected to rise accordingly. The purpose of this study was to examine trends
of lung cancer management and outcomes of surgery in the elderly popula-
tion
Materials/Methods: A retrospective analysis was performed on two sepa-
rate datasets at the UT M.D. Anderson Cancer Center for the years 1997 to
2006. An institutional dataset (n  5950) including patients with NSCLC
was examined to determine patterns of management. A separate surgical
dataset (n  1756) was examined to determine surgical outcomes. ‘Elderly’
was defined as 70 years old or greater.
Results: Median age in the registry dataset (n  5950) was 65 years and of
these 1427 (24%) underwent surgery. Of 1159 patients with clinical stage I
NSCLC (median age 69 years), 788 (68%) underwent surgery. Patients in the
youngest age quartile were more likely to undergo surgery, whereas those in
the oldest quartile were less likely (p0.001). Using the surgical dataset (n
 1756), there were 643 (37%) elderly patients (median age 74 years vs. 61
years for younger patients). Older patients had higher (3 points) Charlson
Comorbidity Index (CCI) scores (20% vs. 11%, p0.001). Stage I tumors
were more common in older patients (75% vs. 61%, p0.001). Sub-anatomic
resections were more common in older patients (15.4% vs. 11%, p 0.008).
Pulmonary and cardiac complications were more frequent in older patients.
30-day mortality was lower for younger patients (1.3% vs. 2.9%, p  0.02)
but no difference in combined 30 day/in-hospital mortality was noted (2.9%
vs. 4%). Overall 5-year survival was 59.1% for younger and 49.9% for older
patients (p 0.001). On multivariable analysis, age 70, male gender,
increasing CCI score, and pathologic stage were independent predictors of
worse survival
Conclusions: Increasing age is an independent risk factor for surgical
outcome and also long term survival following pulmonary resection for
NSCLC and appears to influence choice of initial treatment and extent of
resection. Although surgery in the elderly carries higher risk than in young
patients, long-term cure can still be achieved in a significant number of
patients.
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Local Control and Survival Following Concomitant Chemora-
diotherapy in Inoperable Stage I Non-small Cell Lung Cancer
(NSCLC)
M. Campeau, A. Herschtal, G. Wheeler, M. MacManus, A. Wirth, M.
Michael, A. Hogg, E. Drummond, D. Ball, Peter MacCallum Cancer
Centre, Melbourne, Australia
Purpose/Objective(s): Concomitant chemoradiotherapy (CRT) increases
survival rates compared to radical radiotherapy alone (RT) in stage III
NSCLC, as a result of improved local control. The effect of CRT on local
control in stage I NSCLC is less well documented. We therefore retrospec-
tively reviewed local control and survival following CRT or RT for inoper-
able stage I NSCLC patients at our institution.
Materials/Methods: To be eligible for this review, patients had to have
histologically/cytologically proven inoperable stage I NSCLC and to have
undergone complete staging investigations including an F-18 FDG PET scan.
Radiotherapy was planned as (a) 60 Gy in 30 fractions over 6 weeks with or
without concomitant chemotherapy (single-agent carboplatin or cisplatinum-
based doublet); or as (b) 50–55 Gy in 20 fractions without chemotherapy.
Results: Between January 2000 and December 2005, 73 patients were
treated as follows: CRT (60 Gy) - 39; RT (60 Gy) - 23; RT (50–55 Gy) - 11.
The median follow-up time was 18 months (range, 1–81 months). Analysis
was performed as an intent to treat analysis. Four patients did not receive
treatment as planned (CRT: n  1, RT: n  3). The local progression free
survival at 2 years was 66% (95% CI, 49–81%) with CRT and 55% (95%
CI, 28–79%) with RT. The 2-year distant progression free survival was 60%
(95% CI, 41–76%) following CRT and 63% (95% CI, 41–80%) after RT.
The 2-year progression free survival rates were 57% (95% CI, 39–73%) and
50% (95% CI, 28–72%), respectively. The 2-year survival rate for patients
treated with CRT was 57% (95% CI, 41–72%) and 33% (95% CI, 18–51%)
in patients receiving RT.
Conclusions: In spite of the use of CRT and routine staging with FDG PET,
both local and distant recurrence remain important causes of treatment failure
in patients with inoperable stage I NSCLC.
Author Disclosure Block:
M. Campeau, None; A. Herschtal, None; G. Wheeler, None; M. MacMa-
nus, None; A. Wirth, None; M. Michael, None; A. Hogg, None; E.
Drummond, None; D. Ball, None.
107
Four-dimensional Lung Tumor Tracking for Peripheral and
Central Tumors during Stereotactic Radiotherapy: The Dose is
Important
J. Nuyttens1, N. van der Voort van Zijp1, M. Hoogeman1, J. Praag1, R. van
Klaveren1, P. Pattynama2, P. Levendag1, 1Erasmus MC/Daniel den Hoed
Cancer Center, Rotterdam 3008 AE, Netherlands, 2Erasmus MC, Rotterdam
3008 AE, Netherlands
Purpose/Objective(s): To report on local recurrence, and fiducial placement
toxicity of the first 121 tumors in the lung treated at our institution with the
CyberKnife.
Materials/Methods: Of the 121 tumors, 95 were early stage lung cancer
tumors and 26 oligo- or solitary metastases. Seventy-seven tumors were  3
cm and 44 were 3 cm. In total, 18 tumors were located centrally. Platinum
fiducials and intravascular embolisation coils were used as markers. In total,
357 markers were placed: 107 intrapulmonal for 41 tumors, 236 intravascular
for 77 tumors, 10 extrapulmonal in 2 patients for fixed tumors to the
thoracical wall, and 4 bronchoscopically placed markers in 1 patient. Eighty
six peripheral tumors were treated with a total dose of 60 Gy (20 Gy/fr), 17
with a total dose of 45 Gy (15 Gy/fr). Central tumors were treated with 6*8
Gy (6 tumors), 5*9 Gy (5 tumors) or 5*10 Gy (7 tumors). PTV  GTV 
5 mm. The dose to the PTV was prescribed to the 70–85% isodose line. The
response was evaluated according to the RECIST criteria with a CT 8–12
weeks after the last treatment and routinely thereafter. The median follow up
was 10.2 months (range, 2–30). The median age was 75 years old (range:
34–90).
Results: The 2-year local control for peripheral tumors with a total dose of
60 Gy and those with 60 Gy was 97% and 66% (p0.01), respectively.
Local control at 15 months for central tumors was 74%. In total, 8 tumors in
6 patients recurred locally: 2 tumors were treated with 60 Gy (20 Gy/fr), 4
tumors with 45 Gy (15 Gy/fr), and 2 with 45 Gy (9 Gy/fr). Seven patients
(6%) had a pneumothorax after intrapulmonal placement. A thorax drain was
placed in 3 patients.
Conclusions: Four-dimensional tumor tracking for tumors in the lung
resulted in a 2 year local control of 96% with doses of 60 Gy in 3 fractions.
Six local recurrences were reported with a total dose of 45 Gy in 3 or 5
fractions. For this reason we treat peripheral tumors with 3x20Gy and
escalated the dose for central tumors to 5 fractions of 10 Gy and currently to
5 fractions of 12 Gy. Due to the availability of alternative marker implan-
tation methods for high-risk patients, a low toxicity was observed for marker
placement.
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Continuous Subpleural Infusion of Local Anesthetic Improves
Pain Control after Video-Assisted (VATS) Lobectomy
S. Oseni1, P. Prest2, B. Egleston1, D. Edmondson1, J. Flaherty1, A. Leb-
enthal1, W. Scott1, 1Fox Chase Cancer Center, Philadelphia, PA, 2Philadel-
phia College of Osteopathic Medicine, Philadelphia, PA
Purpose: Epidural analgesia and/or systemic narcotics are used for pain
control after VATS lobectomy but can cause hypotentsion, urinary retention,
itching, respiratory depression, somnolence and nausea. We examined the
effect of a continuous subpleural infusion of local anesthetic on pain control
and narcotic use after VATS lobectomy.
Methods: With IRB approval, we reviewed consecutive patients undergoing
VATS lobectomy for clinical stage I lung cancer. Control patients received
only patient-controlled narcotic analgesia (PCA) for at least 24–48 hours
with supplemental narcotics as needed (PCA group). Intervention patients
received the same regimen with local anesthetic infusion (ropivacaine 0.2%)
through subpleural catheters (SC) placed during VATS (SC group). Pain was
measured with a visual analog pain scale (VAS). Inverse probability of
treatment weighted estimators, with weights derived from propensity scores,
were used to balance covariates known to influence perioperative outcomes
(gender, age, preop FEV1, and Charlson comorbidity index) between co-
horts. Bootstrap methods provided standard errors. Narcotics administered
were converted into morphine equivalents and reported as total dose or total
dose per body mass index (BMI). Endpoints were mean highest pain score
and narcotic use for postop 0–24 and 25–48 hours.
Results: We evaluated 64 patients (29 PCA, 35 SC). Mean pain scores were
not significantly different between groups (3.23 PCA v 3.48 SC for 0–24 hrs
(p .68); 2.58 PCA v 3.32 SC for 25–48 hrs (p .27). Mean total morphine
dose (mg) and mean total morphine dose/BMI were both significantly
decreased in the SC group for the 0–24 hr period only (mean total morphine
38.1 v 27.8, p.024 and mean total morphine/BMI 1.15 v .79, p .024).
Length of stay and overall complications did not differ between groups. We
identified no complications of local anesthetic infusion. Conclusion: PCA
narcotic analgesia with subpleural local anesthetic infusion provided similar
pain control with less narcotic use in patients during the first 24 hrs after
VATS lobectomy compared to PCA narcotic analgesia alone. These findings
merit prospective study.
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SUVs from Staging FDG-PET do not Predict Treatment Out-
comes for Early Stage NSCLC Treated with SBRT
M. J. Burdick, K. L. Stephans, C. A. Reddy, T. Djemil, G. M. M. Videtic,
Cleveland Clinic, Cleveland, OH
Purpose/Objective(s): To determine whether standardized uptake values
(SUVs) from staging 2-deoxy-2-[18F] fluoro-D-glucose (FDG) positron
emission tomography (PET) studies are associated with outcomes for early
stage non-small cell lung cancer (NSCLC) treated with stereotactic body
radiotherapy (SBRT).
Materials/Methods: Seventy-four medically inoperable patients with doc-
umented pre-treatment PET SUVs were treated between 10/17/03 and
8/17/07 with SBRT for T1N0M0 or T2N0M0 NSCLC. SBRT was admin-
istered as 60 Gy in 3 fractions, 50 Gy in 5 fractions, or 50 Gy in 10 fractions
using abdominal compression and image-guided SBRT. Cox proportional
hazards regression was performed to determine whether PET SUV, age,
KPS, gender, tumor stage, or smoking history influenced the following
outcomes: nodal failure (NF), distant metastases (DM), and overall survival
(OS). PET SUV was evaluated both as a continuous variable and a dichot-
omous variable (5 or 5).
Results: Biopsy proof of lung cancer was feasible only in 50 patients
(67.6%) and was contraindicated in the remainder. Fifty patients had T1N0
disease and 24 had T2N0 disease. Median SUV was 6.5 (range 2–60).
Twenty patients had SUVs 5 while 54 had SUVs’5. Median follow up was
15.3 months (range 1.9–47.6 months). There were 3 local failures, 6 nodal
failures, 17 distant metastases, and 20 deaths. 10 patients had no evidence of
disease at the time of death, 5 died of unknown causes, and 5 deaths were due
to cancer. One-year local control, NF, DM, and OS rates were 95.6%, 6.9%,
25.3%, and 84.2%, respectively. In univariable analysis, PET SUV, defined
either as a continuous or dichotomous variable, did not predict for NF, DM,
or OS. On multivariable analysis, both T1 stage predicted for OS with a RR
0.298 (p  0.0086, 95% CI 0.121–0.735) and smoking pack-year history
predicted for OS with a RR of 1.016 (p  0.0237, 95% CI 1.002–1.029).
Conclusions: Pretreatment PET SUVs did not predict for NF, DM, or OS in
patients treated with SBRT for early stage NSCLC.
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Importance of Image Guided Patient Setup in Stereotactic Body
Radiation Therapy (SBRT) of Early Stage NSCLC
W. A. Hall, A. Sethi, R. B. Love, S. N. Nagda, Loyola University Stritch
School of Medicine, Maywood, IL
Purpose: Patient setup errors can significantly alter target dose in radiation
therapy. Image guided radiation therapy (IGRT) has the potential to reduce
setup errors that may be critical in SBRT due to relatively small target
margins used. We quantify setup errors in stage I NSCLC patients undergo-
ing SBRT and evaluate their impact on target dose.
Methods and Materials: Twenty-nine stage I lung cancer patients treated
with SBRT (median 50 Gy/5 Fx) were included in the study. 153 setup
fractions were evaluated. Prior to treatment, patients were setup on the
treatment table in a two-step process. First, each patient was aligned to
treatment position using infrared (IR) markers placed on the chest. This
procedure is equivalent to patient setup in a non-IGRT environment. Next,
orthogonal kV x-rays were taken and compared to digitally reconstructed
radiographs (DRR) of the treatment isocenter obtained from planning CT.
Novalis Exactrac® 5.5 (BrainLAB, Germany) was used to robotically move
the patient to the treatment isocenter and verification x-rays were taken prior
to treatment. The magnitudes of correction shifts in the lateral, longitudinal,
and vertical direction were recorded. These shifts represent setup errors that
would result if the patients were treated without IGRT. Finally, we calculated
the mean setup error for each patient and evaluated its impact on the
delivered target dose using dose volume histograms.
Results: Mean(mm)  SD (range) errors in the lateral, longitudinal, and
vertical direction were 3.48  3.49 (19.51, 21.3), 5.29  5.1 (20.19,
14.2), and 4.37  4.51 (25.35, 24.04) respectively. The overall mean
setup error (radial vector) for all fractions was 7.79  7.64mm. The dose
impact of not accounting for setup errors on a representative sample of
patients (spanning typical targets) was found to be 26.1% lower target
prescription dose and 38.3% reduction in target minimum dose.
Conclusion: Patient setup errors can be quantified using IGRT. In SBRT of
early stage lung patients, these errors can lead to unacceptably large reduc-
tion in target dose. We recommend use of custom target margins based on
IGRT derived setup data for SBRT procedures.
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Excellent Negative Predictive Value (NPV) of Early PET-CT in
the Follow-up of Lung Cancer Pts Treated with Stereotactic
Radiation Therapy (SRT)
C. Aitken1, D. Johnstone1, A. Recht2, M. Seltzer1, 1Dartmouth-Hitchcock
Medical Center, Lebanon, NH, 2Beth Israel Deaconess Medical Center,
Boston, MA
Purpose/Objective: SRT is increasingly used for pts with medically inop-
erable lung cancer. The role of PET-CT in following such pts is not clear. We
therefore reviewed our experience in this area.
Materials and Methods: 14 pts with newly diagnosed clinical Stage I (10)
or recurrent (4) cancer without evidence of nodal disease were treated with
4-dimensional linac-based stereotactic radiation therapy and had at least 1
follow-up PET-CT. 11 pts had 2 or more follow-up PET-CT scans. Pts
received 3750 cGy in 3 fractions (peripheral tumors) or 3–6 fractions
(central/hilar tumors). Dose was prescribed to the 65–87% isodose line. Pts
were followed with PET-CT every 3 mo for the first year and then every 6
mo. A negative PET-CT was defined as no residual activity greater than
mediastinal blood pool activity.
Results: The primary site was PET-negative on the first PET-CT (median 2.3
mo after SRT) in 8 of 14 pts. Six of these patients remained free of disease
at a median follow-up of 7.5 mo and 2 pts have not had subsequent imaging.
Of the 6 pts with persistent FDG avidity at the treated site, 4 have had
additional PET-CT: 1 had concurrent development of a new avid 2-mm
superior mediastinal node. At 1 year, this pt had metastatic disease and
persistent PET-activity at the treated site; 1 had increased PET activity. On
6 mo follow-up scan he developed metastatic disease, with continued local
persistence. The remaining two pts had decreased, but persistent activity;
both became PET-negative at the 6-month scan. Ten pts had 2 or more
PET-CT scans. The NPV and positive predictive values (PPV) of the first
PET for subsequent local failure were 100% and 60%, respectively. The
crude local control rate was 76%.
Conclusions: These early results suggest that early PET-CT following SRT
predicts outcome at the treated site. Additional pts and further follow-up are
needed to confirm this finding.
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Induction Chemotherapy Followed by Thoracic Irradiation
with or without Concurrent Chemotherapy in Locally
Advanced Inoperable NSCLC: A Randomized Multicenter
Italian Phase III Trial.
M. Tiseo1, L. Boni2, T. Scolaro2, G. Fasola3, U. Ricardi4, V. D’Alessandro5,
F. De Marinis6, A. Favaretto7, A. Grimaldi8, A. Ardizzoni1, 1University
Hospital of Parma, Parma, Italy, 2National Institute for Cancer Research,
Genova, Italy, 3Azienda Ospedaliero-Universitaria Santa Maria della Mi-
sericordia, Udine, Italy, 4University of Torino, S Giovanni Battista Hospital,
Torino, Italy, 5IRCCS Casa Sollievo della Sofferenza, S.G. Rotondo, Italy,
6San Camillo-Forlanini, Roma, Italy, 7Istituto Oncologico Veneto IRCCS,
Padova, Italy, 8Ospedali Galliera, Genova, Italy
Background: The combination of chemotherapy (CT) and radiotherapy
(RT)is standard of care in the treatment of inoperable stage III NSCLC. The
aim of this trial was to assess whether the addition of concurrent (CT) to
thoracic RT following induction CT was able to improve treatment outcome.
Methods: Eligible patients were required to have inoperable stage III
NSCLC, age 70 years, PS 1 and FEV1 1L. Planned accrual was 300
patients to detect a 30% mortality reduction with the addition of concurrent
CT in the experimental arm (a´  5%, aˆ  20%). Control arm consisted of
2 cycles of paclitaxel 200 mg/m2 combined with either carboplatin AUC 6 or
cisplatin 80 mg/m2 (investigator choice) followed by 60–61.2 Gy continuous
thoracic RT (180–200 cGy/fraction for 5 days/week for 6–7 weeks). Exper-
imental arm consisted of identical induction CT and thoracic RT with
concomitant paclitaxel 60 mg/m2 weekly for 6–7 weeks.
Results: Due to slow recruitment, accrual was terminated early, at the time
of the second planned interim analysis when 151 eligible patients had been
randomized. Patients characteristics were well balanced in the two arms
(median age 61 years; males 91%; stage IIIB 67%; PS 0 60%; squamous
histology 42%). Induction CT was well tolerated in both control and
experimental arm. RT was completed as planned in 88% and 77% of patients,
respectively, with a median total RT dose of 60 Gy in both arm. Nearly 80%
of patients in experimental arm completed concurrent weekly paclitaxel.
Treatment toxicity was manageable in both arms (G3–4 esophagitis 3 vs
8%), without statistically significant differences. Overall response rate and
median progression free survival did not differ according to treatment (54%
vs 52% and 7.1 vs 8.4 months). With a median follow up of 5 years, median
survival was 13.1 vs 15.1 months with a 3-year survival rate of 21.2% vs
21.9% in the control and experimental arm, respectively (HR 0.99).
Conclusions: Although the accrual was terminated early, the results of this
study, by means of a “futility analysis”, seem to exclude a clinically
meaningful benefit with the addition of concurrent weekly paclitaxel to
sequential chemoradiation.
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The Impact of Mediastinal Nodal Volume on the Outcome of
PET-Staged, Radically Resected Stage IIIA (N2) Non-small Cell
Lung Cancer (NSCLC)
D. W. Y. Wong1, M. M. Tin1, B. C. McCaughan1, M. J. Boyer1, P.
Fitzgerald2, 1Royal Prince Alfred Hospital, Sydney, Australia, 2NHMRC
Clinical Trials Centre, Sydney, Australia
Introduction: The management of Stage IIIA (N2) NSCLC is controversial.
This could be due to variation in the extent of N2 disease at presentation. We
hypothesized that among patients with N2 disease, those with the smallest
burden of nodal disease i.e. incidental nodal metastases detected on final
pathology would have superior outcome compared to those with obvious
nodal disease on staging CT or PET.
Method: We conducted a retrospective analysis of patients with pathologi-
cally confirmed N2 IIIA NSCLC, treated with radical surgery from January
1995 to December 2007 at the Sydney Cancer Centre. All patients were
staged with CT and PET prior to definitive treatment. The patients were
grouped into three categories: (1) those with obvious nodal disease on CT,
(2) with nodal disease detected only on PET (3) with incidental nodal
metastases found on final pathology. Mediastinoscopy was not routinely
performed.
Results: 195 patients were identified. 61% were males with median age 66
(range 41–83). 20% were diagnosed as Stage IIIA (N2) on CT, 42% on PET,
and 38% on final pathology. 30 day mortality was 2.6%. 92% had complete
resection. 34% had chemotherapy (56% neoadjuvant). 73% had adjuvant
radiotherapy. Group 1 had the highest proportion of patients receiving
chemotherapy but the rates of complete resection and adjuvant radiotherapy
were similar among the groups. Median follow-up was 27 months. Median
survival was 27.2 months for all patients, 25.2 months for Group (1), 24.2
months for Group (2) and 28.6 months for Group (3). 2 year disease free and
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overall survivals were 41.2% and 55% for all patients, 41.2% and 50.4% for
Group (1), 37.0% and 51.3% for Group (2), 44.5% and 61.6% for Group (3)
respectively (p value DFS 0.139, OS 0.107).
Conclusion: The overall outcome for this cohort of Stage IIIA (N2) NSCLC
patients treated with radical surgery  chemotherapy /radiotherapy is com-
parable to published data. Mediastinal nodal volume did not appear to affect
the outcome. This could be potentially due to the high rate of complete
resection, the greater proportion of patients with CT-detected nodes receiv-
ing chemotherapy and the ability of adjuvant radiotherapy to eradicate
residual microscopic disease.
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Pemetrexed and Cisplatin with Concurrent Thoracic
Radiation Therapy (TRT) Followed by Docetaxel in Stage III
Non-small Cell Lung Cancer (NSCLC) Patients (pts)
S. M. Gadgeel1, J. C. Ruckdeschel1, A. Wozniak1, B. Patel2, W. Chen1, R.
Venkatramanamoorthy1, D. Hackstock1, A. Turrisi1, 1Karmanos Cancer
Institute, Detroit, MI, 2John Dingell VA Medical Center, Detroit, MI
Purpose/Objective(s): Standard treatment of stage III NSCLC remains
concurrent chemotherapy and TRT. However not all chemotherapy drugs can
be combined with TRT at full systemic dosages. We are conducting a phase
II study evaluating the combination of pemetrexed and cisplatin, at full
systemic doses with TRT followed by docetaxel in stage III NSCLC pts.
Materials/Methods: Eligibility includes, stage IIIA or IIIB NSCLC, PS 
1, FEV1  1 liter, diffusion capacity  50%, predicted V20  40%. Pts
were treated with pemetrexed at 500 mg/m2 and cisplatin every 3 weeks for
3 cycles with concurrent TRT to 66 Gy. First 6 pts received cisplatin at
60mg/m2 and the following 11 pts received cisplatin at 75mg/m2. After
concurrent therapy, pts received docetaxel at 75mg/m2 every 3 weeks for 3
cycles with growth factor support. Planned accrual is 28 pts.
Results: 21 pts have been registered. Pt. characteristics: Median Age- 60
(47–77), 62% males, 67% stage IIIB, 52% adenocarcinomas. Median FEV1
was 2.3 liters (1.1–3.4) and median predicted V20 was 28% (7–40). 12 pts
(66%) have completed all 6 cycles of chemotherapy without dose reduction
and received TRT to 66 Gy. Five more pts received all 3 cycles of cisplatin
and pemetrexed with TRT. Grade 3/4 toxicities, all observed during concur-
rent therapy, were Grade 3/4 neutropenia- 8 pts, Grade 4- thrombocytopenia-
2 pts, Grade 3 renal failure- 2 pts, Grade 3 pneumonitis- 1 pt. Grade 3/4
esophagitis- 2 pts. Five pts were hospitalized for treatment related toxicities
during the concurrent treatment. Confirmed response by RECIST criteria was
observed in 10 pts (53%, Wilsons 90% CI- 34%–71%, 2 pts. not assessed).
4 more pts had tumor shrinkage. 4 pts have progressed- 2 pts had brain as the
only site of progression.
Conclusions: Combination of pemetrexed and cisplatin at full systemic
doses with concurrent TRT followed by docetaxel is feasible in pts with stage
III NSCLC. Toxicity and efficacy with this regimen, in treated pts, compares
favorably with other regimens tested. Accrual on the study is ongoing.
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Long-term Follow-up of a Phase I/II Trial of Dose Escalating
3-dimensional Conformal Thoracic Radiation Therapy with
Induction and Concurrent Carboplatin and Paclitaxel in
Unresectable Stage IIIA/B Non-small Cell Lung Cancer
T. E. Stinchcombe1, C. B. Lee1, D. T. Moore2, M. Rivera3, J. Halle4, S.
Limentani5, J. G. Rosenman4, M. A. Socinski1, 1Division of Hematology/
Oncology, Multidisciplinary Thoracic Oncology Program, Lineberger Com-
prehensive Cancer Center, University of North Carolina, Chapel Hill, NC,
2Division of Biostatistics and Data Management, Lineberger Comprehensive
Cancer Center, University of North Carolina, Chapel Hill, NC, 3Division of
Pulmonary Medicine, Multidisciplinary Thoracic Oncology Program,
Lineberger Comprehensive Cancer Center, University of North Carolina,
Chapel Hill, NC, 4Division of Radiation Oncology, Multidisciplinary Tho-
racic Oncology Program, Lineberger Comprehensive Cancer Center, Uni-
versity of North Carolina, Chapel Hill, NC, 5Carolinas Medical Center,
Charlotte, NC
Purpose/Objective(s): We conducted a modified phase I/II trial investigat-
ing the incorporation of dose escalating 3-dimensional conformal thoracic
radiation therapy (TCRT) into the treatment paradigm of induction and
concurrent carboplatin and paclitaxel in patients with unresectable stage
IIIA/B non-small cell lung cancer (NSCLC).
Materials/Methods: Patients received two cycles of induction carboplatin
(area under the curve (AUC) of 6) and paclitaxel (225 mg/m2) on days 1, and
22. On day 43 concurrent TCRT and weekly  6 of carboplatin (AUC2)
and paclitaxel (45 mg/m2) was initiated. The TCRT dose was escalated from
60 to 74 Gy in 4 cohorts (60, 66, 70, and 74 Gy), and the 74 Gy cohort was
expanded into a phase II trial. Results: : Sixty-two patients were enrolled; the
median age 57 years (range, 36–82), 38 were male (62%), 61 (98%) had a
performance status of 0 or 1, 27 (44%) had stage IIIA disease, 21 (34%)
had  5% weight loss, and the median FEV-1  2.10L (range 1.02 to 3.75).
With a median follow-up of 9.2 years (range 7.4 to 10.6 years) the median
progression-free survival (PFS), time to tumor progression (TTP), and
median overall survival (OS) (with 95% confidence intervals (CI)) were 10
months (8.5 to 17 months), 15 months (9 to 50 months), and 25 months (18
to 37 months), respectively. The 5-year PFS and OS rates (with 95% CI)
were 21% (12 to 32%) and 27% (17 to 39%), respectively. The 10-year OS
rate was 14% (95% CI, 7 to 25%). The rate of isolated brain metastasis
(n60) was 15% (95% CI, 7 to 27%), and the rate of local progression
(n53) was 34% (95% CI, 22 to 48%).
Conclusions: The 5-and 10-year overall survival rate observed on long term
follow-up compares favorably to other treatment approaches in patients with
stage III NSCLC. However, isolated brain metastases and local recurrences
continue to be a significant problem with this treatment approach.
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A Comparison of Gated and Non-Gated Radiotherapy for Lung
Cancer Using a Biological Model for Lung Dose
L. J. Lee1, R. Schneider2, E. Hutchinson2, J. Feng2, G. Sharp2, J. Wolfgang2,
K. Doppke2, A. Niemierko2, N. Choi2, 1Harvard Radiation Oncology Pro-
gram, Boston, MA, 2Massachusetts General Hospital, Boston, MA
Background: Tumor motion associated with normal respiration may lead to
significant changes in target position during radiation treatment for lung
cancer. For accurate targeting, our institution routinely uses four-dimensional
computed tomography (4DCT) to delineate tumor motion. To evaluate the
potential benefit of respiratory gating on lung dose, we compared DVH
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parameters and equivalent uniform dose (EUD) for gated and non-gated
treatment plans using 4DCT.
Methods: We retrospectively analyzed 4DCT data sets and treatment plans
for 7 patients treated with gated radiotherapy at Massachusetts General
Hospital from 2005–2007. For gated treatment, the GTV was contoured at
full expiration (50% phase). For non-gated treatment, the internal target
volume (ITV) was created from GTV composites at the 0 and 50% phase of
the respiratory cycle. PTV coverage was at least 95% of the prescribed dose
of 63 Gy in 1.8 Gy fractions. DVHs were generated for the GTV, ITV, PTV,
right lung, left lung, and combined lung. EUD was used to compare
inhomogeneous dose distributions for the gated and non-gated plans.
Results: Primary tumors were located in the right or left lower lobe with
superior to inferior (SI) peak-to-peak respiratory motion of 20–65 mm
(median SI25 mm). Movement in the lateral (lat) and AP direction was
4–10 mm (median lat5, AP9 mm). The median tumor size was 4.7 cm
(range: 2.6–7.3 cm). For non-gated radiotherapy, the individual ITVs ranged
from 14 to 480 cc (mean ITV167 cc). The individual GTVs were 8 to 261
cc (mean GTV103 cc) for gated treatment. The mean lung dose (MLD)
was 19.1 Gy for non-gated radiotherapy and 18.4 Gy for gated radiotherapy.
For all 7 patients, the EUD for lung was reduced for gated treatment by
0.1–2.4 Gy (1.0–11.9%).
Conclusion: This study represents an initial dosimetric comparison of gated
versus non-gated radiotherapy for lung cancer patients with lower lobe
tumors. Based on our clinical experience with 4DCT, primary lung tumors
located in the lower lobes can move significantly with diaphragmatic motion.
Initial findings suggest that gated treatment provides a variable degree of
lung sparing. Clinical predictors of lung sparing with gated radiotherapy
warrant further investigation.
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The Influence of Gender, Race and/or Marital Status on Sur-
vival in Lung Cancer Patients: Meta-Analysis of Radiation
Therapy Oncology Group (RTOG) Trials
B. Movsas1, K. Bae2, J. Coyne3, V. Gamerman2, C. Bryan3, R. Komaki4, C.
Langer3, H. Choy5, W. Curran6, D. Watkins Bruner3, 1Henry Ford Hospital,
Detroit, MI, 2Radiation Therapy Oncology Group, Philadelphia, PA, 3Uni-
versity of Pennsylvania, Philadelphia, PA, 4MD Anderson Cancer Center,
Houston, TX, 5UT Southwestern, Dallas, TX, 6Emory University, Atlanta, GA
Purpose/Objective(s): This analysis focuses on the influence of gender, race
and/or marital status on overall survival (OS) in RTOG non-operative
non-small cell lung cancer (NSCLC) trials.
Materials/Methods: This meta-analysis used data from 1365 patients treated
on 9 prospective RTOG non-operative NSCLC studies activated during the
1990’s. The combination of the presence of chemotherapy (yes vs. no) and
accrual year (1991–1994,1995–1998,1999–2002) were used to stratified the
data. Heterogeneity of the data was tested by 2 test statistics by Cochran for
the pooled hazard ratios (HR) weighted by its variance. The impact of
gender, marital status (married/partnered vs. single/divorced/widowed), and
race (White vs. Non-White) was considered. Analyses for subgroups by the
combination of gender, marital status, and/or race were also conducted. Cox
proportional hazards models were utilized. Age, KPS, weight loss, stage,
histology, location of primary tumor, biological equivalent dose, deviation
from protocol dose, and education level were adjusted in the model. A
two-sided p-value 0.05 was considered statistically significant.
Results: The data were homogeneous with respect to the HRs of OS. Males
had significantly (1.23 times) higher mortality than females adjusted for
other covariates (95% CI[1.1–1.4]). However, race and marital status were
not independently predictive for OS. White males (HR1.25) and Non-
White males (HR1.28) had significantly higher mortality than White
females. Single males (HR1.35) and married males (HR1.23) had sig-
nificantly lower OS than married females. Married White males (HR1.23),
single White males (HR1.46), and married Non-White males (HR1.33)
had significantly lower OS than married White females.
Conclusions: These results suggest that while certain combinations of
gender, race and/or marital status are important regarding OS, gender appears
to be the most significant factor driving survival results among non-operative
NSCLC patients. Research supported by PA Dept of Health CURE Program
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Mediastinal Nodal Volume Predicts for Survival in Stage III
NSCLC
B. A. Alexander1, M. Othus2, H. B. Caglar3, A. M. Allen3, 1Harvard
Radiation Oncology Program, Boston, MA, 2Dana-Farber Cancer Institute,
Boston, MA, 3Dana-Farber Cancer Institute/Brigham and Women’s Hospi-
tal, Boston, MA
Purpose: To determine if the volume of the primary tumor and/or medias-
tinal nodes correlate with outcome in Stage III NSCLC treated with CRT.
Materials and Methods: The records of patients treated with chemoradia-
tion (CRT) Between 9/01 and 7/06 at the Dana-Farber/Brigham and Wom-
en’s Cancer Center for stage III NSCLC were reviewed with IRB approval.
The primary tumor volumes in the lung parenchyma (TV) as well as
mediastinal nodal tumor volumes (NV) were retrospectively contoured as
separate structures in the ECLIPSE treatment planning system. Survival was
estimated using the Kaplan-Meier method and association of the variables
with outcome was assessed by a multivariate Cox proportional hazards
model.
Results: 107 patients were identified in this time period who met criteria for
analysis. 57 patients were male (53%). 4% had a ECOG performance status
of 2 and the remainder had a PS of 0–1. Median dose of RT was 60 Gy
(46–70Gy). 31 (29%) patients were treated with neoadjuvant CRT followed
by surgery and the remaining 76 patients were treated with CRT alone.
47(44%) patients had stage IIIA disease and the remainder had stage IIIB
NSCLC. The median follow-up is 15 months and the median potential
follow-up is 32 months. The median OS, LRC, DC is 15 mos, 10 mos and
10 mos respectively. The ability to undergo surgical resection to correlate
with improved OS. (p.0057) In this analysis in addition to surgery we
showed that increased TV as well as increased NV were inversely correlated
with OS. (HR-1.09 and p.00012 for NV and HR-1.035, p.0057) Inter-
estingly, these factors were also correlated with local control but not with
distant control as only stage ( IIIA vs IIIB) were correlated with distant
control (HR1.70 p.0035) . Removing the 31 patients who were resected
from the analysis the results were unchanged with both TV and NV inversely
correlated with OS. When we divided the data into quartiles the lowest
quartile for NV had a median survival of over 36 mos vs. 12 months for the
highest quartile with HR 2.08 p.0002. This was true whether or not patients
underwent surgical resection.
Conclusion: In a large series of patients treated with CRT for Stage III
NSCLC NV and TV were both significant predictors of survival with NV
being the most significant variable.
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Multimodality Therapy Improves Survival in Elderly Patients
with Locally Advanced Non-small Cell Lung Cancer
H. Paripati, N. J. Karlin, A. C. Dueck, H. J. Ross, Mayo Clinic Arizona,
Scottsdale, AZ
Purpose/Objective: Concurrent combined modality therapy is optimal treat-
ment for patients (pts) with Stage III non-small cell lung cancer (NSCLC).
However, elderly pts (75) often receive palliative chemotherapy or sup-
portive care only, despite good performance status. This study evaluated the
treatment, outcomes and survival in elderly pts with Stage III NSCLC versus
pts 75 years old.
Materials/Methods: A retrospective review of data from the Lung Cancer
Registry at Mayo Clinic Arizona (MCA) was conducted. Pts with newly
diagnosed Stage III NSCLC from 1998–2006 were analyzed for type of
therapy, outcomes and survival.
Results: 394 pts with newly diagnosed Stage III NSCLC were identified
from 1998 –2006. 246 (62%) pts were 75 years old, and 148 (38%) were
75 years old. Among 379 patients with treatment data available, 44.5%
of pts 75 years old received combined chemoradiation therapy vs. only
21% of pts  75 years old (p0.0001). The median survival in the 75
age group was 14 months vs. 10 months in the 75 age group (p 
0.0014). In the 75 age group, median survival was 16 months in pts who
received combined modality treatment vs. 14 months in the other treat-
ments group (p  0.0177). In the elderly group, median survival was 15
months in the combined modality group vs. 8 months in the pts who
received other treatments (p  0.0042). Thus, the median survival was
significantly improved among the pts who received combined chemora-
diation independent of age.
Conclusions: Optimizing oncologic care for geriatric pts is an emerging field
in oncology. Clinical trial enrollment, outcome and toxicity data for elderly
pts with cancer is sparse. Our results confirm that older pts are less likely to
receive optimal therapy and are often treated palliatively, regardless of
functional or comorbidity status. Similar studies are desperately needed to
help improve management of the burgeoning geriatric oncology population.
Physician bias, patient bias, lack of formal geriatric assessment, and social
issues may all contribute to underuse of potentially curative therapy and poor
clinical trial accrual for older patients.
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Imaging Cellular Proliferation During Therapy: A Pilot Study
of Serial 18F-FLT-PET Scanning During Chemoradiation for
Non-small Cell Lung Cancer
S. J. Everitt1,2, R. J. Hicks1, T. Kron1, M. Schneider-Kolsky2, D. Binns1, T.
Walter1, D. Ball1, M. Mac Manus1, 1Peter MacCallum Cancer Centre,
Victoria, Australia, 2Monash University, Victoria, Australia
Purpose/Objective(s): We report the results of a prospective study of the
effects of chemoRT on serial18F-3-deoxy-3-fluoro-l-thymidine (18F-FLT)-
PET scans in patients with non-small cell lung cancer (NSCLC). FLT is a
marker of cellular proliferation in normal and tumor tissues.
Materials/Methods: Five patients with locally-advanced NSCLC underwent
radical chemoRT (60 Gy in 6 weeks with concurrent cisplatin and etoposide).
RT was planned using baseline FDG-PET/CT. Patients also underwent
baseline and serial 18F-FLT PET/CT scans during RT. Each patient had 2
FLT-PET scans during RT, selected from days 2, 8, 15 and/or 29 to provide
a range of time-points for response assessment.
Results: Baseline 18F-FLT PET/CT scans were concordant with baseline
18F-FDG PET/CT scans at all primary sites. Subsequent 18F-FLT PET scans
showed dramatic changes in tumor and normal tissues during chemoRT.
18F-FLT uptake in tumor was seen on day 2 (after 2Gy) (2/2 cases), on day
8 (2/2 cases) and on day 29 (only 1/3 cases). A flare of 18F-FLT tumoral
uptake occurred in one case after 2Gy (SUVmax 1.22 x baseline), followed
by reduced FLT activity at 10Gy to 0.60 x baseline. The second patient
scanned after 2Gy had a decrease in 18F-FLT SUVmax to 0.73 x baseline.
There was a reduction in SUVmax in all cases with tumour visible on day 8
and 29 scans (mean 0.61 x baseline). After only 2 Gy a significant reduction
of uptake was apparent in the bone marrow, corresponding to the radiation
fields. After 10 Gy a complete absence of uptake of 18F-FLT in the ribs and
spine clearly outlined boundaries of the radiation fields, consistent with an
early cessation of proliferation.
Conclusions: 18F-FLT can be detected in patients at various time-points
during therapy. These findings demonstrate significant potential for evaluat-
ing early therapeutic response and for quantifying radiation damage to bone
marrow.
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The Impact of Adjuvant Radiotherapy on the Outcome of
PET-Staged Radically Resected Stage IIIA (N2) Non-small Cell
Lung Cancer
M. Tin1, D. Wong1, P. Fitzgerald2, M. J. Boyer1, B. C. McCaughan1, 1Sydney
Cancer Centre, NSW, Australia, 2NHMRC Clinical Trials Centre, NSW,
Australia
Purpose/Objective(s): Adjuvant radiotherapy (A-RT) has been investigated
as a means of improving loco-regional control and overall survival of stage
IIIA N2 non-small cell lung cancer [NSCLC], after radical surgery. How-
ever, there has been a reticence to use A-RT since the PORT meta-analysis,
which suggested a detriment to overall survival. 18FDG-Positron Emission
Tomography [PET] can improve patient selection for A-RT by detecting
unknown distant metastases. The purpose of this study is to determine
whether A-RT improves survival in Stage IIIA (N2) NSCLC patients staged
with PET.
Materials/Methods: We conducted a retrospective analysis of the patients
with pathological stage IIIA N2 NSCLC treated with radical surgery A-RT
from January 1995 to December 2007 at the Sydney Cancer Centre. All
patients were staged with PET and CT. We compared the outcomes of
patients who had adjuvant radiotherapy versus those who had no radiother-
apy.
Results: 195 patients were identified. There were 119 males and 76 females,
with median age 66 [range 41–83]. 92% had a complete resection. 30 day
mortality was 2.6%. 73% had adjuvant radiotherapy. 19% had neo-adjuvant
chemotherapy and 15% had adjuvant chemotherapy. Complete resection
rates were similar between the two groups but a larger proportion of patients
in the A-RT group received chemotherapy. With a median follow up of 27
months, median survival was 10 months for no radiotherapy group and 29
months for adjuvant radiotherapy group. 2 year DFS and OS was 18% and
36% for no radiotherapy versus 46% and 62% for adjuvant radiotherapy [p
value DFS 0.001, OS 0.001]. 5 year DFS and OS was 3% and 4% for no
radiotherapy versus 22% and 32% for adjuvant radiotherapy [p value DFS
0.001, OS  0.001]. Multivariate analysis confirmed survival advantage
with a HR of 0.406 [p value 0.001].
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Conclusions: Adjuvant radiotherapy appears to improve disease free and
overall survival in this series, confirming the emerging evidence of its benefit
in locally advanced disease. However, the potential for selection bias should
be taken into account in this non-randomised setting. The higher proportion
of patients on chemotherapy may have contributed to the superior results in
the A-RT group.
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Molecular Diagnosis and Individual Target Therapy: Detecting
Egfr Mutations in NSCLC by IHC with Antibodies
J. Yu1, D. Li2, X. Zhou2, C. Reeves1, K. Crosby1, H. Haack1, B. Smith1, T.
Gu1, R. Polakiewicz1, M. Comb1, et al., 1Cell Signaling Technology, Inc,
Danvers, MA, 2Second Xiangya Hospital, Central South University, Chang-
sha, China
Background: NSCLC patients carrying the somatic mutation of epider-
mal growth factor receptor (EGFR) have been shown to be hyperrespon-
sive to the EGFR tyrosine kinase inhibitor Gefitinib and Erlotinib. The
most common NSCLC associated EGFR mutations are the in-frame
deletion in exon 19 (E746 A750del) and the point mutation replacing
leucine with arginine at codon 858 in exon 21 (L858R), accounting for
85–90% EGFR mutations. The ability to detect mutated gene products
in cancer cells can identify patients most likely benefit from such
therapies.
Methods: We generated rabbit monoclonal antibodies (RmAb) against
EGFR with E746-A750 deletions and L858R point mutation. We tested
the antibodies by western blot, Immunofluorescence (IF) and immuno-
histochemistry (IHC) and used the antibodies staining 40 molecularly
pre-typed tumors by IHC. Then, we used IHC by a panel of four
antibodies (two mutant antibodies, a total EGFR antibody and a pan-
keratin antibody) to screen 340 cases of tumor samples with unknown
genotype by IHC.
Results: The western blot, IF and IHC were confirmed that the antibodies
can specifically detect the mutant EGFR proteins. 40 molecular pre-typed
samples were 100% matching the data of DNA sequencing. In those 340
cases of tumor samples, 28 cases were stained positive by L858R
antibody and 24 cases were stained positive by deletion antibody. The
positive rate by both antibodies is 15.3%. The DNA of all IHC positive
and negative adenocarcinoma samples were sent to do DNA sequencing,
which showed the sensitivity of the IHC with the antibodies is 92.5% and
the specificity is 95.8%. Some tumor samples carrying the mutations with
low percentage of cancer cells were missed by direct DNA sequencing,
but positive by IHC with mutant EGFR antibodies.
Conclusions: The IHC combined mutant EGFR antibodies and total
EGFR antibody can be used to detect the EGFR mutations and measure
the expression level of EGFR protein in tumors. In addition, this IHC
assay enables us to examine paraffin blocks from small biopsy samples,
which are difficult to extract enough high quality DNA for sequencing.
This assay can be used to screen lung cancer patients for the treatment
with EGFR kinase inhibitors in a clinical setting.
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Overcoming a CYP1A1/1A2 Mediated Induction of Metabolism
by Escalating Erlotinib Dose in Current Smokers - Pharmaco-
kinetic and Exploratory Survival Analyses in Patients with
Advanced Non-small Cell Lung Cancer
W. J. Petty1, A. N. Hughes2, M. E. R. O’Brien3, J. B. Chick4, E. Rankin5, P.
Woll6, D. Dunlop7, M. Nicolson8, R. Boinpally9, A. Price10, 1Wake Forest
University, Winston-Salem, NC, 2Northern Centre For Cancer Treatment,
Newcastle-Upon-Tyne, United Kingdom, 3Royal Marsden Hospital, Sutton,
United Kingdom, 4OSI Pharmaceuticals, Oxford, United Kingdom, 5Nin-
ewells Hospital, Dundee, United Kingdom, 6Weston Park Hospital, Sheffield,
United Kingdom, 7Beatson Oncology Centre, Glasgow, United Kingdom,
8Aberdeen Royal Infirmary, Aberdeen, United Kingdom, 9OSI Pharma-
ceuticals, Boulder, CO, 10Edinburgh Cancer Centre, Edinburgh, United
Kingdom
Background: Erlotinib improves survival in unselected advanced
NSCLC pts in the 2nd/3rd line setting, however the magnitude of benefit
is reduced in current smokers (Shepherd, 2004). Cigarette smoking
induces CYP1A1/1A2 and is hypothesized to alter erlotinib pharmacoki-
netics (PK) such that if a higher dose of erlotinib would be feasible it may
improve outcome in current smokers.
Methods: The maximum tolerated dose (MTD) of erlotinib in advanced
NSCLC pts currently smoking 10 cigarettes per day for  1yr was
previously determined to be 300mg daily (Hughes et al ASCO 2007). Pts
were randomized to erlotinib at 300 mg or 150 mg daily and PK assessed at
Day 14. Pts could receive erlotinib beyond day 14 at an investigator-selected
dose until progression or intolerable toxicity. Exploratory survival analyses
were performed based on the investigator-selected Day 15 dose to obtain
estimates of survival to assist with design of future randomized, comparative
clinical trials.
Results: Thirty-five patients were randomized to 300 mg (n18) or 150
mg (n  17). Common, related adverse events (all grades) were (150
arm:300 arm): skin toxicity (29%:67%), diarrhea (18%:50%), and fatigue
(35%:28%). Erlotinib exposure (Cmax and AUC0-Tau) was dose-propor-
tional with median steady-state trough erlotinib plasma concentrations
(C24) of 0.375 and 1.22 ı`g/mL for the 150 mg and 300 mg arms,
respectively. Non-randomized survival analyses based on investigator-
selected dose on Day 15 demonstrated a median survival of 5.45 months
(95% CI: 3.19 –10.09) for 13 patients receiving 150 mg and 9.56 months
(95% CI: 6.34 - not reached) for 20 patients receiving erlotinib at an
escalated dose (250 or 300 mg).
Conclusions: 1) Steady-state trough plasma concentrations demonstrate the
mean erlotinib exposure in currently smoking pts is higher in pts receiving
300 mg than 150 mg once daily. 2) The incidence of rash/diarrhea at 300 mg
were comparable to never/former smokers treated with 150 mg in previous
studies. 3) The potential efficacy benefit of a higher erlotinib dose in current
smokers warrants further evaluation.
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Gefitinib Versus Docetaxel in Previously Treated Advanced
Non-small Cell Lung Cancer (NSCLC) (INTEREST): Quality of
Life (QOL) Analyses
V. Hirsh1, E. Kim2, T. Mok3, M. Socinski4, M. Sellers5, E. Lowe6, D.
Meddis6, A. Armour5, J. Douillard7, 1McGill University Health Centre,
Montreal, QC, Canada, 2University of Texas MD Anderson Cancer Centre,
Houston, TX, 3Hong Kong Cancer Institute, Chinese University of Hong
Kong, Hong Kong, China, 4Lineberger Comprehensive Cancer Center,
University of North Carolina, Chapel Hill, NC, 5Astrazeneca, Macclesfield,
United Kingdom, 6Astrazeneca, Wilmington, DE, 7Centre Rene Gauducheau,
Nantes, France
Purpose/Objective(s): The Phase III INTEREST study, involving 1466
patients with pretreated advanced NSCLC, demonstrated noninferior overall
survival (OS) with gefitinib (IRESSA) compared with docetaxel (median OS
7.6 vs 8.0 months; hazard ratio 1.020, 96% confidence interval [CI] 0.905–
1.150) and a more favorable tolerability profile for gefitinib. Below are
quality of life (QoL) data from this study.
Materials/Methods: The FACT-L questionnaire was administered at base-
line and every 3 weeks until treatment discontinuation. FACT-L Total Score,
Trial Outcome Index (TOI; physical  functional well-being  lung cancer
subscale [LCS] scores of FACT-L), and LCS score were assessed. Clinically
relevant improvement was defined as an increase from baseline of 6 points
for FACT-L and TOI and 2 points for LCS, maintained for 21 days.
Improvement rates were compared using multivariate logistic regression in
the evaluable-for-QoL (EFQ) population.
Results: Overall compliance for FACT-L completion was 65% for gefitinib
and 73% for docetaxel, with 97% of forms evaluable. The EFQ population
included 966 patients (gefitinib, 490; docetaxel, 476); baseline demographic
and disease characteristics for these evaluable patients were similar to the
overall population (adenocarcinoma, 56.6%; female, 38.0%; performance
status 0/1, 88.6%). QoL improvement rates (FACT-L Total Score) were
25.1% with gefitinib vs 14.7% with docetaxel (odds ratio [OR] 1.99; 95% CI
1.42–2.79; p0.0001); similar results were obtained using TOI: 17.3% vs
10.3% (OR 1.82; 95% CI 1.23–2.69; p0.0026). Symptom improvement
rate (LCS) was 20.4% with gefitinib vs 16.8% with docetaxel (OR 1.29; 95%
CI 0.93–1.79; p0.1329). In the V-15–32 and SIGN studies, QoL improve-
ment rates were also greater for gefitinib compared with docetaxel.
Conclusions: Significantly more patients experienced a clinically relevant
improvement in QoL with gefitinib compared with docetaxel. No significant
differences in symptom improvement were found. Oral therapy with gefitinib
has demonstrated noninferior OS, a more favorable tolerability profile and
superior QoL compared with IV docetaxel in pretreated advanced NSCLC
patients.
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A Prognostic Model to Predict Survival in Bevacizumab (B)-
Eligible Non-small Cell Lung Cancer (NSCLC) Patients Treated
with Standard Chemotherapy: ECOG Data
T. Hoang1, S. E. Dahlberg2, A. Sandler3, J. Brahmer4, J. Schiller5, D.
Johnson3, 1University of Wisconsin, Madison, WI, 2Dana-Farber Cancer
Institute, Boston, MA, 3Vanderbilt University, Nashville, TN, 4Johns Hopkins
University, Baltimore, MD, 5University of Texas Southwestern Medical
Center, Dallas, TX
Objectives: (1) Determine clinical factors predicting 6-month progression
free survival (6M-PFS) and 1-year overall survival (1Y-OS) in B-eligible
NSCLC patients treated with paclitaxel and carboplatin (PC) with or without
B; (2) Build a prognostic model to predict survival in this patient population.
Methods: We analyzed data of 850 eligible patients with advanced NSCLC
who were treated in the randomized study E4599 [NEJM 255(24), 2006].
Major exclusion criteria include squamous cell subtype, brain metastasis,
significant hemoptysis, and PS1. Based on 26 pretreatment clinical and lab
variables, we performed univariate and multivariate analyses to identify
prognostic factors. We used Cox regression with 50% randomly sampled
data to build nomograms to predict 6M-PFS and 1Y-OS. The model was
validated with the remaining 50% of data.
Results: In multivariate analysis, 11 independent factors predicting short
1Y-OS (p value; prognostic score) were: skin met (0.0001; 130), Body
Mass Index 18.5 (0.0003; 81), adrenal met (0.0002; 52), serum LDH ULN
(0.0001; 48), mediastinal nodal met (0.02; 42), male (0.0002; 37), PS 0
(0.0001; 35), serum albumin LLN (0.0001; 32), non-adeno/non-BAC
subtype (0.006; 30), bone met (0.0002; 29), and treatment without B (0.05;
25). Seven independent factors predicting short 6M-PFS were: skin met
(0.0001; 103), treatment without B (0.0001; 37), liver met (0.0002; 33),
serum albumin LLN (0.0001; 29), bone met (0.0001; 27), mediastinal
nodal met (0.07; 21), and PS 0 (0.01; 19). Using those factors, we success-
fully built 2 nomograms to predict 6M-PFS and 1Y-OS.
Conclusion: PCB therapy is one of several factors which could influence
survival in advanced, non-squamous NSCLC. Using our proposed model, the
probability of achieving 6M-PFS and 1Y-OS with standard treatment
(PC/-B) can be estimated. For example, a male patient with PS1, NSCLC-
NOS, bone met, and PCB triplet has a prognostic score of 131
(37353029) and therefore, estimated 1Y-OS of 47%. With PC doublet,
the prognostic score and estimated 1Y-OS is 156 and 39%, respectively. This
prognostic model may provide a tool for decision making as well as research
design.
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Exploring Predictive and Prognostic Histological Effects for
Common First-Line Regimens for Advanced Non-small Cell
Lung Cancer (NSCLC): Retrospective Analysis of a 3-Arm
Randomized Trial
G. V. Scagliotti1, Y. D. Zhao2, A. M. Liepa2, F. de Marinis3, M. Rinaldi4, L.
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Background: Historically, NSCLC histology has not played a prominent
role in the selection of first-line cytotoxic regimens. However, a recent phase
III trial comparing pemetrexed/cisplatin (PC) and gemcitabine/cisplatin (GC)
demonstrated greater efficacy for PC in nonsquamous (adenocarcinoma and
large cell) patients (pts) than in squamous cell carcinoma pts (Scagliotti et al,
J Clin Oncol 2008). Here we explore the potential predictive and prognostic
role of histology with other platinum-based regimens.
Methods: Survival and time to progression (TtP) data from the Italian phase
III trial comparing paclitaxel/carboplatin (PCb) and GC to vinorelbine/
cisplatin (VC) (Scagliotti et al, J Clin Oncol 2002) were analyzed to assess
if histology was predictive of treatment effect or prognostic (regardless of
treatment). Using Cox multiple regression, factors included treatment (PCb,
GC, VC), histology (squamous, adenocarcinoma, large cell, other), gender,
ECOG performance status (PS) (0/1, 2), stage (IIIb, IV), number of meta-
static sites (1, 1), and smoking history (yes, no). A second model
considered histology as squamous or nonsquamous. An interaction value of
0.1 was considered significant.
Results: Data from 607 randomized pts were analyzed. Baseline pt and
disease characteristics were well distributed across arms (78% male, 93% PS
0/1, 81% stage IV, 79% smoker, 24% 1 metastatic site, 51% adenocarci-
noma, 31% squamous, 7% large cell). No significant treatment-by-histology
interaction was seen in either model for either endpoint. However, histology
was a significant prognostic factor for survival in the first model (p0.018)
and marginally significant for TtP (p0.078). Subsequent pairwise compar-
isons of histology groups demonstrated a statistically significant survival
advantage for squamous cell pts over adenocarcinoma pts (p0.002).
Conclusions: For pts treated with PCb, GC or VC, histology was not
predictive of treatment effect for either survival or TtP. Histology was
prognostic for survival, with better outcomes associated with squamous cell
carcinoma, a finding that may be unique to this study.
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BRIDGE: An Open-label Phase II Trial Evaluating the Safety of
Bevacizumab (BV)  Paclitaxel/carboplatin (PC) as 1st-line
Treatment for Patients (pts) with Advanced, Previously
Untreated, Squamous Non-small Cell Lung Cancer (NSCLC)
J. Hainsworth1, P. Compton2, D. Strickland2, C. G. Azzoli3, 1Sarah Cannon
Cancer Center, Nashville, TN, 2Genentech, Inc., South San Francisco, CA,
3Memorial Sloan-Kettering Cancer Center, New York, NY
Objectives: In the Phase II study AVF0757g of BV  CP as 1st-line
treatment for NSCLC, squamous histology was found to be a risk factor for
severe ( Grade 3) pulmonary hemorrhage (PH) [Johnson DH et al, J Clin
Oncol. 2004;22:2184]. Subsequently, pts with predominantly squamous
histology were excluded from Phase III E4599 and BO17704 (AVAiL)
studies. This preliminary report on study AVF3744g (BRIDGE) assesses the
safety of delayed BV administration in pts with locally advanced or meta-
static squamous NSCLC.
Methods: BRIDGE was an open-label, single-arm, multicenter pilot study
including PC alone in cycles 1 and 2, and PC BV in cycles 3 to 6, followed
by BV until disease progression or unacceptable toxicity. Eligible pts had
Stage IIIb (with pleural effusion), Stage IV, or recurrent squamous NSCLC;
no recent arterial thromboembolic events, gastrointestinal perforation, or
hemoptysis; no untreated brain mets; no intrathoracic lesion(s) with cavita-
tion; no anticoagulation therapy.
Results: Between 4/4/06 and 3/3/08, 44 pts were enrolled. As of 3/5/08, 27
pts had received at least 1 dose of BV, and 14 pts had withdrawn from the
study prior to receiving BV; 3 pts had not reached Cycle 3 of PC and had not
received BV yet. Among BV-treated pts, median age was 65 (range, 48 to
80), 66.7% were male, and 96.3% had Stage IV disease. The median number
of BV doses was 4.0 (range, 1 to 15), and, as of 5/29/08, 29.6 % of pts
remained on BV treatment. To date, there have been 3 reports of PH in 2 pts.
One pt had grade 1 PH during cycle 3, withdrew due to progressive disease
on the same day, and recovered. A second pt developed grade 3 PH after
post-progression treatment, 44 days after the last BV dose; PH resolved 2
days later, but 57 days after the last dose of BV the pt developed Grade 5 PH.
Preliminary severe PH incidence was 1/27 pts (3.7%).
Conclusions: To date, there has been an acceptable observed rate of severe
( Grade 3) PH in this study, in which patients with squamous NSCLC are
treated with BV beginning after 2 cycles of PC. No new safety signals have
been identified. Additional safety and efficacy data will be presented.
Author Disclosure Block:
J. Hainsworth, Genentech, Inc., H. Research grants; P. Compton, Stock -
Genentech, Inc., A. Financial Interest/Stock Options; Genentech, Inc., F.
Employment; D. Strickland, Stock - Genentech, Inc., A. Financial Interest/
Stock Options; Genentech, Inc., F. Employment; C.G. Azzoli, Genentech,
Inc., H. Research grants; Allos Therapeutics, H. Research grants; Sanofi-
Aventis, H. Research grants.
129
Sabre-l: A Randomized Phase II Trial Evaluating the Safety
And Efficacy of Combining Sunitinib (S) with Bevacizumab
(BV)  Paclitaxel/carboplatin (PC) as First-line Treatment For
Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC)
M. A. Socinski1, M. Samant2, D. Strickland2, M. Kozloff3, 1University of
North Carolina, Chapel Hill, NC, 2Genentech, Inc., South San Francisco,
CA, 3Ingalls Hospital and the University of Chicago, Harvey, IL
Objectives: BV, a humanized monoclonal antibody that neutralizes VEGF,
improves progression-free and overall survival in 1st-line metastatic, non-
squamous NSCLC. Sunitinib (S), an oral inhibitor of multiple receptor
tyrosine kinases, has shown some single-agent activity in NSCLC. Preclin-
ical models suggested that the addition of S to BVPC could result in greater
inhibition of the VEGF signaling pathway. SABRE-L was a Phase II
randomized open-label study to compare the safety and efficacy of
BVPC  S for patients (pts) with locally advanced metastatic, or recurrent
non-squamous NSCLC.
Methods: Study enrollment was to consist of 3 phases. Phase I: BV (15
mg/kg) PC q3w, S (25 mg) qd 2 wks on 1 wk off. If tolerated, phase 2
would include a pt arm with S at 37.5 mg qd; phase 3 would include S at
highest tolerable dose (25 or 37.5 mg qd).
Results: Between March 2007 and January 2008, 56 pts were randomized
(26 BVPC, 30 BVPCS 25 mg). Due to poor tolerability, pts were never
escalated to 37.5 mg S and the study was closed. At the time of analysis,
estimated mean treatment duration was 9.5 wks for the BVPC arm and 7.6
wks for the BVPCS arm. There were similar proportions of grade 3
adverse events (AE) and serious AEs in the two arms. However, 63% of pts
had an AE that resulted in S dose interruption or modification, with 13%
requiring S dose reduction and 40% S discontinuation. The most frequently
reported AEs were hematologic (neutropenia, febrile neutropenia, and throm-
bocytopenia) and fatigue. Pts receiving BVPCS required more BV
interruptions (30% vs 19% for BVPC) and BV discontinuation (40% vs
23%) due to AEs, compared with pts receiving BVPC alone. There were
3 Grade 5 events (renal failure, disease progression, unknown) in the
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BVPC arm and 2 (disease progression, anaphylaxis to paclitaxel) in the
BVPCS arm.
Conclusion: SABRE-L reached a protocol-defined objective in the first
phase, determining that the addition of S to BVPC was not well-tolerated
at these doses and schedules in first-line non-squamous NSCLC, and the
study was closed. Additional safety and efficacy data will be presented.
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Activity of XL647 in Subjects with NSCLC who Progressed
after Prior Benefit from Gefitinib or Erlotinib: Final Data from
Phase 2
N. A. Pennell1, V. A. Miller2, H. A. Wakelee3, P. Lara4, J. Cho5, N.
Chowhan6, D. Costa7, N. Vrindavanam8, R. Yanagihara9, T. J. Lynch10, 1The
Cleveland Clinic Foundation, Cleveland, OH, 2Memorial Sloan-Kettering
Cancer Center, New York, NY, 3Stanford University, Palo Alto, CA, 4Uni-
versity of California-Davis, Davis, CA, 5New Bern Cancer Care, New Bern,
NC, 6Cancer Care Center, Inc., New Albany, IN, 7Beth Isreal Deaconess
Medical Center and Harvard Medical School, Boston, MA, 8Signal Point
Hematology Oncology, Middletown, OH, 9Gilroy, Gilroy, CA, 10Massachu-
setts General Hospital Cancer Center and Harvard Medical School, Boston,
MA
Background: XL647 is a small molecule inhibitor of EGFR, HER2, and
VEGFR2. First-generation EGFR TKIs (erlotinib, gefitinib) are active in
NSCLC, particularly in pts with EGFR activating mutations and amplifica-
tion. Pts who respond to erlotinib or gefitinib relapse and no standard therapy
exists for this population. In	50% of cases this is associated with the EGFR
T790M mutation. Preclinically XL647 inhibits the growth of cell lines which
harbor both L858R and T790M mutations. This study examined the activity
of XL647 in pts who have relapsed after benefit from erlotinib or gefitinib.
Methods: Simon two-stage study with primary endpoint of best confirmed
response rate.
Eligibility: Adult pts with relapsed or recurrent NSCLC (Stage IIIB or IV)
with documented PD after  12 weeks of clinical benefit from erlotinib or
gefitinib, or pts with T790M mutations.
Treatment: 300 mg XL647 as a single daily dose.
Assessment: Response evaluated by RECIST. Tumor and/or plasma DNA
were analyzed for EGFR mutations.
Results: Enrollment is complete with 41 pts [31F/10M; median age 61 yrs
(range 27–90)]. The following best responses were observed in 39 evaluable
pts: 1 cPR, 19 SD, and 19 PD. Two pts discontinued before first assessment:
1 had ventricular ectopy due to underlying cardiac arrhythmia, and 1
withdrew consent due to diarrhea and nausea. EGFR T790M mutations were
detected in 10/37 pts analyzed; 3 experienced SD (2.8, 3.7 and  5.2 m) and
7 PD. The median PFS (KM-estimate) of pts with T790M mutations was
1.9 m (95% CL 1.4–2.8) compared to 3.7 m (95% CL 1.9–4.0) for pts
without detectable T790M. The most common AEs were g1/2 diarrhea, rash,
nausea, and fatigue. Three pts with SD discontinued due to drug-related AEs:
g4 pulmonary emboli; g2 creatinine elevation (pt had one functional kidney);
g3 increased LFTs.
Conclusions: Treatment with XL647 resulted in a 51% clinical benefit rate
(20/39 patients) in pts with advanced NSCLC who progressed after erlotinib
or gefitinib. XL647 was generally well-tolerated and showed clinical activity
in this heavily pretreated pt population. Shorter median estimated PFS in pts
with EGFR T790M indicates that this remains a poor prognostic factor.
Mature data on PFS and OS are pending.
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Increased Benefit from Bevacizumab (BEV) in Younger Women
with Advanced NSCLC on Eastern Cooperate Oncology Group
(ECOG) E4599
H. A. Wakelee1, S. E. Dahlberg2, J. R. Brahmer3, J. H. Schiller4, M. C.
Perry5, C. J. Langer6, A. B. Sandler7, C. P. Belani8, D. H. Johnson7,
1Stanford University, Stanford, CA, 2Dana Farber Cancer Institute/ECOG,
Boston, MA, 3Johns Hopkins University, Baltimore, MD, 4University of
Texas-Southwestern, Dallas, TX, 5University of Missouri, Columbia, MO,
6University of Pennsylvania, Philadelphia, PA, 7Vanderbilt University,
Nashville, TN, 8Pennsylvania State University, Pittsburgh, PA
Purpose/Objectives: Women (W), especially older W, with adv NSCLC
live longer than men (M) in recent analyses of both SWOG and ECOG trials.
Menopausal status was postulated as one explanation given the role of
estrogen in lung cancer. On ECOG chemotherapy trials (N1590) the
median survival time (MST) for W  60 y was 11.6 mo vs. 9.0 mo for W 
60 (logrank p.03), but no significant difference by age for M was seen. We
therefore looked for age-sex interactions with the addition of BEV to
chemotherapy in E4599.
Methods: E4599 randomized patients (pts) to carboplatin/paclitaxel /-
BEV, an antibody to VEGF. Eligible pts (N850) were divided into male
and female cohorts by treatment (/- BEV) and separated into age groups:
60 or  60 y. Survival was calculated separately for each cohort using the
method of Kaplan-Meier. Known prognostic factors such as performance
status (PS), weight loss, and stage were also compared for each sex/age
cohort using two-sided Fisher’s exact tests.
Results: 850 eligible pts were included in this analysis with 387 (46%) W
and 463 (54%) M. 160 (41%) and 168 (36%) of W and M respectively
were 60 y. There were no significant associations between known prog-
nostic factors (PS, weight loss, and stage) and sex or age. A statistically
significant interaction between age and treatment among females was found
in a Cox model predicting overall survival that took toxicity into account. For
W 60 y the MST was 13.8 mo vs 12.8 mo -/ BEV (p  0.2) indicating
no benefit with BEV. In W  60 y though, the MST was 11 mo vs. 15.5 mo
/ BEV (p 0.12). For W 45 (N19) the MST was 5.8 mo vs 16.8 mo
/ BEV (p0.07). The p-value for the age 60 by treatment interaction
was statistically significant among W (p.03) after adjusting for age and
treatment. For M, both age groups had clear benefit with BEV. The age by
treatment interaction among females was not a statistically significant pre-
dictor of progression free survival (p  0.5).
Conclusions: With chemo alone, W with adv stage NSCLC, especially
those 60 y, live longer than M with the disease. However, a trend toward
survival advantage with BEV is seen in M both  and  60 y, but only in
W  60 y. Menopausal status may play a role in these observations.
Author Disclosure Block:
H.A. Wakelee, Genentech, H. Research grants; S.E. Dahlberg, None; J.R.
Brahmer, None; J.H. Schiller, None; M.C. Perry, None; C.J. Langer,
None; A.B. Sandler, None; C.P. Belani, None; D.H. Johnson, None.
Abstracts Journal of Thoracic Oncology • Vol. 3, No. 11, Supplement 4, 2008
Copyright © 2008 by the International Association for the Study of Lung CancerS282
132
Phase II Study of Sunitinib as Maintenance Therapy in Patients
with Locally Advanced or Metastatic Non-small Cell Lung
Cancer (NSCLC)
N. Blais1, R. D. Page2, J. D. Hainsworth3, J. Soria4, J. Laskin5, J. T. Hamm6,
P. Selaru7, S. T. Kim7, R. Chao7, R. Gervais8, 1Hopital Notre-Dame du
CHUM, Montreal, QC, Canada, 2Center for Cancer and Blood Disorders,
Fort Worth, TX, 3Sarah Cannon Research Institute, Nashville, TN, 4Institut
Gustave Roussy, Villejuif, France, 5BC Cancer Agency, Vancouver, BC,
Canada, 6Norton Healthcare, Inc., Louisville, KY, 7Pfizer Global Research
and Development, La Jolla, CA, 8Centre Francois Baclesse, Caen, France
Background: Sunitinib malate (SUTENT®, SU) is an oral, multitargeted
tyrosine kinase inhibitor of VEGFRs, PDGFRs, KIT, FLT3, CSF-1R and
RET, approved for the treatment of advanced RCC and imatinib-resistant/
intolerant GIST. This study assessed the clinical activity and safety of SU
when used as maintenance therapy following standard first-line chemother-
apy in patients (pts) with locally advanced or metastatic NSCLC.
Methods: In this open-label multicenter study, pts with stage IIIB/IV
NSCLC were treated with carboplatin (C) (AUC6 mgmin/mL) plus
paclitaxel (P) (175–225 mg/m2) for up to 4 cycles followed by SU mono-
therapy (50 mg/day in 6-wk cycles: 4 wks on treatment, 2 wks off [Schedule
4/2]). Pts without response or stable disease, or those who could not complete
4 cycles of C/P due to toxicity were also allowed to continue with SU
monotherapy. Primary endpoint was 1-year survival; other endpoints in-
cluded overall survival (OS), objective response rate (according to RECIST),
and safety.
Results: Of 87 pts enrolled, 84 were treated in this study. Median age was
60 years (range: 30–81); 96% of pts had stage IV disease. By histology, 33%
had adenocarcinoma, 23% had squamous cell carcinoma, and 23% had large
cell carcinoma. Of 84 pts treated, 56 (67%) completed 4 cycles of C/P; 65 pts
were treated with SU. Median duration of treatment on SU was 2.6 months
(range: 1–22). Thirty-seven pts (57%) were discontinued from SU due to
insufficient clinical response and 14 pts (22%) due to adverse events.
Probability of 1-year survival was 41% (95% CI: 30, 52) and median OS was
10.5 months (95% CI: 8.1, 12.4). As of June 2008, 1 patient remains on SU
therapy 22 months post-C/P without progression. Most frequently reported
(non-hematologic) grade 3/4 AEs during SU therapy included fatigue/
asthenia (24%), diarrhea (9%), and stomatitis (5%). Most frequent grade 3/4
hematologic laboratory abnormalities were lymphopenia (21%) and neutro-
penia (13%). Updated data will be presented.
Conclusions: SU 50 mg/day on Schedule 4/2 dosing is tolerable as mainte-
nance therapy following C/P in pts with locally advanced or metastatic
NSCLC. The relative activity observed in the study warrants further study.
Author Disclosure Block:
N. Blais, None; R.D. Page, Research support from Pfizer, H. Research
grants; J.D. Hainsworth, Research funding from Pfizer, H. Research grants;
J. Soria, Receives advisory board honoraria, C. Consulting Fees/Honoraria;
J. Laskin, Roche Canada, Lilly Canada, AstraZeneca Canada, Amgen
Canada, C. Consulting Fees/Honoraria; J.T. Hamm, Research funding from
Pfizer, H. Research grants; P. Selaru, Pfizer employee, F. Employment; S.T.
Kim, Pfizer employee, F. Employment; R. Chao, Pfizer employee, F.
Employment; R. Gervais, None.
133
Treatment Outcomes by Tumor Histology in Eastern Cooperative
Group (ECOG) Study E4599 of Bevacizumab (BV) with Paclitaxel/
Carboplatin (PC) for Advanced Non-small Cell Lung Cancer (NSCLC)
A. B. Sandler1, G. Kong2, D. Strickland2, D. H. Johnson1, 1Vanderbilt-
Ingram Cancer Center, Nashville, TN, 2Genentech, Inc., South San Fran-
cisco, CA
Background: BV  PC has previously been shown to extend overall
survival (OS) in patients (pts) with advanced non-squamous NSCLC (San-
dler et al, N Engl J Med 2006, 355:2542–50). A retrospective analysis of
treatment effects based on different histologic subtypes is presented here.
Methods: Pts with cytologically- or histologically-confirmed non-squamous
metastatic NSCLC were treated with BV  PC or PC alone. Cytologic or
histologic confirmation was based on tumor aspirates or biopsy at the
investigative site; centralized review of histology was not performed. For
each histologic subtype, median survival time was determined using Kaplan-
Meier methodology for randomized pts; hazard ratios (HR) and 95% confi-
dence intervals (CI) were obtained using an unstratified Cox proportional
hazards model. The histology-by-treatment interaction was tested with a
stratified multivariate Cox regression model.
Results: Sample sizes for the NSCLC histology subsets were generally
similar between treatment arms, and the majority of pts in both arms had
adenocarcinoma as the predominant histology. For the 444 pts randomized to
PC and the 434 pts randomized to BV  PC, median OS was 10.3 mos and
12.3 mos, respectively, with HR for BV of 0.80 (95% CI: 0.69–0.93). Of
these pts, 68.6% had adenocarcinoma, with median OS 10.3 mos for PC
alone (n302) and 14.2 mos for BV  PC (n300), HR 0.69 (95% CI:
0.58–0.83); for undifferentiated large cell histology, median OS was 8.7 mos
for PC alone (n30) and 10.0 mos for BV  PC (n18); for histology not
otherwise specified, median OS was 10.0 mos for PC alone (n86) and 9.5
mos for BV  PC (n79). Further details according to histology subtypes
and secondary endpoints will be provided.
Conclusions: As previously reported, BV PC significantly prolongs OS in
patients with advanced or recurrent non-squamous NSCLC. In this retro-
spective review of histologic subsets, the estimates of treatment effect varied,
while the confidence intervals for each overlap the overall trial results. The
largest histologic subset, adenocarcinoma, had a particularly favorable out-
come.
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Prognostic Factors for Outcome of Patients Treated with
Gamma Knife Stereotactic Radiosurgery for Brain Metastases
from Non-small Cell Lung Cancer
M. Giovannini, e. roca, v. gregorc, p. picozzi, c. belli, m. vigano`, a.
bolognesi, g. melloni, p. zannini, e. villa, et al., San Raffaele Scientific
Institute, Milano, Italy
A retrospective study was conducted analyzing the clinical out-
come and prognostic factors in patients (pts) treated with gamma
knife stereotactic radiosurgery (GK-SRS) for brain metastasis from
non-small cell lung carcinoma (NSCLC). From November 2000 to
May 2008 117 pts were treated. All pts received GK-SRS to a
median marginal and maximal dose of 25 and 46 Gy respectively.
Median age was 63 years (24 pts  70) 27 were females, 57 pts had
solitary brain metastasis; the median number of lesions per patient
treated was 3; 27.5% of pts had Karnofsky performance status (KPS)
100, 18.1% 90, 15.6%  70; about RPA score (defined as RPA I:
age 65, KPS  70, controlled primary tumor, no extracranial
metastasis; RPA III: KPS 70; RPA II: all other cases) 20.7% were
classified RPA I and only 3.8% RPA III. No serious toxicity was
registered. The median follow-up was 9.1 months for the entire
population and 31.4 months for those who were alive at the last
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follow-up (4 pts lost at follow up); 25 pts underwent radical surgical
resection of the primary lung tumor. Univariate and multivariate
analyses were used to test the impact on survival of various clinical
parameters such as age, gender, KPS, RPA score, brain metastasis
presentation (synchronous vs metachronous), presence of extracra-
nial metastasis, number of brain lesions (solitary vs multiple) and
brain lesion site (sovratentorial vs subtentorial). The overall median
and 5-year survival for the entire cohort were 8.7 months and 9%,
(95% C.I. 4.5–17.4) respectively. Poor KPS (p0.001), age 55
(p0.02), low RPA score (p0.03), subtentorial lesions with syn-
chronous presentation (p0.01) and synchronous brain lesions as-
sociated with extracranial metastasis (p0.04) seem to be detrimen-
tal on survival. In conclusion, GK-SRS can be considered a safe
treatment modality; clinical parameters seem to be the most useful
drivers for the selection of pts who really benefit in terms of
outcome from GK-SRS which can improve dramatically survival in
such pts whose outcome is otherwise considered very poor.
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Frequency of Insulin-like Growth Factor 1 (IGFR-1) Expression
and Correlation with Clinical and Selected Molecular Parame-
ters in Advanced Non-small Cell Lung Cancer (NSCLC) Pa-
tients (pts)
M. Batus, M. J. Fidler, S. Basu, J. S. Coon, L. Buckingham, K. Kaiser-
Walters, S. McCormack, P. D. Bonomi, Rush University Medical Center,
Chicago, IL
Purpose: The epidermal growth factor receptor (EGFR) signaling pathway
has become an important target in lung cancer with the success of EGFR
tyrosine kinase inhibitors (TKI). The IGFR-1 signaling pathway has also
been implicated in oncogenesis and cancer cell survival. The aim of the study
was to determine the correlation of IGFR-1 expression with both clinical
features of previously treated advanced NSCLC pts and molecular markers
in the EGFR pathways in pts treated with gefitinib.
Methods: Consecutive Expanded Access Trial pts with 1 week gefitinib
were included for analysis. 83 pts had tissue evaluated for IGFR-1 immu-
nohistochemistry (IHC). IGFR-1 positivity was defined as presence of any
staining. 81 patients were evaluated for EGFR protein expression by IHC;
EGFR gene copy number, and chromosome 7 copy number (c7) by fluores-
cence in situ hybridization (FISH), FISH positivity as defined by Cappuzzo
et al, JNCI, 2005.
Results: 78 pts had tissue with both IGFR-1 expression and FISH analyses
available: median age 66, 36(46.2%) men, 48(61.5%) with adenocarcinoma,
12(15.4%) never smokers, and 71(91.0%) with performance status(PS) of 0.
The response rate (including CR and PR) to gefitinib was 15.38%. Median
progression free survival was 3.0 months. Median overall survival was 7.3
months. Positive IGFR-1 score ( 0) was seen in 71.08% of tissue samples.
Positive IGFR-1 was marginally associated with smoking (p0.1). No
significant association was found between IGFR-1 score and age, gender,
histology, or PS. There was a significant association between IGFR-1
positivity and the following parameters: EGFR IHC (p0.002), c7 (p0.03),
and EGFR gene amplification (p-0.01).
Conclusions: IGFR-1 expression is relatively frequent in NSCLC. In this
group of NSCLC pts, IGFR expression by IHC did not correlate with clinical
parameters. The significant correlations between IGFR expression by IHC
and increased EGFR protein expression, EGFR gene amplification and c7
polysomy, suggest that combining an IGFR inhibitor with an EGFR TKI
might improve outcomes in selected NSCLC pts.
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Insulin-like Growth Factor Receptor 1 (IGF-1R) and Outcome
Measures in Advanced Non-small Cell Lung Cancer (NSCLC)
Patients Treated with Gefitinib(G)
M. Fidler, S. Basu, L. Buckingham, K. Kaiser, S. McCormak, J. Coon, P.
Bonomi, Rush University Medical Center, Chicago, IL
Background: Increased expression of IGF-1R has been hypothesized to
impart resistance to epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors. Our objective was to associate clinical outcomes of advanced
NSCLC G treated patients (pts) with IGF-1R expression.
Methods: Consecutive Expanded Access Trial pts with  1 week G were
included. Tissue was evaluated for IGF-1R immunohistochemistry (IHC).
IGF-1R positivity was defined as any staining present.
Results: 150 pts were enrolled. 83 had tumor available for IGF-1R IHC: 38
male (45.8%), median (Md) age 66, 13 never-smokers (15.7%), 51 adeno-
carcinoma (61.4%), 78 pts ECOG performance status 0–1 (94.0%). For these
83 pts, the response rate (complete response (CR)  partial response (PR))
was 14.5 %, disease control rate (CR PR stable disease) was 57.8%, Md
progression free interval (PFI) 3.0 months (mo); Md overall survival (OS)
7.3 mo. Landmark analysis with 35 pts (42.2 %) with rapidly progressive
disease (PFI 70 days) excluded, showed a significant association between
positive IGF-1R expression and prolonged Md PFI (5.7 mo vs. 4.0 mo,
respectively, p  0.05). No significant association was found between
IGF-1R positivity and response, rapid progression, squamous histology, or
OS. Time from diagnosis  12 mo was significantly correlated with pts that
had sufficient tissue for IGF-1R studies, p  0.0125, and these pts (83) had
significantly prolonged PFI and OS compared with pts (67) that did not have
sufficient tissue available (3.1 mo vs. 1.9 mo, p  .0001 and 7.3 mo vs. 3.4
mo, p  .0002, respectively).
Conclusions: Though counter-intuitive, our results suggest improved effi-
cacy with IGF-1R expression and G therapy in previously treated advanced
NSCLC pts. Our results are similar to those of Cappuzzo et al. (Annals of
Oncology, 2006) where longer Md survival was seen in G treated pts whose
tumors had high IGF-1R expression. Further study of the relationship
between IGFR and EGFR and of combinations of EGFR and IGFR inhibitors
in NSCLC should be considered. These results also suggest that clinical trials
in NSCLC requiring tissue specimens sufficient for molecular analysis may
select for good prognosis pts.
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Phase II Study of Gemcitabine and Carboplatin Plus Bevaci-
zumab for Stage III/IV Non-small Cell Lung Cancer: Prelimi-
nary Results
M. J. Kraut, H. Terebelo, R. Bloom, Providence Cancer Institute, Southfield,
MI
Purpose/Objective(s): In a randomized, phase III study of patients (pts) with
advanced NSCLC, the addition of bevacizumab 15 mg/kg to paclitaxel/
carboplatin (PC) resulted in prolonged survival and progression-free survival
compared with PC alone (Sandler AB et al, N Engl J Med. 2006; 355:2542–
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50). In the present study, we are assessing the safety and efficacy of BV 15
mg/kg in combination with gemcitabine/carboplatin (GC) for the treatment
of NSCLC. Preliminary results are presented.
Materials/Methods: Eligible pts with stage IV NSCLC, PS 0–1, and
adequate hematologic, renal and hepatic function, were enrolled; pts with
squamous cell carcinoma, tumor in the central airways, baseline hemoptysis,
or brain metastases were excluded. GC/BV treatment was given in q
3-weekly cycles for 6 cycles, with BV continued in stable and responding
patients. G 1250 mg/m2 was given on days 1 and 8 and C AUC 5 was given
on day 1. BV 15 mg/kg was given on day 1. After 7 pts were enrolled, the
study was amended to reduce the dose of G to 1000 mg/m2 on days 1 and 8
due to unacceptable neutropenia. Primary endpoint of the study is time to
progression.
Results: To date, 31 pts have received treatment. There are 15 men and 16
women, median age 68.2 years. The median TTP is currently 5.1 months; the
data are too immature for an estimate of median survival. Grade 4 throm-
bocytopenia occurred in 13% of cycles involving 27% of pts; only 2 platelet
transfusions were required. Grade 4 neutropenia occurred in only 5.5% of
cycles involving 17% of pts; there was one death possibly attributable to
neutropenia. Grade 3 events have included neutropenia, thrombocytopenia,
infection, anemia, fatigue, diarrhea, dyspnea, and dehydration. Adverse
events possible related to BV include Grade 3 hypertension (4 pts), protein-
uria (2pts; one grade 4), and Grade 1–2 epistaxis (13 pts). No thrombosis or
perforation has been reported.
Conclusions: To date, in this population with a higher-than-typical median
age, the addition of BV to GC in pts with NSCLC is generally well tolerated,
with an encouraging time to progression. No unexpected adverse events
possibly related to BV were observed. Enrollment is ongoing.
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Comparison of Patient Outcomes Stratified by Histology Among
Pemetrexed (P)-treated Patients (pts) with Stage IIIB/IV Non-
small Cell Lung Cancer (NSCLC) in Two Phase 2 Trials
G. Peng1, R. Zinner2, Y. Wang1, J. Treat1, M. Monberg1, C. Obasaju1, R.
Herbst2, S. Novello3, G. Scagliotti3, 1Eli Lilly and Company, Indianapolis,
IN, 2MD Anderson Cancer Center, Houston, TX, 3University of Turin, Turin,
Italy
Purpose: Preclinical data indicate that overexpression of thymidylate syn-
thase correlates with reduced sensitivity to P in antifolate-resistant cell lines.
A prespecified subset analysis of a phase 3 trial (Scagliotti G, et al, JCO
2008) among pts with stage IIIB/IV NSCLC showed that P plus cisplatin was
more effective among pts with adenocarcinoma and or large-cell carcinoma
compared with gemcitabine plus cisplatin (11.8 versus 10.4 months,
P.005).
Materials/Methods: This is a retrospective analysis of two phase 2
studies of P 500 mg/m2 plus carboplatin AUC 6 Q 21 days or P 500
mg/m2 plus oxaliplatin 120 mg/m2 Q 21 days in chemonaive patients with
stage IIIB/IV NSCLC. More than three quarters of enrolled patients had
a nonsquamous histology. The primary endpoint of both trials was
response rate (RR). A Cox model of overall survival (OS) and progres-
sion free survival (PFS) with main effects for squamous histology was
used. Since a potential for imbalances between histologic groups with
respect to prognostic factors existed, the models were cofactor-adjusted
by including terms for ECOG performance status, disease stage, and
gender. Unadjusted medians within histologic subgroups were calculated
using the Kaplan-Meier method.
Results: In the dataset, there were 100 pts with nonsquamous and 29 with
squamous histology. Mean age was 60 years for squamous and 61 for
non-squamous pts. The number of nonsquamous versus squamous pts with
disease stage IIIB:IV was (20:79) vs. (10:19) male:female gender was
(65:35) vs. (26:3), and with ECOG PS 0:1 was (24:76) vs. (6:23). RR was
30.0% for non-squamous and 17.2% for squamous pts. OS was 10.5 months
for non-squamous and 9.8 months for squamous pts (Adj HR  0.95; 95%
CI  0.52, 1.74). PFS was 5.6 months for non-squamous and 4.7 months for
squamous patients (Adj. HR0.72; 95% CI  0.43, 1.19).
Conclusions: Among stage IIIB/IV NSCLC pts treated with P plus carbo-
platin or P plus oxaliplatin, nonsquamous was associated with nearly twice
the RR and a 19% longer PFS. Increased benefit of P treatment among
nonsquamous pts is consistent with the significant results from a prespecified
analysis of a previous phase 3 trial.
Author Disclosure Block:
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Outcomes Were Similar Across Histological Subgroups in a
Three Arm Phase III Trial of Gemcitabine in Combination with
Carboplatin (GC) or Paclitaxel (GP) versus Paclitaxel Plus
Carboplatin (PC) for Advanced Non-small Cell Lung Cancer
(NSCLC)
J. Treat1, M. Edelman2, C. Belani3, M. Socinski4, C. Obasaju1, M. Monberg1,
R. Chen1, 1Eli Lilly and Company, Indianapolis, IN, 2University of Maryland
Greenbaum Cancer Center, Baltimore, MD, 3Penn State Cancer Institute,
Hershey, PA, 4Multidisciplinary Thoracic Oncology Group, Lineberger
Comprehensive Cancer Center, University of North Carolina, Chapel Hill,
NC
Purpose/Objectives: G and P are active, commonly used agents in platinum-
based regimens for advanced NSCLC. Analyses of 3 separate phase III trials
have shown pemetrexed to be associated with improved clinical outcomes
among patients with adeno and large cell histology compared with patients
with squamous histology (Scagliotti JCO 2008, Ciuleanu ASCO 2008,
Peterson ECCO 2007). This retrospective analysis examined whether any
differences were present by histology in a three arm trial of GC or GP versus
a standard regimen of PC.
Materials and Methods: 135 chemonaı¨ve patients with stage IIIB or IV
NSCLC were randomly allocated to receive: G 1000 mg/m2 days 1 and 8
plus C AUC 5.5 day 1 (GC); or G 1000 mg/m2 days 1 and 8 plus P 200
mg/m2 day 1 (GP); or P 225 mg/m2 plus C AUC 6.0 day 1 (PC). Stratification
was based on stage, baseline weight loss, and brain mets. Cycles were
repeated every 21 days up to 6 cycles or disease progression. Clinical results
were retrospectively analyzed in by patient histology, which was classified as
squamous (Sq), adeno or bronchioloalveolar (AB), large cell (LC), or other
(O).
Results: In the study, 202 pts had Sq, 555 had AB, 45 had LC, and 333 had
O. Disease stage III:IV95%:5% for Sq, 87%:13% for AB, 93%:7% for LC,
and 91%:9% for O. Brain mets7% of Sq, 19% of AB, 13% of LC, and 21%
of O. Comparing Sq versus non-Sq, RR was 35% for Sq and 28% for non-Sq
(P.04). Median survival was 9.5 m for Sq, 8.7 m for AB, 7.7 m for LC, and
7.9 m for O. Median TTP was 5.0 m for Sq, 4.9 m for AB, 3.9 m for LC, and
3.9 m for O. These outcomes did not vary by histology across treatment
groups. Myelosuppresion did not vary across histologies, except for G3/4
neutropenia, which was 33% for Sq, 34% for AB, 48% for LC, and 24% for
O (P.003).
Discussion: In this trial of commonly used platinum and non-platinum
regimens in advanced NSCLC, OS and TTP did not vary according to
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histologic subtype or treatment arm. This contrasts with trials of pem-
etrexed, which have shown a consistent benefit of treatment among
non-Sq compared to Sq histologies. RR in this trial was greater for Sq
versus non-Sq histology.
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Phase 1 Pharmacokinetics, Safety and Efficacy of ABT-869 in
Non-small Cell Lung Cancer (NSCLC)
J. Steinberg1, N. Gupta1, Q. Qin1, B. Goh2, C. Wong3, R. Pradhan1, J. Qian1,
R. Soo3, R. Humerickhouse1, 1Abbott Laboratories, Abbott Park, IL, 2Na-
tional Laboratory Hospital, Singapore, Singapore, 3National University
Hospital, Singapore, Singapore
Purpose/Objective(s): ABT-869 is an orally bioavailable, potent and spe-
cific inhibitor of all vascular endothelial growth factor and platelet derived
growth factor family receptor tyrosine kinases (RTKs). In preclinical tumor
growth studies, ABT-869 exhibited efficacy in human fibrosarcoma, breast,
colon, and small-cell lung carcinoma xenograft models.
Materials/Methods: In study M04–710 conducted in refractory solid tumor
patients in Singapore, ABT-869 was orally administered once daily at
bedtime under fasting conditions in 21-day cycles. Maximum observed
plasma concentration (Cmax), time to Cmax (Tmax), area under the concentra-
tion-time curve (AUC) from 0 to 24 h and total area (AUCinf) were
determined by standard noncompartmental analysis using WinNonlin Pro-
fessional v. 5.2.
Results: Of 33 patients, 8 with NSCLC, enrolled in study M04–710 at
treatment doses ranging between 0.10 and 0.30 mg/kg, 6 of 29 that had
post-baseline CT scans were diagnosed with NSCLC. PK parameters were
calculated using the data from the 7 NSCLC patients from whom PK samples
were taken. Tmax was approximately 3 h and the elimination half-life was
17.8  5.6 h (mean  SD). The oral plasma clearance, dose normalized
steady state Cmax and exposures were calculated to be 2.9 0.9 L/h, 0.022
0.006 g/mL/mg and 0.30 0.05 g*hr/mL/mg, respectively. Among all 33
patients, 2 incidences of grade 3 proteinuria and 1 of grade 3 hypertension
were observed at the 0.10 mg/kg dose, and 2 incidences of grade 3
proteinuria and 1 incidence of grade 3 hypertension were observed at the
0.25 mg/kg dose. In this study, 3 of 8 NSCLC patients (1 at each of the 10
mg, 0.25 mg/kg and 0.30 mg/kg doses) experienced stable disease for  3
months and 2 experienced a partial response, 1 treated at 10 mg and 1 at 0.30
mg/kg with 33% and 40%, respectively, maximum reduction in the sum of
the longest diameter of all target lesions. Cavitation of pulmonary lesions
was suggestive of tumor necrosis.
Conclusions: ABT-869 is a novel RTK inhibitor with an acceptable safety
profile and an early demonstration of anti-tumor activity. The 0.10 and 0.25
mg/kg doses are currently being evaluated in a randomized phase 2 NSCLC
study.
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Radiographic and Patient (Pt) Characteristics for Non-small
Cell Lung Cancer (NSCLC) from the ARIES Study: A Bevaci-
zumab (BV) Treatment Observational Cohort Study (OCS)
D. Spigel1, M. Kosty2, P. Kumar3, T. Lynch4, S. L. Teng5, L. Wang5, A.
Sing5, 1Sarah Cannon Research Institute, Nashville, TN, 2Scripps Clinic, La
Jolla, CA, 3Dept. of Medicine, University of Minnesota, Minneapolis, MN,
4Hematology/Oncology, Massachusetts General Hospital, Boston, MA, 5Ge-
nentech, Inc., South San Francisco, CA
Objectives: BV (Avastin®) is an anti-VEGF monoclonal antibody that
prolongs progression-free and overall survival in advanced NSCLC pts.
However, clinical outcomes in the general population, and clinical and
radiographic characteristics that are potential risk factors for serious adverse
events (SAEs) associated with BV therapy, are poorly defined. Randomized
clinical trials (RCTs) such as ECOG 4599 excluded many pts that may be at
risk for BV-related SAEs such as CNS and pulmonary hemorrhage (PH).
ARIES is a prospective OCS enrolling a representative population of pts with
NSCLC for longitudinal follow-up (F/U), and will define clinical outcomes
associated with BV treatment in a real-world setting.
Methods: ARIES is conducted at 276 US sites. Eligible pts have advanced,
non-squamous NSCLC and are receiving 1st-line BV-containing therapy.
Planned NSCLC accrual is 2000 pts. There are no protocol-specified treat-
ments or assessments. Data is collected at baseline (BL) then quarterly,
including targeted AEs and BV-related SAEs. BL scans are requested for all
pts to assess association of BL radiographic characteristics (location, size and
cavitation) with severe PH. All scans are reviewed by an independent review
facility.
Results: As of 2/14/08, there were 996 evaluable NSCLC pts. Median F/U
is 6.1 mos; 84% of pts have 1 quarterly update. Key BL characteristics:
65 yrs, 49% (compared to 42% in E4599); ECOG PS 2, 10%; brain
metastasis (mets), 8%; therapeutic anticoagulation (AC), 6%; prior hemop-
tysis, 8%. BL radiographic features (n530): central tumor, 33%; cavitation,
19%; all cavitations to date were3 cm in diameter. Bleeding events: severe
PH (Grade 3) occurred in 5 pts, and CNS hemorrhage (Grade 3) occurred
in just 1 pt.
Conclusions: ARIES includes pts with NSCLC underrepresented in prior
RCTs, such as pts with ECOG PS 2, brain mets, therapeutic AC, and older
pts. ARIES will expand on current knowledge about BV treatment for
advanced NSCLC. Based on preliminary data, rates of PH and CNS hem-
orrhage are low. BL tumor characteristics such as central location and
cavitation are common. Updated data will be presented at the meeting for
1400 pts.
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Preliminary Results of a Randomized Phase II Trial of Pem-
etrexed (P)  Carboplatin (Cb)  Enzastaurin (ENZ) Versus
Docetaxel (D)  cb as First-line Treatment of Patients with
Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC)
D. Kocs1, R. Raju1, M. Socinski2, T. Stinchcombe2, S. Rousey1, D. Barrera1,
Y. Wang1, J. Bromund3, J. Treat3, C. Obasaju3, 1US Oncology, Houston, TX,
2University of North Carolina, Chapel Hill, NC, 3Eli Lilly and Company,
Indianapolis, IN
Purpose/Objectives: ENZ is a selective, oral serine/threonine kinase inhib-
itor. The combination of PCb has shown clinical activity in two phase 2 trials
of advanced NSCLC. A phase 3 trial among pts with stage IIIB/IV NSCLC
showed that P  cisplatin (C) provides similar efficacy with better tolera-
bility than gemcitabine  C (Scagliotti, IASLC 2007; PRS-03). This open-
label three-arm trial was designed to assess PCb ENZ versus a control arm
of DCb.
Material/Methods: Pts with Stage IIIB (with pleural effusion) or IV
NSCLC, ECOG PS of 0 or 1, and no prior systemic therapy were enrolled.
Pts were equally randomized to one of three arms: (A) P 500 mg/m2 and Cb
AUC 6 every 3 wks  6 cycles with ENZ given orally as a loading dose of
1200 mg or 1125 mg followed by 500 mg daily until disease progression; (B)
The same regimen of PCb without ENZ; or (C) D 75 mg/m2 and Cb AUC 6
every 3 wks  6 cycles. All pts received steroid prophylaxis and those
receiving P were administered folic acid and vitamin B12.
Results: Baseline characteristics for arms A (N65), B (N68), and C
(N66) were male gender: 55%, 54%, and 56%; median age: 67, 67, and 65;
brain metastasis: 8%, 9%, and 6%; ECOG PS 0:1 24%:49%, 47%:44%,
and 53%:39%. Median relative dose intensity in arm A was 98% for P and
93% for Cb; in arm B, 99% for P and 92% for Cb; and in arm C, 99.7% for
D and 96% for Cb. Compliance with ENZ in am A was 82.4%. The number
of pts assessed for safety was 50 for arm A, 59 for arm B, and 55 for arm C.
G3/4 neutropenia was 22%/12% for arm A, 23.7%/6.8% for arm B, and
18.2%/29.1% for arm C. G3/4 febrile neutropenia was 2.0%/0.0% for arm A,
1.7%/0.0% for arm B, and 5.5%/3.6% for arm C. G3/4 thrombocytopenia
was 20.0%/12.0% for arm A, 23.7%/6.8% for arm B, and 3.6%/0.0% for arm
C. G3/4 anemia was 14.0%/0.0 for arm A, 16.9%/0.0 for arm B, and
3.6%/0.0% for arm C. G2 alopecia was 0.0% for arm A, 6.8% for arm B, and
16.4% for arm C.
Conclusions: PCb  ENZ and DCb appear to be well tolerated in advanced
NSCLC. In this trial, first-line treatment with PCb  ENZ (compared with
DCb) was associated with a greater incidence of G3/4 anemia or thrombo-
cytopenia but less G4 neutropenia and G2 alopecia.
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Sunitinib (SU) in Combination with Pemetrexed (Pem) in
Patients (Pts) with NSCLC and Other Advanced Solid
Malignancies
L. Q. M. Chow1, D. J. Jonker1, S. A. Laurie1, S. G. Diab2, C. Canil1, M.
McWilliam1, E. Wang3, A. D. Thall3, S. G. Eckhardt4, D. R. Camidge4, 1The
Ottawa Hospital Cancer Center, Ottawa, ON, Canada, 2Rocky Mountain
Cancer Centers, Aurora, CO, 3Pfizer Global Research and Development, La
Jolla, CA, 4University of Colorado Cancer Center, Aurora, CO
Purpose/Objectives: Sunitinib malate (SUTENT®; SU) is an oral multitar-
geted tyrosine kinase inhibitor of VEGFRs, PDGFRs, KIT, FLT3, CSF-1R
and RET, approved multinationally for the treatment of advanced RCC and
imatinib-resistant/intolerant GIST. SU enhanced the antitumor activity of
Pem in NSCLC xenograft studies. This ongoing, open-label, phase I, dose-
escalation study investigated the maximum tolerated doses (MTDs) of
SUPem in pts with advanced solid malignancies.
Methods: Successive pt cohorts received oral SU at 25, 37.5, or 50 mg/day
as a continuous daily dose (CDD schedule; 3-wk cycles) or for 2 wks of a
3-wk cycle (Schedule 2/1), with escalating doses of Pem at 300–500 mg/m2
IV q21d. MTD was the highest dose at which 0/3 or 1/6 pts had
dose-limiting toxicity (DLT) during cycle 1. Safety, pharmacokinetic (PK)
profiles (SU, Pem and SUPem), and objective response (RECIST) were
also evaluated. The CDD schedule data is presented here.
Results: As of March 2008, 20 pts (NSCLC n3) received SU (CDD
schedule) Pem in 4 dose-escalation cohorts. The CDD schedule MTD was
established as SU 37.5 mg  Pem 500 mg/m2. DLTs were Grade 3 (G3)
febrile neutropenia (SU 37.5 mg  Pem 500 mg/m2; n1), G3 anorexia 7
days and G5 cerebral hemorrhage (SU 50 mg Pem 500 mg/m2; each n1).
The most frequent non-hematologic adverse events across all CDD cohorts
were anorexia, constipation, and fatigue. PK data revealed no clinically
significant drug-drug interactions. Two pts (bile duct cancer: SU 37.5 mg 
Pem 300 mg/m2; NSCLC: SU 50 mg  Pem 500 mg/m2) have had partial
responses maintained for 8 cycles, and 8 pts have had stable disease (8
weeks [2 pts for 6 months]) across the 4 CDD cohorts. Updated data,
including data from an expansion cohort of NSCLC pts, will be presented.
Conclusions: The MTD on the CDD schedule (SU 37.5 mg/day  Pem 500
mg/m2 q21d) has a manageable safety profile and shows preliminary evi-
dence of antitumor activity. This combination is undergoing further study in
NSCLC pts.
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Dual MET-EGFR Inhibition for Erlotinib-Resistant Lung
Cancer
P. C. Ma1,2, Z. Tang1, R. Du1, S. Jiang1, C. Wu1, C. Flask1, B. Halmos1, Z.
Lee1, Y. Wang1, J. A. Kern1, 1Case Western Reserve University, Cleveland,
OH, 2University Hospitals Case Medical Center, Case Comprehensive Can-
cer Center, Cleveland, OH
EGFR tyrosine kinase inhibitors (TKIs) have been approved for advanced
lung cancer treatment. However, initial responders invariably develop sec-
ondary resistance, partly due to the “gatekeeper” T790M mutation. MET
plays key role in human tumorigenesis and has been shown to be an attractive
target in lung cancer. MET amplification may also mediate erlotinib-resis-
tance. Here, we evaluated the role of MET inhibition in EGFR-TKI resistant
lung cancer. Many NSCLC cell lines co-expressed both MET and EGFR,
including A549 (wild-type MET/EGFR, mutant-KRAS) and H1975 (wild-
type MET, L858RT790M-EGFR, wild-type KRAS). H1975 cells had
co-activated MET and EGFR, but did not have genomic MET mutation, and
had no MET amplification. We showed that the MET inhibitor SU11274, at
2 uM, promoted apoptosis of H1975 cells, whereas MET-negative H520 cells
did not. For in vivo studies of targeted inhibition, we developed a highly-
sensitive bioluminescence imaging model of lung cancer murine xenografts.
SU11274 resulted in statistically significant retardation of H1975 tumor
xenograft growth, when compared to diluent control. Multimodal microPET/
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MRI imaging demonstrated that SU11274 induced early tumor metabolic
response in H1975 xenografts. SU11274 also showed efficacy in inducing
A549 cells in vitro apoptosis and in vivo xenograft regression. MET and
EGFR were both functional in A549 and H1975 cells, with signaling
cross-talks. SU11274 plus EGFR-TKIs potentiated MET inhibition of
ERBB3 signaling downstream cell proliferation-survival signal transduction.
Knock-down studies in H1975 cells using siRNA-MET/EGFR, alone or in
combination, validated the efficacy of dual MET-EGFR signal path inhibi-
tion to circumvent erlotinib-resistance. Finally, dual SU11274-erlotinib treat-
ment effectively inhibited H1975 cells with abrogation of cell motility/
migration and complete regression of murine xenograft growth with massive
necrosis. Here, we show that MET-based targeted inhibition can be a
potential treatment strategy for erlotinib-resistant lung cancer. Optimized
MET inhibition may be achieved with combination treatment using EGFR-
targeting inhibitors such as erlotinib or irreversible EGFR-TKI.
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Survivin is Associated with IGF-1R Expression and Predicts
Activity of its Inhibitor in NSCLC
S. Witta1, R. Dziadziuszk2, K. Yoshida3, F. Hirsch1, 1University of Colorado
Cancer Center, Lakewood, CO, 2Medical University of Gdansk, Gdansk,
Poland, 3University of Colorado Health Sciences Center, Lakewood, CO
Purpose/Objective(s): Insulin-like growth factor-1 receptor (IGF-1R) is a
promising target for lung cancer therapy and encouraging results from phase
II studies with IGF-1R inhibitors are already reported. The aim of this study
was to correlate the expression of IGF-1R and the activity of its inhibitor
with survivin and molecules involved in epithelial-mesenchymal transfor-
mation (EMT).
Materials/Methods: Tissue samples from eighty five surgically treated
patients with NSCLC and 15 lung cancer cell lines treated with the IGF-1R
TKI cyclolignan picropodophyllin (PPP) were analyzed for IGFR-1R, Sur-
vivin, E-cadherin, ErbB3 and EGFR expression by real time RT-PCR.
Results: SCC histology associated significantly with survivin and with
IGF-1R expression (p  0.033, p  0.007; respectively). Significant corre-
lations were detected between IGF-1R and survivin and between IGF-1R and
E-cadherin expression (r .27, p 0.008; r .47, p 0.001; respectively).
In cell lines, only expression of survivin correlated with activity of the
IGF-1R TKI, PPP (r  0.81, p  0.001).
Conclusions: IGF-1R and Survivin expression is higher in SCC tumors.
Survivin expression is a potential predictor of response to IGF-1R TKI.
Future studies will evaluate this association in patients treated with IGF-1R
inhibitors.
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Apricoxib, A New Potent COX-2 Inhibitor in Combination
with Erlotinib in Metastatic or Recurrent Non-small Cell
Lung Cancer (NSCLC) Patients: A Phase I Study
K. L. Reckamp1, R. Patel2, B. Gitlitz3, L. Chen4, D. Jezior5, S. Zaknoen5,
1City of Hope Comprehensive Cancer Center, Duarte, CA, 2Comprehensive
Blood and Cancer Center, Bakersfield, CA, 3University of Southern Califor-
nia, Norris Cancer Center, Los Angeles, CA, 4Nevada Cancer Institute, Las
Vegas, NV, 5Tragara Pharmaceuticals, San Diego, CA
Objectives: Apricoxib is a once-daily oral, potent and selective inhibitor of
COX-2. The COX-2 pathway plays a key role in tumor growth, angiogenesis
and resistance to therapy. Preclinical studies of apricoxib show in vitro and
in vivo activity in human lung cancer xenograft models. COX-2 signaling
activates the Erk/MAPK pathway, thus combinations of COX-2 and EGFR
inhibitors are of interest, particularly in NSCLC. The purpose of this study
was to determine the safety and feasibility of combining apricoxib with
erlotinib in NSCLC patients and to determine the recommended Phase II
dose (RPIID) based on either the MTD or the optimum biologic dose (OBD).
OBD was based on decreases in PGE-M, a urinary metabolite of PGE2.
Methods: Pts with recurrent or metastatic NSCLC were treated with erlo-
tinib (150 mg PO daily) and escalating doses of apricoxib (100–1200 mg PO
daily). Prior treatment with an EGFR TKI was allowed. PK for apricoxib and
erlotinib were evaluated. PGE-M a urinary metabolite of PGE2, was col-
lected at baseline and Day 15 of C1 and Day 1 of C2. The RPIID was to be
based on  75% inhibition of PGE-M and/or the MTD. DLT was defined as
drug related G3 and G4 events.
Results: 19 patients have been enrolled (3 at apricoxib 100mg; 4 at apricoxib
200mg, 12 at apricoxib 400mg). Characteristics: Sex: M/F: 7/12; Age range
54–81; The majority were ECOG PS 0 or 1. Number of prior therapies: 1–5.
There were no DLTs; most common adverse events include G1 and G2
nausea, diarrhea and rash. 2 serious adverse events (gastric ulcer, SOB) and
2 deaths due to disease progression occurred. The RPIID selected was 400mg
based on decline in urinary PGE-M and PK. Of 14 evaluable patients: 1 PR,
8 SD, and 5 PD as best response. SD was seen in pts having failed prior
EGFR TKI therapy. Apricoxib pharmacokinetics revealed a median Tmax of
2 hours (range 1.5–4), mean (SD) T1/2 of 11.8 (5.3) hours, Cmax of 313.0
(99.6) ng/ml and AUC (0-t) of 2816 (1204) ng.h/ml.
Conclusions: 1) Apricoxib and erlotinib have been safely administered in
this Phase I study. 2) The RPIID of the combination is apricoxib 400mg and
erlotinib 150mg. 3) The activity observed warrants further evaluation in a
randomized Phase II study. That study is ongoing.
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Cyberknife Radiosurgery for Primary and Recurrent Lung
Cancer and Metastatic Cancer to the Lung in a Community
Center
D. E. Smith, Radiation Medical Group, Inc., San Diego, CA
Purpose/Objective(s): To report results of Cyberknife radiosurgery directed
to the lung in a community center.
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Materials/Methods: A total of 37 patients were treated over an 18 month
period. Eighteen patients had primary non-metastatic lung cancer (T1 11
patients, T2 3 patients, T3 3 patients, T4 1 patient), and three patients had
Stage IV disease (2 patients with bilateral disease at presentation, 1 with a
single brain metastasis). Six patients had recurrent lung cancer, and ten
patients had metastatic disease to the lung. All patients were medically
inoperable. Thirty-one of the patients were treated with doses intended to
eradicate the targeted tumor (BED  100 Gy). Six patients were treated
palliatively with the goal of improving local symptoms (BED 100 Gy).
Results: With a median followup of 9 months there has been one local
failure (LC  97%). This was a patient with T2N0 disease. Seventeen of the
18 patients with primary non-metastatic lung cancer have no evidence of
disease. Patients who were treated palliatively achieved palliation of their
symptoms. Side effects include one patient with radicular numbness, 4
patients experienced transient chest wall pain, 1 patient experienced a grade
2 skin reaction, and 1 patient has radiation pneumonitis not requiring
steroids.
Conclusions: Local control of primary and recurrent lung cancer and cancer
metastatic to the lung appears readily achievable in a community setting in
the short term using the Cyberknife. Treatments are well-tolerated with few





Safety and Efficacy of Sunitinib in Combination with Carbopla-
tin (C) Plus Paclitaxel (Pac) in Patients (Pts) with Advanced
Solid Tumors (STs): a Phase I Study
E. I. Heath1, G. R. Blumenschein2, R. B. Cohen3, P. M. LoRusso1, N.
LoConte4, S. T. Kim5, R. Chao5, G. Wilding4, 1Karmanos Cancer Institute,
Detroit, MI, 2University of Texas, Houston, TX, 3Fox Chase Cancer Center,
Philadelphia, PA, 4University of Wisconsin, Paul P. Carbone Comprehen-
sive Cancer Center, Madison, WI, 5Pfizer Global Research and Develop-
ment, La Jolla, CA
Background: Sunitinib malate (SUTENT®, SU) is an oral multitargeted
tyrosine kinase inhibitor of VEGFRs, PDGFRs, KIT, FLT3, CSF-1R, and
RET, approved for the treatment of advanced RCC and imatinib-resistant or
-intolerant GIST. Safety and antitumor activity of SU in combination with
carboplatin (C) plus paclitaxel (Pac) in patients (pts) with advanced STs was
assessed in this phase I study.
Methods: Enrolled pts had advanced STs for which curative therapy was not
available. Escalating daily doses of SU 25, 37.5 or 50 mg/day for 2-wks of
a 3-wk cycle (Schedule 2/1) or on a continuous daily dosing (CDD) schedule
for 3-wks in combination with C (AUC6mgmin/mL)  Pac (175–200
mg/m2) were given every 21 days. Dose limiting toxicities (DLTs) and
adverse events (AEs) were evaluated to determine the maximum tolerated
dose (MTD) of the combination. Serial pharmacokinetics samples were
collected in patient cohorts.
Results: As of Feb 2008, 28 pts were enrolled. Median age was 53 yrs
(range: 32–76); 68% of pts had ECOG PS of 1. STs of enrolled pts included
NSCLC and pancreatic (each n4), melanoma, mesothelioma, and SCLC
(each n3), and other (n11). Due to early discontinuation prior to the start
of C/P, 5 pts on Schedule 2/1 were not evaluable for DLTs. On Schedule 2/1,
there was 1 DLT observed at 25 mg (grade 4 ischemic optic neuropathy) and
2 DLTs at 37.5 mg (grade 5 GI hemorrhage, grade 3 neutropenic infection).
One DLT occurred at 50 mg on the CDD schedule (grade 4 thrombocyto-
penia). Most frequently reported grade 3/4 hematologic AEs (both schedules)
included neutropenia (n15) and thrombocytopenia (n12). Other fre-
quently reported AEs included nausea (n15), fatigue (n13), diarrhea and
vomiting (both n7). Of the 24 evaluable pts (pts who took at least one dose
of the combination on either schedule), 2 pts had a confirmed partial response
(SCLC and ovarian cancer). Preliminary pharmacokinetic data suggest there
are no drug-drug interactions observed. Updated data will be presented.
Conclusions: Results suggest that the assessed dose levels are tolerable and
of potential clinical value in advanced ST pts. Further investigation of MTD,
safety, and efficacy of the combination is ongoing.
Author Disclosure Block:
E.I. Heath, Primary investigator of Pfizer studies, H. Research grants; G.R.
Blumenschein, Investigator in Pfizer sponsored clinic trials, H. Research
grants; R.B. Cohen, Research grant from Pfizer, H. Research grants; P.M.
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Sunitinib (SU) Plus Erlotinib (E) for Metastatic Non-small Cell
Lung Cancer (NSCLC): A Novel VEGFR-EGFR Combination
Treatment Strategy
R. Govindan1, G. Blumenschein2, H. J. M. Groen3, A. Szczesna4, J. Strausz5,
J. Montesinos6, L. Tye7, R. C. Chao7, G. V. Scagliotti8, 1Alvin J Siteman
Cancer Center, Washington University School of Medicine, St Louis, MO,
2University of Texas, MD Anderson Cancer Center, Houston, TX, 3Univer-
sity Medical Center, Groningen, Netherlands, 4Regional Lung Diseases
Hospital, Otwock, Poland, 5Koranyi National Institute for Pulmonology,
Budapest, Hungary, 6Corporacion Sanitaria Parc Tauli, Sabadell-Barce-
lona, Spain, 7Pfizer Global Research and Development, La Jolla, CA,
8University of Turin, Department of Clinical and Biological Sciences, Or-
bassano (Turin), Italy
Purpose: VEGFR and EGFR (HER1) are two key targets in NSCLC that
share common downstream signaling pathways affecting tumor vasculature.
Resistance to single-target agents may develop via bypassing inhibited
pathways, thus rational combinations inhibiting multiple signaling pathways
may be less prone to drug resistance. Preclinical models and clinical data
support co-targeting of VEGFR and EGFR vs. co-inhibition of each indi-
vidual target. Sunitinib malate (SUTENT®; SU) is an oral multitargeted
inhibitor of tyrosine kinases, including VEGFRs, PDGFRs, KIT, RET,
CSF-1R, and FLT3. SU  erlotinib (E) is a novel VEGFR-PDGFR-EGFR
triple inhibition treatment strategy that may confer additive or synergistic
anti-tumor effects and increase clinical benefit in patients (pts) with advanced
NSCLC. Two ongoing studies will assess its efficacy and tolerability.
Methods: Both studies included NSCLC pts 18 years with stage IIIB/IV
disease, ECOG PS 0/1, and prior treatment with 1/2 chemotherapy regimens
(including a platinum-based regimen). SUN 1058 is a randomized, multi-
center, phase II study evaluating the safety/tolerability of SU at 37.5 mg as
a continuous daily dose (CDD) E 150 mg/day vs. placebo E 150 mg/day
(4-week cycles); a non-randomized lead-in cohort was used to evaluate
safety/tolerability. SUN 1087 is a randomized, multicenter, pivotal phase III
study: 956 pts will be randomized to SU 37.5 mg CDD  E 150 mg/day or
to placebo E 150 mg/day (4-week cycles). Primary endpoint for SUN 1058
and SUN 1087 is progression-free survival (PFS) and overall survival (OS),
respectively; secondary endpoints include OS and PFS, respectively. Both
studies will evaluate 1-year survival, duration of confirmed response, safety,
and patient-reported outcomes.
Results: SU  E was well tolerated in the lead-in cohort of the SUN 1058
study, and 2/12 pts had durable partial responses. Enrollment is ongoing in
the randomized phase II portion of SUN 1058 and SUN 1087.
Conclusions: Early data from SUN 1058 support co-administration of SU
and E as a novel VEGFR-PDGFR-EGFR co-inhibition treatment strategy in
NSCLC. SUN 1087, a pivotal phase III study, will address its potential as
2nd/3rd-line treatment option.
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Epha2 is Over-expressed and Functionally Active in Lung
Cancer
L. Faoro1, N. Choong2, G. M. Cervantes1, M. S. Tretiakova1, A. N. Husain1,
E. E. Vokes1, R. Salgia1, 1University of Chicago, Chicago, IL, 2Medical
College of Wisconsin, Milwaukee, WI
Purpose/Objective(s): The Eph receptor tyrosine kinases and their mem-
brane-bound ligands, the ephrins, are overexpressed and may be functionally
important in many cancers. We investigated the expression, mutation, and
cytoskeletal function of EphA2 in lung cancer.
Materials/Methods: Expression of EphA2 in a lung cancer tumor tissues
was examined using IHC and in lung cancer cell lines using immunoblotting
and immunofluorescence. Mutational analysis was performed by sequencing
exons and intron/exon boundaries. The functional role for EphA2 was
investigated by assessing the activation status of the receptor and the effect
of ephrinA1 on lung cancer cell motility, adhesion and invasion.
Results: 197 tumors were evaluated and EphA2 overexpression was found in
60% of lung cancers and only 10% of normal lung tissue. All non-small cell
lung carcinomas (NSCLC) had similar rates of EphA2 overexpression but the
receptor was overexpressed in only 30% of small cell lung carcinomas
(SCLC). The expression of EphA2 was significantly higher at metastatic sites
compared to primary tumors. A unique missense mutation was identified in
the first fibronectin III domain, G391R, in a NSCLC cell line. EphA2 was
activated through stimulation by its ligand in lung cancer cells which resulted
in up-regulation of phosphorylated p130Cas and talin. The adhesion of lung
cancer cells to vitronectin was reduced with EphrinA1 stimulation but was
unchanged with fibronectin and collagen surfaces. Prolonged stimulation of
EphA2 resulted in a reduction of cell migration of lung cancer cells, in a
scratch assay. Silencing of EphA2 via siRNA lead to decreased cell growth
and viability of NSCLC.
Conclusions: We show that EphA2 is overexpressed in lung cancer cells.
EphA2 seems to be functionally important in regulating adhesion and
motility of lung cancer cells, and downstream effects on focal adhesion
proteins. EphA2 represents a novel molecule potentially involved in pro-
gression of lung cancer, and maybe a useful molecular therapeutic target.
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Paxillin is a Potential Molecular Therapeutic Target Against
Lung Cancer
R. Jagadeeswaran, S. Yala, R. Salgia, University of Chicago Medical
Center, Chicago, IL
Paxillin is an adaptor protein and a target of many oncogenes such as
BCR/ABL, v-Src, and E6. In transformation mechanisms through these
oncogenes, paxillin is routinely recruited and phosphorylated. We evaluated
the role of paxillin and MET in lung cancers. Using a panel of lung cancer
cell lines, we examined the levels of paxillin in relationship to oncoproteins
such as MET and EGFR. It is interesting to note that in lung cancer cell lines,
there was a correlation of expression between paxillin and MET, and not
EGFR. Mutational analysis of paxillin was performed in genomic DNA. In
lung cancer tissues, we have found that paxillin was mutated. The frequency
of paxillin mutations in NSCLC was highest in large cell carcinomas, then
adenocarcinomas, and thereafter squamous cell carcinomas. A127T paxillin
mutation, the most frequent mutation detected in NSCLC specimens, was
also identified in H69 and H249 SCLC cell lines. In the mutant SKLU-1
cells, starvation induced colocalization of the paxillin with mitochondria and
Bcl-2. Gene copy number analysis demonstrated amplification of paxillin
and MET together in NSCLC tissues. Exogenous expression of the MET/
PXN gene stimulated cell proliferation and anchorage-independent growth.
Furthermore, PXN/MET gene knockdown inhibited cell growth in NSCLC
cells. Nude mouse modeling revealed considerable differences in wild-type
paxillin versus A127T paxillin transfected H522 NSCLC cells. Immunohis-
tochemical analysis of xenografts were examined using an antibodies specific
for nuclear antigen Ki-67 and CD31. IHC revealed that as compared to
control vector H522, there was enhanced tumor growth, cell proliferation and
increased microvessel density in wild type paxillin H522 xenografts. Mi-
crovessel ratios in H522 (paxillin negative), H522 WT paxillin and H522
mutant paxillin, revealed a redistribution of microvessel to the periphery of
the tumor. There was five fold increased microvessel ratios(TM/TC) in the
A127T paxillin xenograft when compared to control. Paxillin appears to be
an important adaptor molecule, especially in lung cancer. Furthermore,
interactions of paxillin with MET would be a useful prognostic/predictive
and/or therapeutic strategy for the future.
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Radiosensitization of Lung Cancer by Z-VAD, a Pan-Caspase
Inhibitor
L. Moretti, K. W. Kim, C. D. Willey, B. Lu, Vanderbilt University,
Nashville, TN
Purpose/Objectives: Radioresistance of lung cancer results in an unaccept-
able rate of loco-regional failure. We have previously demonstrated that
inhibition of apoptosis via knockdown of Bak and Bax results in an increase
in lung cancer radiosensitivity in vitro through upregulation of autophagy, an
alternate type of programmed cell death. In this study, we examine the
radiosensitizing effects of Z-VAD, a broad spectrum irreversible caspase
inhibitor, on H460 lung cancer cells in vitro and in an in vivo mouse model.
Methods: Apoptosis was inhibited by Z-VAD (N-benzyloxycarbonyl-valyl-
alanyl-aspartyl-fluoromethylketone). Clonogenic assay was used to deter-
mine radiosensitivity. H460 lung cancer xenografts were generated for tumor
growth delay study and immunohistochemistry was performed on tumor
sections for cell proliferation (Ki67 staining), angiogenesis (von Willebrand
Factor staining) and apoptosis (TUNEL). Autophagy was determined by
punctate localization of GFP-LC3 protein and western blotting of ATG5-
ATG12 and Beclin-1 proteins. Human umbilical vein endothelial cells were
examined for Z-VAD activity by tubule formation assay.
Results: Z-VAD markedly radiosensitized H460 lung cancer cells, with a
radiation dose enhancement ratio of 1.31 (p0.003). The enhanced tumor
cytotoxicity was associated with overexpression of autophagic proteins
ATG5-ATG12 and Beclin-1 and increased punctate localization of GFP-LP3
characteristic of autophagosome formation (37% vs 12%). Z-VAD also
resulted in inhibition of tubule formation in irradiated vascular endothelial
cells. The administration of Z-VAD with radiation in a lung tumor xenograft
produced a significant tumor growth delay compared to radiation alone with
minimal changes in body weight ratio. Analysis of the tumor sections
revealed that the combined treatment resulted in marked reduction of
apoptosis as well as decreased cell proliferation. Furthermore, a dramatic
decrease in vascular density was observed with Z-VAD and radiation.
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Conclusions: Z-VAD significantly radiosensitized lung cancer models and
vasculature. This study demonstrates the potential of caspase inhibition as a
promising strategy to enhance the therapeutic ratio of radiotherapy in lung
cancer.
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Germline C-met Juxtamembrane Domain Mutations in Lung
Cancer Elicit Abnormal Vulval Phenotypes in C. Elegans and
Synergize With Nicotine: Implications for Cancer Development
S. Loganathan, S. S. Siddiqui, R. Salgia, University of Chicago, Chicago, IL
Lung cancer is the leading cancer killer in both men and women in the United
States. About 90% of all lung cancer deaths among women are from
smoking. NSCLC is a difficult disease to treat which the cells having
important physiological role in the process of growth and differentiation.
Lung cancer is now recognized to be the result of a multi-step process.
Among the events that can lead to malignant transformation is the unregu-
lated expression of growth factors and components of their signaling path-
ways. In lung cancer HGF-HGFR/c-Met is over-expressed and mutated.
c-Met receptor is an attractive potential target for novel therapeutic inhibition
in lung cancers. Previously we have identified c-Met mutations (R988C,
T1010I) in the juxtamembrane domain, which is responsible for abnormal
morphogenetic movement in NSCLC cell lines and in cancer biopsies. To
investigate the in vivo function and molecular mechanism of these mutations
in c-Met gene, we have generated transgenic Caenorhabditis elegans strains
that harbor wild type or mutant human R988C c-Met and mutant T1010I
c-Met recombinant plasmids. Our results show that expression of the mutant
human c-Met forms affect a number of post-embryonic cell lineages and cell
migration affecting hypodermis, muscle and gonad development causing
pleiotropic phenotypes such as, vulva-less, multi-vulva, pseudo-vulva, ab-
normal vulva formation, defective locomotion, muscle development, cell
migration, gonad development and germ line proliferation. Other phenotypes
include body size variants such as dumpy and small. Interestingly, exposure
of c-Met mutant transgenic worms to nicotine resulted in enhanced abnormal
vulval development, fecundity and locomotion. These vulva phenotypes are
highly reminiscent of mutations in semaphorin like SMP-1, EGF like LIN-3,
EGF receptor Let-23, Notch like LIN-12 receptor, LET-60/Ras, and Wnt
signaling in C. elegans. These transgenic lines have potential for the analysis
of structure and function relationship for various human c-Met mutations and
for screening novel drug targets using high throughput screens using the
small nematode.
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Vandetanib with Intrapleural Catheters: A Novel Approach to
Treat Symptomatic Malignant Pleural Effusions Associated
with Non-small Cell Lung Cancer: A Preliminary Report
C. A. Jimenez1, A. Onn2, G. A. Eapen1, R. C. Morice1, J. V. Heymach1,
W. K. Hong1, R. S. Herbst1, 1UT M. D. Anderson Cancer Center, Houston,
TX, 2Sheba Medical Center, Tel Hashomer, Israel
Objective: Vascular Endothelial Growth Factor (VEGF) is a key regulator
on the formation of malignant pleural effusions (MPE). The inhibition of
VEGF receptor tyrosine kinase phosphorylation using vandetanib on mice
bearing lung cancer with pleural effusion (PE) decreases its formation. We
hypothesize that inhibition of VEGF receptor with vandetanib may decrease
PE production in patients with non-small cell lung cancer (NSCLC).
Methods: Prospective open label non-randomized trial on 25 patients with
NSCLC and symptomatic MPE requiring insertion of intrapleural catheter
(IPC), receiving 300 mg/day of vandetanib during ten weeks. The primary
objective is to assess the effect of vandetanib on the time to IPC removal.
Secondary objectives are: to measure the amount of daily PE drainage; to
measure VEGF, IL-6, IL-8, bFGF, LDH, total protein, pH in serum and PE;
to evaluate the expression of VEGFR, EGFR on tumor cells of MPE; to
assess the effect of vandetanib on tumor burden; to evaluate the effect of
vandetanib on QOL and dyspnea.
Results: Trial opened in May/2007. Forty two patients have been screened
and 13 patients have been enrolled. Four patients did not receive vandetanib
(non-compliance1; benign PE2; small PE1). One non-evaluable patient
had an IPC with a defective cuff and catheter dislodgment 27 days after
insertion, requiring IPC removal on day 39 with chest tube placement due to
pneumothorax. Six patients had IPC removed on days 13, 14, 14, 15, 22 and
28. One patient had IPC removed on day 142 after 10 weeks of treatment.
One patient had dislodgment of IPC with empyema (related adverse event,
RAE) needing chest tube placement and IPC removal 22 days after insertion,
but had vandetanib for 10 weeks. Another patient had QTc prolongation
(RAE) after dose reduction at 7 weeks. A third patient had neurological
symptoms (RAE), stopping the medication after 6 weeks. Best tumor
response was stable disease5; partial response1; and disease progres-
sion3.
Conclusions: The combination of vandetanib and IPC is a promising
strategy to shorten the time to IPC removal in patients with NSCLC and
symptomatic recurrent MPE. Funded by: DoD IMPACT grant.
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Stereotactic Body Radiation Therapy for Salvage or Second
Primary Non-small Cell Lung Cancer in Patients Previously
Treated with Conventional Thoracic Radiation Therapy
C. L. Hallemeier, J. Yuan, B. J. Gerbi, L. C. Cho, Department of Thera-
peutic Radiology, University of Minnesota Medical School, Minneapolis, MN
Purpose/Objective(s): To review the clinical outcomes of patients treated
with stereotactic body radiation therapy (SBRT) for non-small cell lung
cancer (NSCLC) who had previously received conventionally fractionated
thoracic radiation therapy (CFXRT).
Materials/Methods: Six medically inoperable patients with NSCLC who
had received CFXRT were treated with SBRT for local recurrence (n4) or
second primary (n2) NSCLC. Mean previous CFXRT dose was 59 Gy
(range 50–64). In the 4 patients treated for local recurrence, the stage at
initial CFXRT was IB (n2), IIA, and IIIB and the interval from CFXRT to
SBRT was 10, 15, 24 and 53 months. In the 2 patients with new primary
NSCLC, the interval from CFXRT to SBRT was 94 months and 120 months.
All patients had PET/CT scans prior to SBRT to exclude regional and/or
metastatic disease. SBRT immobilization consisted of fixation in a custom-
ized stereotactic body frame with abdominal compression. SBRT prescrip-
tion dose was 45 Gy delivered in 5 fractions to the 85% (n5) or 80% (n1)
isodose line covering the PTV with heterogeneity corrections. Dose was
delivered from 10 non-coplanar 6 MV photon beams. Daily set-up verifica-
tion consisted of CT scan prior to verification (n5) or cone-beam CT
(n1).
Results: Mean tumor maximal length was 2.7 cm (range 1.3–4.0). Mean
PTV was 51 cc (range 26–111). Median follow-up was 11 months (range
5–16). Common Toxicity Criteria v3.0 toxicities included asymptomatic
radiation pneumonitis on CT (grade 1) in 2 patients, subjective increase in
dyspnea (grade 2) in 2 patients, and pneumothorax requiring chest tube
placement (grade 2) in 1 patient. Target lesion local control was seen in 5 of
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6 patients (83%). One local failure occurred at 4 months after SBRT. One
patient experienced metastatic progression in the contralateral lung. Five of
6 patients remained alive at last follow-up. One patient expired from
underlying cardiac disease.
Conclusions: In patients with locally recurrent or second primary NSCLC
after treatment with CFXRT, SBRT resulted in good local control with
minimal acute or subacute toxicity. Long-term follow-up is needed as
patients remain at risk for late complications.
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A Phase I Study of Sorafenib in Combination with Weekly
Topotecan in Treatment of Recurrent or Refractory Small Cell
Lung Cancer
J. Leach, E. Anderson, K. Swenson, M. Menge, M. Tsai, Park Nicollet
Institute, St. Louis Park, MN
Purpose/Objective(s): The primary objective of this study was to determine
the safety of administering topotecan given on a weekly schedule combined
with sorafenib in a patient cohort of recurrent or refractory small cell lung
cancer.
Materials/Methods: Patients with a diagnosis of small cell lung cancer who
had progressed or recurred following treatment with platinum based combi-
nation chemotherapy were eligible. Topotecan was administered at a dose of
4 mg/m2 intravenously on days 1, 8 and 15 of a 28 day cycle. Sorafenib was
administered in a standard 33 dose escalation design starting at 200 mg
daily with a plan to dose escalate up to 400 mg bid.
Results: 9 patients were enrolled (6 F; 3 M) with a median age of 62.9. 1
DLT of grade 3 foot pain was noted in the 400 mg bid cohort. Grade 3 or 4
thrombocytopenia was seen in 2 patients, grade 3 anemia in one patient.
Grade 1 or 2 skin rash was seen in 5 patients. There have been no episodes
of hemorrhage. 6 patients have had stable disease.
Conclusions: Weekly topotecan and sorafenib is a feasible and well tolerated
regimen at full doses of both drugs in patients with recurrent small cell lung
cancer.
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Phase II Trial of Weekly Topotecan with Carboplatin in the
First-line Treatment of Patients with Extensive-stage Small Cell
Lung Cancer
T. Greco1, D. R. Spigel1, J. Gandhi2, J. D. Peyton3, D. Shipley3, T. Markus1,
P. Graham1, S. Jones1, H. A. Burris1, J. D. Hainsworth1, 1Sarah Cannon
Research Institute, Nashville, TN, 2Associates in Oncology & Hematology,
Chattanooga, TN, 3Tennessee Oncology, PLLC, Nashville, TN
Purpose/Objective(s): Carboplatin and topotecan are each commonly used
in the treatment of small-cell lung cancer (SCLC), however there are limited
data for this combination in the first line setting. In this multicenter,
community-based phase II trial, we evaluated carboplatin and weekly topo-
tecan in patients (pts) with previously untreated extensive-stage SCLC. This
trial was designed with the primary aim of achieving an objective response
rate (ORR) of 70% (a´ .05, aˆ .20), and secondary aims to assess progression-
free survival (PFS), toxicity, and overall survival (OS).
Materials/Methods: Pts with ECOG PS 0–1, measurable disease, adequate
organ function, and signed informed consent were eligible. All pts received
carboplatin AUC5 IV day 1 and topotecan 4mg/m2 IV on days 1, 8, each
every 21 days for up to 6 cycles, with restaging every 6 weeks (per RECIST).
Results: Between 5/06 and 6/08, 45 pts have been enrolled (n60 planned).
The median follow-up is 7 months (range1–15 months). Pt characteristics:
median age 65 years (range 40–83 years); male, 54%; ECOG PS 0, 18%.
Response data are available for 30 pts: CR 1 pt, PR 16 pts (ORR 57%, 95%
CI 37%–75%), SD 9 pts (30%), and PD 3 pts (10%). 1 pt stopped therapy due
to toxicity. The median PFS is 9.2 months (median OS not reached). Grade
(G) 3/4 non-hematologic toxicity in 6%: anorexia, diarrhea, fatigue, hypo-
natremia, pain, pneumonia, vomiting (9% each) and dehydration (15%).
G3/4 hematologic toxicity included anemia (32%), neutropenia (62%), and
thrombocytopenia (32%). There were 3 potentially treatment-related deaths
due to pneumonia, sepsis, and anemia (1 pt each).
Conclusions: Preliminary analysis reveals myelosuppression as the primary
toxicity and the OOR to be less than 70%, but with activity comparable to
other first line platinum-based regimens.
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Increasing Knowledge about Lung Cancer in Primary Care
Providers (PCPs): Effects of a Multidisciplinary Lecture Series.
A. M. Traynor1, T. R. Wassenaar1, T. L. Weigel1, T. C. Campbell1, M.
Mehta1, D. Khuntia1, M. A. Mathiason2, K. R. Oettel2, 1University of
Wisconsin Carbone Cancer Center, Madison, WI, 2Gundersen Lutheran
Cancer Center, LaCrosse, WI
Background: Timely referral of patients with lung cancer to specialists
optimizes therapeutic options. Wassenaar et al. demonstrated that PCPs in
Wisconsin would be less likely to refer a hypothetical patient with lung
cancer to an oncologist, and that they are less knowledgable about treatment
options in lung cancer, compared to breast cancer (JTO 2007;2:722–8). We
designed a six-part multidisciplinary lung cancer lecture series for PCPs,
with the objective of correcting this knowledge base deficiency.
Methods: Our educational intervention was a series of six lectures covering
the evaluation and treatment of early and late stage lung cancer. Lectures
were presented during the Fall of 2007 at the regularly scheduled weekly
noontime PCP educational conference. PCPs in a 300-member multidis-
ciplinary medical clinic were given pre-and post-intervention surveys, con-
sisting of 10 questions addressing the care of a hypothetical patient with lung
cancer.
Results: One-hundred and twenty surveys were distributed and 64 pairs of
pre- and post-intervention questionnaires were returned for comparison (53%
rate of paired samples). No statistically significant improvement in lung
cancer knowledge base resulted from the educational intervention. Specifi-
cally, responses to questions regarding recognition of early symptoms,
referral for curative treatment, or care of and referral for advanced stage
disease were unchanged. Further, knowledge of the survival benefit from
post-operative chemotherapy did not increase (61% of respondents were
aware of this benefit both pre- and post-intervention).
Conclusions: Our intervention failed to impact responses to a questionnaire
regarding lung cancer care among PCPs. Possible reasons that will be
investigated for this lack of effect include the operating characteristics of the
intervention and questionnaire, and the difficulty in altering perceptions of
lung cancer in PCPs in light of prior medical education and/or life experi-
ences. Our study suggests that interventions other than traditional lecture-
based learning are needed to enhance the lung cancer knowledge base among
PCPs.
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Patient Out-of-Pocket Payments for Oral Oncologic Therapies:
Results from a U.S. Claims Data Analysis
E. M. Pelletier1, J. C. Tierce2, C. M. Reyes3, 1IMS Consulting, Watertown,
MA, 2IMS Consulting, Falls Church, VA, 3Genentech, Inc., South San
Francisco, CA
Objectives: The primary objective is to evaluate patient out-of-pocket
(OOP) payments for oral therapies used to treat oncologic disease, including
non-small cell lung cancer (NSCLC), in U.S. managed care plans. Methods:
Patients 18 years of age with 1 of 13 oral oncologic therapies from
1/1/2006 to 3/31/2007 were identified from a nationally-representative data-
base of medical and pharmacy claims from over 90 U.S. health plans. The
oral oncologics evaluated were bexarotene, capecitabine, dasatinib, erlotinib,
gefitinib, imatinib, lapatinib, lenalidomide, sorafenib, sunitinib, temozolo-
mide, thalidomide, and vorinostat. OOP payments were calculated as the
allowed amount (dollar amount a health plan allows for a therapy, including
any member liability) minus the paid amount (dollar amount paid by a health
plan for a therapy).
Results: 13,732 patients with evidence of at least 1 of 13 oral oncologic
therapies were identified. The mean age was 59.1 years, 48.4% were male,
and 86% had a commercial payer; 16.4% of patients were diagnosed with
malignant neoplasm of trachea, bronchus, or lung. Capecitabine had the
lowest OOP payment, averaging $80, while lenalidomide had the highest
average OOP payment at $366. For NSCLC oral agents, the mean OOP
payments for erlotinib was $164 (interquartile range: $15-$53) and $154 for
gefitinib (interquartile range: $17-$42). Indemnity plans and Medicare risk
and self-insured payers had increased mean OOP payments for most thera-
pies.
Conclusion: This study evaluated OOP payments for oral oncologic thera-
pies using current claims data. Among the 13 oral oncologics studied, the
average OOP costs ranged from $80 to $366. The average OOP cost for oral
NSCLC therapies gefitinib and erlotinib were in the middle of the range
compared to other oral oncologics. As costs of therapies increasingly become
part of treatment decisions, an understanding of patient OOP costs will be
critical in informing choices.
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The Effect of Intravenous Contrast on Radiation Therapy Dose
Calculations for Lung Cancer
W. Shi, University of Florida Shands Cancer Center, Gainesville, FL
Purpose/Objective(s): The aim of this study was to evaluate the effect of
intravenous contrast on the radiation dose calculations for lung cancer
treatment planning.
Materials/Methods: Nonionic, iodinated intravenous contrast (Iohexol) was
administered during the treatment planning computed tomography (CT) scan
of 9 patients with node positive non-small cell lung cancer. The potential
effect of intravenous contrast was studied by changing the density of the
contrast-enhanced vessels in the chest and assessing the resulting changes in
the doses calculated during treatment planning. Five patients were treated
with IMRT, and four patients were treated with 3D conformal radiation
therapy. Three different contrast scenarios were generated: 1) A “normal
contrast” scenario where the density of the vessels was unchanged from the
contrast enhanced treatment planning CT. 2) A “no contrast” scenario where
the vessels were contoured and assigned a uniform density of 1.0. 3) A “super
contrast” scenario where the vessels were contoured and assigned a uniform
density of 1.7. A treatment plan was generated from the “normal contrast”
planning scan and the treatment parameters were then applied to the other 2
scenarios. The effect of intravenous contrast was quantified by calculating the
percent change of dose in a variety of targets and normal structures.
Results: Dose differences between the “normal contrast” and “no contrast”
scenarios were about 0.1% for planning target volumes (PTV). The “super
contrast” scenario also demonstrated very little differences (less than 0.6%)
when compared to the other two scenarios. Importantly, the impact of
contrast oncritical structure dose calculation in the three scenarios was also
small (3% in a worse case senario).
Conclusions: The use of contrast improves target definition in treatment
planning. Previously there was concern that the use of contrast would
interfere with the accurate calculation of dose in Lung cancer patients. In this
study we so no clinically relevant effect on dose calculations using contrast.
We have concluded that planning lung radiation treatment from CT scans
that contain intravenous contrast does not result in clinically significant




Inflammation and its Significance in the Carcinogenesis of Non-
small Cell Lung Cancer
A. Beltran, M. Johansson, B. He, L. M. Coussens, D. M. Jablons, University
California San Francisco, San Francisco, CA There is evidence that inflam-
mation can accentuate carcinogenesis. Inflammatory leukocytes promote
epithelial cancer through soluble growth/survival factors to initiated cells
contributing to tissue remodelling and thus the physiological processes
necessary for tumorigenesis are regulated in part by leukocytes and their
mediators. Infiltration of recruited macrophages into the lung parenchyma of
Non-small cell lung cancer (NSCLC) patients correlates with poor prognosis,
suggesting a functional interface between recruited immune cells and cancer.
In order to determine the functional significance of the immune microenvi-
ronment in NSCLC, we use a transgenic mouse model of denovo NSCLC
development, i.e. CC10-Tag mice. We are also analyzing human NSCLC and
normal adjacent tissue from surgery to corroborate the mouse findings. Our
results indicate that human NSCLC is associated with significant accumula-
tion of CD45 leukocytes compared to adjacent normal lung tissue. These
leukocytes are characterized by increased percentages of CD3FoxP3 T
regulatory (Treg) cells, but not of myeloid-derived suppressor cells (MDSCs)
that are CD45CD34; CD11bCD14-CD15 or CD14 and HLA-DR-/
low, indicating that local immunosuppression in NSCLC is likely imparted
by Tregs as opposed to MDSCs. The functional significance of these
recruited leukocytes is being assessed, by genetically manipulating our
CC10-Tag mice rendering them deficient for all adaptive immune cells
(CC10-Tag/RAG1-/-), T-helper and Treg cells (CC10-Tag/CD4-/-), T-killer
cells (CC10-Tag/CD8-/-) and B cells (CC10-Tag/JH-/-). Our data show that
complete adaptive immune-deficiency in CC10-Tag mice results in a signif-
icant diminution in tumorigenesis that involves reduced activation of tumor
angiogenesis. We are determining whether these effects are B cell-, CD4
T cell-, CD8 T cell or Treg- dependent, and the extent by which they
regulate hallmarks of neoplastic progression (airway epithelial cell prolifer-
ation/differentiation, angiogenesis) and the phenotype of recruited leuko-
cytes. The results from these studies will reveal how adaptive immunity
regulates NSCLC development, both in contributing to neoplasia as well as
local immunosuppression.
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CyberKnife Radiosurgery for Early Stage Lung Cancer: The
NCH Experience
S. Nigh, K. Bowersox, P. Lobo, N. Mohideen, J. Silver, K. Vehlow, J.
Smudde, Northwest Community Hospital, Arlington Heights, IL
Objective: To assess our experience with CyberKnife Stereotactic Radio-
surgery for patients with early stage non-small cell lung cancer (NSCLC)
who were either medically inoperable or who refused surgery. End points
included clinical/radiological response, local control (LC), quality of life,
disease free and overall survival.
Methods: Eligible patients included those with T1 or T2 NSCLC treated
between 8/23/06 and 11/20/07. Twenty-three patients met the eligibility
criteria and are the subject of this review. Each patient was staged based on
current NCCN guidelines. Patients ranged in age from 44–91; there were 16
women and 7 men. The median tumor volume was 40.3 cc (range 15–159 cc)
with the largest tumor 5.0 cm in greatest diameter. The median dose
delivered was 5400 Gy (range of 4500 to 6000 Gy) in 3 to 4 sessions.
Patients were treated using the Synchrony vest with both internal (fiducials)
and external (infrared LED markers) tracking to compensate for tumor
movement during treatment delivery.
Results: At a median follow-up of 12 months (range 1–19) all lesions treated
were locally controlled as confirmed by CT or PET/CT imaging. Sixteen
patients (70%) achieved a clinical complete reponse (CR), 7 (30%) had a
partial response (PR) using the RECIST criteria. There were 6 patients whose
disease progressed either in regional nodes (2), nodes and ipsilateral lung (1),
or distant metastases (3). The disease free survival was 70%; the overall
survival was 78% and the median survival has not yet been reached. The
treatment was well tolerated with only 1 patient developing a grade 3
pneumonitis; ECOG performance status remained stable after treatment and
baseline PFT’s were also recorded for future comparison.
Conclusion: SBRT using the CyberKnife Synchrony Respiratory Tracking
System appears to be a viable therapeutic option for patients with medically
inoperable, lymph node negative NSCLC. The local control, survival and
quality of life appear comparable to surgically treated patients and other
reported stereotactic radiosurgery series. Longer follow-up and results from
prospective studies are needed to prove the efficacy of this approach.
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Cyberknife Radiosurgery for Patients with Medically Unresect-
able Non-small Cell Lung Cancer- The Winthrop-University
Hospital Experience
J. A. Haas, M. R. Witten, S. L. Schubach, J. Goncalves, O. Ortiz, M. Hon,
J. Matera, K. Episcopia, J. Lauritano, A. J. Katz, Winthrop-University
Hospital, Mineola, NY
Purpose/Objectives: Stereotactic Body Radiation Therapy (SBRT) has been
shown to be effective in the academic setting in treating patients with
medically inoperable early stage non small cell lung cancer. This study was
performed to see if comparable results could be obtained using the Cy-
berknife in the community setting at Winthrop-University Hospital.
Materials/Methods: 21 consecutive patients with medically inoperable
stage I non small lung cancer patients treated at Winthrop-University
Hospital from 2006–2008 were evaluated. All patients had documented
comorbid medical conditions precluding surgical resection after evaluation
by a thoracic surgeon. All patients were treated using the Cyberknife robotic
linear accelerator with the synchrony system to track tumors during respi-
ration. Peripheral tumors were treated to a dose of 6000 cGy in 3 fractions
of 2000 cGy each. Central tumors were treated to a dose of 4800 cGy in 4
fractions of 1200 cGy each. All patients had followup CT scans and the
results were compared to their pre-SBRT CT scans.
Results: The median followup was 8 months. The median FEV-1 was 1.12
liters. 19 of 21 patients had radiographic stable, complete or partial response
(90%) 2 patients had radiographic evidence of progressive disease (10%.) No
patients had expired during the course of this analysis.
Conclusions: SBRT in the community setting is associated with excellent
local control and survival in a population of frail patients with medically
inoperable early stage non small cell lung cancer. SBRT should be consid-
ered a treatment option for this subset of patients.
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Volumetric Response Assessment of NSCLC during Radiation
Therapy using Deformable Image Registration
E. J. Filion, J. N. Chu, T. H. La, Q. T. Le, H. A. Wakelee, P. G. Maxim,
B. W. Loo, Stanford Hospital, Stanford, CA
Purpose/Objective(s): We conducted a study to analyze radiation treatment
planning CT scans done both before and during a course of radiation therapy
to determine the rate of tumor volume change with treatment in non-small
cell lung carcinoma (NSCLC).
Materials/Methods: We selected for analysis consecutive patients with
locally advanced NSCLC treated with curative intent, who had both pre-
treatment and mid-treatment planning CT scans as part of an adaptive
radiotherapy approach. The gross tumor volume on the initial planning CT
(iniGTV) was compared to that at mid-treatment (midGTV) for each patient.
An automated deformable image registration was performed between the
initial CT and mid-treatment CT using the MIMcontouring software package
(MIMvista Corp., Cleveland, OH), and the midGTV was generated by
applying the same deformation to the manually contoured iniGTV used for
treatment planning. An additional evaluation of the accuracy of deformable
registration was performed as follows: each midGTV contour was manually
corrected (midGTVm) and compared to the automatically generated one
(midGTVa), using a standard similarity index (SI) defined such that its value
ranges from 0 for complete disagreement to 1 for complete spatial agreement
between volumes.
Results: 18 patients were identified for analysis (stage IIB-IV). All received
concurrent chemotherapy except one patient (HIV); the most common
regimen was carboplatin-paclitaxel (76%). The average delivered dose at the
time of the mid-treatment CT was 32 Gy (range 18–42 Gy). The mean
volume decrease between iniGTV and midGTVm was 30.3 mL (range
3.8–84.5 mL). The mean relative volume decrease was 27%, with 4 patients
having a volume decrease of more than 40%, and 2 patients having a volume
decrease of less than 10%. The mean SI between automatically deformed and
manually corrected midGTV was 0.91, confirming a high degree of accuracy
of the automated deformable registration.
Conclusions: Contrary to the conventional impression, early tumor response
to chemoradiotherapy is observed in a significant proportion of patients with
NSCLC. Automatic deformable registration appears to be a reliable method
for measuring volumetric response on serial scans.
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Cisplatinum Plus Docetaxel as Induction Chemotherapy Prior
to Radical Locoregional Treatment for Patients with Stage III
Non-small Cell Lung Cancer: Results of a Prospective Phase II
Study
J. Berros, E. Esteban, G. Crespo, C. Muriel, M. Fdez de Sanmamed, N.
Villanueva, P. Jime´nez, Y. Ferna´ndez, J. Fra, A´. J. Lacave, et al., Hospital
Universitario Central de Asturi, Oviedo, Spain
Purpose/Objective(s): Comparative studies have indicated that induction
chemotherapy with cisplatinum regimens improves overall survival of pa-
tients with stage III NSCLC compared with surgery and/or radiotherapy
alone. Nevertheless, the optimal third generation cisplatinum combination
remains controversial. The aim of the present study has been to test the value
of cisplatinum and docetaxel as induction chemotherapy prior to radical
locoregional treatment in non-selected patients with stage III.
Materials/Methods: Eligibility included histological or cytological proven
chemonaı¨ve clinical stage III (A or B not wet), measurable disease, age 75
years, Karnofsky performance status (KPS)  70, adequate renal and hepatic
function. Patients were treated with 75 mg/m2 of cisplatin and docetaxel
repeated every three weeks for three cycles. Tumor assessments were
performed after three cycles of treatment and before local radical treatment.
Results: From September 2004 to March 2008 a total of 42 pts received at
least one cycle of induction chemotherapy and were considered evaluable for
activity and toxicity. Patient characteristics were: median age: 60 years
(range 36–74), six female/ 36 male , median KPS 80% (60–100), 22 stage
IIIA/20 IIIB . The median cycles of treatment was 3 (1–4) and dose intensity
of cisplatin and docetaxel was 98% . The side effects registered were mild to
moderate with 33.3% of neutropenia (9.5% febrile), 23.8% anaemia, and
2.3% nausea/ vomiting grade 3–4. In an attempt to treat basis (ITT) objective
response rate among 36 eligible patients was 47% (2.1% complete response
and 45.2% partial response). Most patients (73.8%) received radiotherapy as
part of LR treatment. Pathological complete response was confirmed in
12.5% of 8 patients treated with surgery. Median progression free survival
was 215 days. Local and distant failure alone were 16.6% and 4.7%
respectively. Simultaneous local and distant failures were registered in 14.2
% of patients.
Conclusions: CD combination as induction chemotherapy is a tolerable and
active regimen in non-selected patients with clinical stage IIIA-B NSCLC.
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A Dosimetric Comparison of Proton Beam versus 3-D Confor-
mal Post-Operative Radiotherapy for Completely Resected IIIA
Non-small Cell Lung Cancer
A. T. Berman, S. Both, M. Ingram, L. L. Lin, R. Rengan, University of
Pennsylvania School of Medicine, Philadelphia, PA
Purpose: The aim of this study is to compare the dose-volume histograms
(DVH) of all organs at risk (OARs) in a patient with non-small cell lung
cancer (NSCLC) treated with proton beam post-operative radiotherapy
(PB-PORT) vs. three-dimensional conformal post-operative radiotherapy
(PORT).
Methods and Materials: The computed tomography treatment planning
scan of a patient with completely resected IIIA NSCLC treated with PORT
was used for this study. The target and critical structures were delineated.
The 3D-CRT and double-scatter proton beam plans were generated using the
Eclipse treatment planning system (Varian) and were analyzed for various
dosimetric endpoints. The proton plan was constructed with two oblique
parallel-opposed beams (RAO/LPO) and the photon plan of four parallel-
opposed beams (AP/PA and RAO/LPO). The 3D-CRT plan was optimized to
deliver 50.4 Gy (standard dose used for margin negative patients) in 1.8 Gy
fractions and the proton plan was optimized to deliver 50.4 CGE. DVHs were
analyzed for the all OARs.
Results: The mean lung dose (MLD) for PB-PORT was 7.0 CGE and 14.4
Gy with PORT for a relative reduction of 51.7%. The lung volumes outside
the PTV treated to 5, 10, and 20 Gy (V5 , V10 , V20) were 22.3, 19.4, and
15.4% for PB-PORT versus 49.2, 44.1, and 38.3% for PORT with a dose of
50.4 Gy. The lung V20 had a relative reduction of 59.8% with PB-PORT
compared with PORT and the V5 had a relative reduction 54.8%. The
maximum cord doses of both plans were below 45 Gy. The esophageal V50
was reduced from 51.7 to 23.3% with a relative reduction of 54.9%. The
heart V40 with PB-PORT and PORT were similar (22.9 CGE vs. 24.3 Gy).
Both plans achieved adequate coverage of the PTV with the volume treated
to 95% of the prescribed dose (V95) for PORT at 100% and PB-PORT
96.4%.
Conclusion: PB-PORT appears to reduce dose to normal tissues significantly
as compared to 3D-CRT while preserving coverage of the PTV. The
reduction in lung doses (V5 , V20 , MLD) by 50–60% with PB-PORT may
correlate with a decrease in the incidence of radiation pneumonitis and thus
improve the therapeutic ratio. Further studies should be done to correlate the
clinical significance of these findings.
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Planned Interruptions During Combined Chemoradiotherapy
for Stage III Non-small Cell Lung Cancer - Compromised
Treatment or Optimized Care?
T. W. Zusag1, P. S. Mehta2, R. A. Abrams1, L. P. Faber1, P. D. Bonomi1,
1Rush University Hospital, Chicago, IL, 2Rush-Copley Hospital, Aurora, IL
Purpose: Randomized studies in stage III nonsmall cell lung cancer have
shown a benefit to concurrent chemoradiotherapy vs radiotherapy alone or
sequential treatment, although with greater toxicity. Balancing the relative
intensity of chemotherapy and radiation is controversial, and optimal doses
and schedules are not known. In concurrent treatment, we have chosen to
intensify systemic chemotherapy and employ planned interruptions in the
radiation schedule to maintain acceptable toxicity.
Methods and Materials: We reviewed the charts of all patients seen with a
diagnosis of lung cancer in the department of radiation oncology at Rush
University Medical Center (RUMC) from 1999–2004. All stage III patients
treated with curative intent split-course chemoradiotherapy (ChemoRT) are
included in this analysis. 65 patients were found: 46 received definitive and
19 received preoperative ChemoRT.
Results: Median follow-up was 70 months. Overall survival was 16.2
months. Thirteen patients are alive at a median follow up 53.0 months.
Patients undergoing surgery had a median survival of 35 months vs 15.1
months for those who did not. Only 3 patients did not complete all planned
treatment. 12 patients (18.4%) experienced grade 3 or greater acute or late
toxicity, including only one who had grade 3 esophagitis, and 5 with
pneumonitis. Failure occurred locally in 17 patients (26.2%), 3 of them
isolated. Distant failure occurred in 41 patients (63.1%), 27 (41.6%) of them
isolated.
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Conclusions: Split-course chemoradiotherapy in stage III lung cancer pro-
vides outcomes similar to other published reports but with decreased toxicity
and does not appear to compromise local control.
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Diagnostic Value of 9p21 Homozygous Deletion in Malignant
Mesothelioma. Experience at NCI, Cairo
S. H. Shoman1, R. Gaafar1, S. S. Eissa1, E. Koraa2, 1National cancer
institute, Cairo, Egypt, 2Department Chest Diseases, Ain Shams University,
Cairo, Egypt
Purpose/Objective(s): Definitive diagnosis of malignant mesothelioma in
small pleural biopsy and or pleural effusion can be extremely difficult based
on morphology and even immunohistochemistry with high false negative
rate. Homozygous deletion of 9p21 the locus harboring the p16 gene has
been reported as the most common genetic alternation in mesothelioma.
Recent studies demonstrated that this alternation may be useful to differen-
tiate benign from malignant mesothelial cells. The AIM of the study was to
evaluate the diagnostic usefulness of homozygous deletion of 9p21 assessed
by Fluorescence Insitu hybridization (FISH) in small pleural biopsies and
cell block preparation of effusion cytology samples.
Materials/Methods: The study includes 15 cases of malignant mesotheli-
oma with pleural effusion diagnosed and treated at Cairo National cancer
Institute and Ein shams university hospital and 15 cases of cytologically
benign effusions with mesothelial cell hyperplasia. All the cases had avail-
able pleural biopsy and paraffin embedded cell block of the effusion samples.
Beside routine papanicolaou stain, a panel of immunohistochemical markers
(EMA, Calretinin, and TTF-1) was used. FISH analysis was performed using
Vysis p16spectrum orange /CEp9spectrum green probe. The nuclei of 100
cells were evaluated .The specimen containing or 15 nuclei that lacked
signals for 9p21 but showed at least 1signal for chromosome 9 centromere
were considered positive.
Results: Ten cases were diagnosed cytologically positive for malignant
mesothelioma, and 5 cases as suspicious. FISH analysis demonstrated ho-
mozygous deletion of 9 p21 locus in 8/10 of cases diagnosed positive by
cytology and all the 5 cases of suspicious cytology. None of the 15 cases of
reactive pleural mesothelial proliferation showed p16 deletion.
Conclusions: Our study suggests that 9p21 homozygous deletion assessed
by FISH on paraffin embedded tissue may be helpful adjunct for differenti-
ating between malignant mesothelioma and reactive mesothelial prolifera-
tion. Further studies on large series of patients suspicious for mesothelioma
are needed to evaluate the validity and efficiency of such test.
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Early Results of Adjuvant IG-IMRT Following Extrapleural
Pneumonectomy (EPP) for Malignant Pleural Mesothelioma
V. K. Mehta, E. Vallieres, J. Ye, K. McCune, G. Buduhan, R. Aye, B. Louie,
M. Abboud-Finch, T. Wong, Swedish Cancer Institute, Seattle, WA
Purpose/Objective(s): Recent reports of fatal pulmonary complications
associated with the use of IMRT following an EPP have dampened the initial
enthusiasm for this technique. In this report, we review our early clinical
experience with hemithoracic IMRT and IG-IMRT after EPP.
Materials/Methods: Since 2004, 12 mesothelioma patients underwent an
EPP and then received adjuvant IMRT. Five of these patients were treated
with IMRT-IGRT utilizing CBCT on the Elekta Synergy. The CTV was
defined as the surgically violated area inside the chest wall with appropriate
margins. The boost CTV (bCTV) included the areas at higher risk for
residual disease or involved surgical margins as defined in conjunction with
our surgeon and pathologist. A 5 mm margin was added to the CTV and
bCTV to define the planning target volumes of PTV and bPTV. The target
doses were 50.4 Gy to PTV and 60.2 Gy to bPTV was given in 28 fractions.
In addition, the surgical scars and drain sites received a supplemental boost
with electrons of 36 Gy in 20 fractions to supplement the dose received from
the IMRT plan.
Results: At least 96% of the PTV received the prescribed 50 Gy, while 98%
of the bPTV received 95% of the presecribed 60 Gy. The mean contralateral
lung doses was 10.9 Gy (range 9.2–16.5 Gy), the mean V20 7.2% (range
3.3–12.6%), the mean V10 42.1% (range 31–52%), and mean V5 90.3%
(range 82.3–99.7%). Employing our hybrid online correction strategy, the
five patients treated with IGRT-IMRT had setup error reduced to under 3
mm. The average duration of radiotherapy was 41 days (range 39 to 45 days).
The acute toxicities experienced were moderate and manageable. All of these
patients are in continued follow up. One of the patients experienced an
isolated scar site failure at 3 years which was surgically removed. None of
the other patients experienced a local failure. One of the patients developed
a late grade 3 radiation pneumonitis that required 3 months of steroid
treatment. There were no fatal complications.
Conclusions: Our approach of using IMRT and more recently IMRT-IGRT
as adjuvant treatment following an EPP has been well tolerated by this
patient population.
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Thymic Epithelial Tumors: Review of Ten Years Single Institu-
tion Experience
M. Vigano`, V. Gregorc, C. Forni, M. Giovannini, C. Belli, A. Spreafico, C.
Lazzari, G. Negri, P. Zannini, E. Villa, San Raffaele University Hospital,
Milan, Italy
Introduction: Thymic tumors are rare and the therapeutic strategy is still
understudied. However they represent the most common malignancies of the
anterior mediastinum, including thymomas, thymic carcinomas, and thymoic
carcinoids.
Analysis: From 1996 to 2007, 59 patients who referred to our institution
were analyzed. Patients characteristics were: male/female: 33/24; median age
(years): 57; histology classification according to WHO: A5%, AB/B1/B2
 15/15/14%, B329%, C12%; Masaoka: stage II 34% and locally
advanced or advanced 54%. Myasthenia gravis was described in 20, hypo-
gammaglobulinemia in 1 patient. Thirty-six patients were treated with
primary surgery, than adjuvant radiotherapy (69%) or chemotherapy (11%).
The majority of stage II patients received adjuvant radiotherapy. Eight
locally advanced patients were treated with neoadjuvant chemotherapy or
chemo-radiotherapy and 7 became suitable for surgery. Loco-regional recur-
rence was observed in 18% of surgically treated patients. The CDDP-
anthracyclines was the most common chemotherapy regiment. Overall RR to
first-line chemotherapy was about 50%. Second or third-line chemotherapies
were: etoposide, 5-FU, taxotere and experimental treatments.
Conclusions: Our data confirm that thymic malignancies commonly occur in
adults, with no gender preference, and myasthenia gravis appears to be the
most common paraneoplastic syndrome. Multidisciplinary approach is re-
quired: surgical resection for early stages; radiotherapy for both adjuvant and
local-advanced settings; neoadjuvant chemotherapy might be used. Recur-
rences appear to be mostly loco-regional, however response to chemotherapy
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should be improved. Understanding the clinical and biological features
responsible for this disease may be useful for optimizing therapy.
Author Disclosure Block:
M. Vigano`, None; V. Gregorc, None; C. Forni, None; M. Giovannini,
None; C. Belli, None; A. Spreafico, None; C. Lazzari, None; G. Negri,
None; P. Zannini, None; E. Villa, None.
171
Dyrk2 Expression can be a Predictive Marker Forchemotherapy
in Non-small Cell Lung Cancer
S. Yamashita, K. Kawahara, K. Anami, K. Tokuishi, M. Miyawaki, M.
Chyujo, S. Yamamoto, Oita University Faculty of Medicine, Oita, Japan
Purpose/Objective(s): Several predictive markers of treatment and survival
benefit were reported such as ERCC1 in NSCLC (non-small-cell lung
cancer). We report the possibility of DYRK2, a dual-specificity tyrosine-
(Y)-phosphorylation regulated kinase gene to predict benefit from chemo-
therapy for patients in recurrent NSCLC.
Materials/Methods: Forty patients with recurrent disease after surgery
received several combinations of platinum-based chemotherapy. Chemother-
apy effectiveness was evaluated according to RECIST criterion. We used
immunohistochemical analysis to determine the expression of the DYRK2
protein in operative specimens of NSCLC.
Results: We could not find any correlation between age, sex, pathological
stage, tumor size, nodal status, histological type and DYRK2 expression.
Overall response rate is 22.2% (4 out of 18) in DYRK2 positive group
compared with 4.5% (1 out of 22) in negative group. On the other hand, 17
PD (progressive disease) is consisted of 3 DYRK2 positive patients and 14
DYRK2 negative patients.(p0.0086) The median time to the progression of
disease was 120 days in the DYRK2 negative group, as compared with 310
days in the DYRK2 positive group(HR  1.984, 95% CI  [1.039–3.788],
p  0.034).
Conclusions: Patients with recurrent NSCLC and DYRK2-positive tumors
derived a substantial benefit from chemotherapy, as compared with patients
with DYRK2-negative tumors.
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The Effects of a Multidisciplinary Conference and Clinic on
Non-small Cell Lung Cancer (NSCLS) Treatment and Survival
in a Community Cancer Center
K. R. Oettel1, M. Mathiason1, J. Schroeder1, A. Traynor2, 1Gundersen
Lutheran Hosp/clinics, La Crosse, WI, 2UW-Hospital and Clinics, Madison,
WI
Background: Multidisciplinary evaluation and treatment of lung cancer
optimizes therapeutic options (Laroche C, et al. Thorax 1999;53:445–9). Our
objective was to assess the impact of multidisciplinary evaluation and care on
treatment patterns and survival in a large, multi-specialty clinic.
Methods: In January 2006, we established a weekly multidisciplinary lung
cancer conference in which care plans are formulated prospectively. We also
developed a half-day clinic in which practitioners from surgery, medical and
radiation oncology, are on-site to evaluate patients (pts) who were just
discussed at the conference. We compared treatment and survival for
NSCLC pts treated for the 2 years prior to the conference/clinic, 2004–05,
(“pre-conf.”), with the pts seen during 2006–07 (“post-conf.”).
Results: 187 pts were seen pre-conf. (IB-IIIA: 58; IIIB/IV: 129) and 172
were seen post-conf. (IB-IIIA: 45; IIIB/IV: 127). More stage IIIB/IV pts with
PS 2 were evaluated post-conf. (16 of 129 pts, or 12% vs. 40 of 127 pts, or
31%, p0.001). Use of adjuvant chemotherapy and/or radiation increased in
stage IB-IIIA pts, from 15% to 35%, p0.023. Stage IIIB/IV pts who
received only chemotherapy (17% vs. 28%) or chemoradiation therapy (25%
vs. 32%) increased post-conf.(p0.012). Overall survival did not improve
from pre- to post-conf. for either early (IB-IIIA) or advanced (IIIB/IV) stage
pts disease, despite the more frequent use of chemotherapy. This trend is
possibly explained by the increased use of chemotherapy in advanced stage
pts who were PS 2 (8% pre-conf. vs. 19% post-conf.).
Conclusions: Initiation of our multidisciplinary lung cancer conference/
clinic was associated with increased numbers of pts receiving adjuvant
treatment. In addition, the number of PS 2 pts who were referred, evaluated,
and eventually treated also increased. The more frequent use of chemother-
apy and radiation post-conf. did not yield a survival advantage. The impact
of the increased use of chemotherapy post-conf. on quality of life and
symptom management will be investigated.
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Cyberknife (CK) Stereotactic Radiotherapy (SRT) for Primary
and Metastatic Lung Lesions is Tolerable and Efficacious: Long
Term Experience at the University of Southern California
(USC)
P. Kumar, A. Cheuk, O. E. Streeter, T. D. Kampp, M. A. Astrahan, J. A.
Hagen, University of Southern CA/Norris Cancer Center, Los Angeles, CA
Purpose/Objective(s): We conducted a retrospective review of our experi-
ence to assess the feasibility, safety and efficacy of using CK SRT for the
treatment of lung lesions.
Materials/Methods: Between February 2003 and March 2008, 41 lesions
(35 treated palliatively and 6 treated curatively) were treated in total of 34
patients (28 treated palliatively and 6 treated curatively). The median age
was 63 years (range 18–83). Twenty-five lesions were primary lung tumors
and 16 were metastatic lesions. Patients had either subcutaneous gold fiducial
markers placed into the tumor (n14) or underwent a bronchoscopic place-
ment of a catheter with fiducials using a mini-tracheostomy technique (n 
27) prior to CT treatment planning.
Results: Patients underwent either a single dose of irradiation [stereotactic
surgery (SRS)] or SRT; the median total dose to the tumor was 2500 cGy
(range 1400–4000) in various dose fractionation schemes of 1–5 fractions
using an average of 169 beams (range 60–277). Most plans were prescribed
to the 80% IDL (range 70–85%). Among the lesions treated palliatively for
SOB, DOE, cough and/or hemoptysis, 23 of 27 experienced relief or
stabilization of symptoms. No follow-up data was available for 2 lesions and
worsening of clinical symptoms was observed in 2 patients with 2 treated
lesions due to progression of untreated disease in the lung(s). Additionally,
8 asymptomatic hilar lesions (at risk for obstruction) which were also treated
palliatively showed either a response or stabilization such that no future
obstruction occurred. All 6 patients treated with curative intent showed either
clinical and/or radiographic response to CK SRT. The median follow-up
interval was 5 months (range 0–25) for all patients. Acute toxicity consisted
of radiation pneumonitis in only 1 patient which resolved with steroids and
antibiotics. No patients experienced late toxicity.
Conclusions: CK SRT is safe, feasible and efficacious for the treatment of
primary or metastatic lung lesions with minimal side effects in a very short
treatment course. We plan to initiate a phase I/II trial evaluating CK SRT in
the curative treatment of NSCLC.
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A Phase II Study of Pemetrexed and Gemcitabine Plus Bevaci-
zumab as First Line Chemotherapy for Elderly Patients with
Stage IIIB/IV Non-small Cell Lung Cancer: Interim Analysis
J. Blakely, L. Schwartzberg, F. Schnell, K. Karamlou, M. Walker, E. J.
Stepanski, Accelerated Community Oncology Res Netw, Memphis, TN
Purpose/Objective(s): The combination of pemetrexed and gemcitabine in
treatment of locally advanced or metastatic NSCLC has demonstrated syn-
ergy in both preclinical and clinical studies with a favorable tolerability
profile relative to other doublets. Bevacizumab significantly increases pro-
gression-free and overall survival when added to chemotherapy in colorectal
and NSCLC.
Materials/Methods: Patients with stage IIIB or IV NSCLC and who
were  65 years old were eligible for this study. After informed consent
patients received pemetrexed 500mg/m2, with gemcitabine 1500mg/m2,
plus bevacizumab 10mg/kg, Day 1 of each cycle given every 2 weeks.
The primary efficacy endpoint is the 12 month progression free survival.
Secondary endpoints are the overall response rates (ORR) chemotherapy
induced toxicity profile, delivered dose intensity; clinical benefit rate
(complete  partial  stable disease  24 weeks); and global quality of
life and overall survival. The study is open at 10 community oncology
research sites.
Results: At present, 14 pts (of an eventual total sample of 48) have been
enrolled, with a mean age 76.8 (SD5.5; range 69–85; 7 males). Cancer
stage is IIIB 3, IV 11. The histology is: 11-adenocarcinoma, 2-large cell
carcinoma, 1-other. The number of metastatic sites for the stage IV pts is: 5-
1 site, 4- 2 sites, and 2- 3 sites.
Conclusions: Safety and efficacy data will be presented at the time of the
meeting.
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Gemcitabin Systemic Per-operative Chemotherapy (SPOC) for
Resectable Stage I, II Non-small Cell Lung Cancer: Pilot Study
R. Vaillancourt, J. Bussie`re, Y. Lacasse, F. Laberge, Y. Cormier, Hoˆpital
Laval, Universite´ Laval, Que´bec, QC, Canada
Most non neurological solid tumors continously liberate isolated or clusters
of neoplastic cells from the primary tumor. Clinical and experimental data
suggest that the per-operative period, combined with its surgically induced
immunosuppression, is critical for such dissemination. Therefore the per-
operative period would probably be the ideal timing for adjuvant treatment
to surgery in the hope of significantly reducing metastatic recurrance. Based
on an animal experimental project which suggested that systemic per-
operative chemotherapy (SPOC) is both feasible and safe, we present the first
human pilot study of gemcitabin SPOC for resectable stage I, II non-small
cell lung cancer.
Sixteen patients (10 females) with clinical stage I or II NSCLC were
admitted the night before surgery to receive 1g/sqM of gemcitabin 12
hours prior to surgery, for the next morning. There were no allergic
reactions. General anesthesia was standardized to minimize interactions.
Fifteen lobectomies (3 sleeve, 5 thoracoscopic) and one pneumonectomy
were performed. Mean follow-up was 25.7 months (12– 48). Five patients
presented post-operative complications : one psychosis, 2 pneumonias, 1
atrial fibrillation, 1 right heart failure (congenital absence of pericardium,
left pneumonectomy). Mean post-operative chest drainage was 5.7 days.
Three patients stayed in hospital for more than 7 days: 8,8,9 days. There
were no operative mortality and no thrombocytopenia. Three (3) grade II
neutropenias occurred. Mean pre-op neutrophil count was 5.1x109/l , and
the mean lowest post-op: 2.9x109/l. Five recurrences occurred, 3 of them
retreated with curative intent: 2 surgically, 1 by radio-chemotherapy. One
of the reoperated patients presented a second recurrence and died 20
moths after SPOC. Two other patients died 5 and 25 months post-op of
recurrence. There were no brain metastases at first recurrence. We
conclude from this pilot study that gemcitabin SPOC is most probably
safe and feasible. We are planning a randomized phase II study to assess
potential benefits of this approach.
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Oxidative Stress and NF-eˆB Play Critical Roles in Apoptosis
Induced by Inhibition of Thromboxane Synthase in Lung
Cancer
K. Leung, M. K. Y. Hsin, M. J. Underwood, G. G. Chen, The Chinese
University of Hong Kong, Shatin, NT, Hong Kong
Purpose/Objective(s): Accumulating evidence shows that the inhibition of
thromboxane synthase (TXS) induced apoptosis in cancer cells. We have
previously showed that 1-Benzylimidzole (1-BI), one of the thromboxane
synthase inhibitors, triggered apoptosis in NCI-H460 cells but the mecha-
nism is not defined.
Materials/Methods: Lung cancer cells NCI-H460 cells were treated by I-BI
to inhibit TXS. The level of reactive oxygen species (ROS) was measured
and the activity of NF-kappaB was determined. The impact of changes in
ROS and NF-kappaB on cell functions was analyzed. Antioxidants and the
inhibitor of NF-kappaB were employed to assess their role.
Results: 1-BI induced reactive oxygen species (ROS) generation in lung
cancer cells NCI-H460 but decreased the activity of NF-eˆB by reducing
phophorylated IeˆBa´ (p-IeˆBa´) and the translocation of p65 into the nucleus.
The effect of I-BI on ROS generation and NF-eˆB activity could be prevented
by antioxidant N-acetyl cysteine (NAC). Therefore, in contrast to I-BI, NAC
stimulated cell proliferation and protected the cells from apoptosis. The
pro-apoptotic effect of I-BI appears to associate with a increase in p53, Bax
and Apaf-1. Moreover, 1-BI greatly enhanced the apoptotic effect of TNF-
alpha probably by reducing the NF-eˆB activity.
Conclusions: Our study demonstrates that apoptosis induced by I-BI is
associated with over-production of ROS and the reduction of NF-eˆB and that
application of antioxidant NAC can block the inhibitory effect of I-BI by
neutralizing ROS and re-stock the level of NF-B. The inhibition of TXS is
a potential strategy in anti-lung tumor treatment.
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Expression of Eukaryotic Initiation Factor 4E, Survivn and
VEGF in Human Lung Cancer and Their Clinical Implications
M. Kakihana, K. Nawa, N. Kajiwara, O. Uchida, T. Ohira, M. Tsuboi, N.
Ikeda, Tokyo Medical University, Department of Thoracic Surgery, Tokyo,
Japan
Purpose/Objective(s): In this study, the expression of eIF4E, Survivn and
VEGF protein was immunohistochemistry investigated for their clinical
implications. And also we investigated the level of eIF-4E, survivin and
VEGF on human lung cancer cell line treatment with novel anti-cancer
agents.
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Results: The expression of eIF-4E, survivin and VEGF was immunohisto-
chemistry investigated in 85 surgically resected non-small cell lung cancers
(NSCLCs), and the results of expression status were correlated with patient
clinical data. Using Kaplan-Meier survival curves, for the survivin negative
and eIF-4E negative staining had a significantly better survival than either the
survivin positive and the eIF-4E positive staining group (83.5% versus
47.8%, P0.036). We hypothesized that the induction of prohibiting the
PI3K/AKT/m-TOR signaling pathway may lead to reduce tumor progres-
sion. We demonstrated that the epidermal growth factor receptor tyrosine
kinase inhibitor (erlotinib), m-TOR inhibitor (rapamycin), and histone deac-
ethylase inhibitor (MS-275) induced cell growth inhibition in human
NSCLCs cells were accompanied by G1/S phase arrest.
Conclusions: We showed the suppression level of inhibitory eIF-4E binding
protein (phospho-4E-BP1) rapamycin. This immunohistochemical study sug-
gests that both eIF-4E and survivin may be a therapeutic target and a marker
of tumor recurrence. Furthermore, the results provide insights into the cell
cycle effects of erlotinib and rapamycin may be used as potential surrogate
endpoints of drug action in clinical studies.
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Pilot Study of Adjuvant Topotecan for Patients with Limited
Stage Small Cell Lung Cancer (LD-SCLC) Who Decline Pro-
phylactic Cranial Irradiation (PCI)
H. J. Ross, Mayo Clinic, Scottsdale, AZ
Purpose/Objective(s): Small cell lung cancer (SCLC) accounts for approx-
imately 15% of new lung cancer diagnoses in the US and about 1/3 of
patients present with limited stage (LD-SCLC). Concurrent chemoradiother-
apy followed by prophylactic cranial irradiation (PCI) is standard and
produces long-term survival in about 25% of good PS patients. Some patients
refuse or are ineligible for PCI resulting in poorer outcome. Topotecan is
active against SCLC and penetrates the CNS suggesting that it might reduce
brain metastases in this group.
Materials/Methods: Eligible patients had declined PCI after completing
standard chemoradiotherapy for LD-SCLC with at least a partial response
(PR), had recovered from toxicity with PS 0–1 and had no evidence of brain
metastases. Patients received 1.5 mg/m2/day topotecan IV for 5 consecutive
days every 21 days for four cycles. Primary endpoint was incidence of brain
metastases with secondary endpoints overall and progression-free survival
and toxicity.
Results: Twenty patients enrolled between November, 1999 and May, 2006.
17 patients (85%) completed 4 cycles of topotecan. Brain metastases devel-
oped in 6 patients (30%) at a mean of 159 days (range 84–324). Median
survival was 777 days with median PFS 462 days. Eight patients are alive
without evidence of disease at 569 to 2777 days. Topotecan was well
tolerated with grade 3/4 hematologic toxicity in 13 patients (65%) and
neutropenic fever in 2 patients. One patient had radiation pneumonitis. One
patient died with progressive disease and pneumonia after two cycles of
topotecan.
Conclusions: Adjuvant topotecan was well tolerated. The 30% rate of brain
metastases suggests the possibility that topotecan was active in the brain.
Overall and progression-free survivals are promising. Additional study of
adjuvant topotecan in LD-SCLC patients who do not receive PCI may be
warranted.
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A Retrospective Review of the Incidence of Brain Metastases in
Patients with Extensive Stage Small Cell Lung Cancer
J. Greenspoon, W. Cai, J. Wright, Juravinski Cancer Center, Hamilton, ON,
Canada
Background: Prophylactic cranial irradiation is a recently reported treatment
for patients with extensive stage small cell lung cancer that has been shown
to improve overall survival and quality of life. The benefits of this treatment
at a population level are not clear as the incidence of brain metastasis in this
group of patients is variably reported.
Methods: We completed a retrospective chart review of 130 consecutive
patients with extensive stage small cell lung cancer. All patients seen in
consultation between Jan 1 2004 and Dec 31 2006 were included. Our
primary objective was to determine the incidence of brain metastases, and to
establish the factors (patient and treatment) that were predictive of develop-
ing brain metastasis, using both univariable and multivariable regression
analysis.
Results: The median patient age was 68.3 years (42.5- 84.8) and the median
survival time was 25.6 weeks (1.0–142.7). 84.9% of patients received
systemic therapy, 70.0% of which had a partial imaging and/or clinical
response while 1.8% had a complete response. 29 patients (23.0%) initially
presented with brain metastases while an additional 21 patients (20.8%)
subsequently developed brain metastases after presentation. Weight loss
of  or  5 kg negatively predicted for the development of brain metastases
using univariable analysis (OR 0.24, p  0.03) and multivariable analysis
(OR 0.30, p  0.02). Response to chemotherapy was a strong predictor of
brain metastases using both univariable and multivariable analysis (OR 6.55,
p0.004).
Conclusions: 20.8% of patients developed brain metastasis after initial
presentation. This incidence is lower than previously reported and suggests
PCI should be targeted to patients with a higher risk. Any response to
chemotherapy, and baseline weight loss were independent predictors of
future brain metastases. This study has identified significant patient charac-
teristics that will help us direct therapy and design future prospective clinical
trials for those patients who are most likely to derive benefit from PCI
therapy and not solely experience the side effects of treatment.
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Preliminary Results from a Phase 1 Dose Escalation Trial of
Limited Field Hypofractionated Thoracic Radiotherapy (RT)
for Limited Stage Small Cell Lung Cancer
D. Yee, Q. Chu, C. Butts, A. Joy, D. Fenton, M. Smylie, A. Reiman, W. Roa,
Cross Cancer Institute, Edmonton, AB, Canada
Introduction: The optimal RT regimen for curative therapy of limited stage
small cell lung cancer (LS-SCLC) is undefined. Published data indicates
intensifying RT dose and minimizing overall RT treatment time improve
local control and overall survival for LS-SCLC. Hypofractionation facilitates
dose escalation without prolonging overall treatment time. The purpose of
this study is to define the maximal tolerated dose of hypofractionated chest
RT given with chemotherapy for LS-SCLC.
Materials and Methods: Patients received 1 of 4 RT doses: 54, 58, 62 or 65
Gy. RT was given in 25 daily fractions and started with cycle 2 of
chemotherapy at the latest. Each dose level had 6 patients; accrual to each
dose level was done sequentially based on acute RT toxicity rates in each
dose level. RT was planned with conformal techniques and targeted gross
disease plus margin. Four cycles of concurrent platinum-based chemotherapy
were prescribed with RT. Patients were assessed before, during and after RT
completion for treatment toxicities and disease status. Toxicity was graded
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with NCI Common Toxicity Criteria scales. Disease response was assessed
4–6 weeks after chemoRT completion and complete/ near complete re-
sponders were offered prophylactic cranial irradiation. The maximal toler-
ated RT dose was based on the dose which caused unacceptable acute RT
toxicity rates.
Results: Thirteen LS-SCLC patients have been treated. Dose level 1(54 Gy)
and 2 (58 Gy) have closed and 1 patient has been given 62 Gy. There have
been no RT-related deaths. Maximum acute RT toxicities were grade 2
esophagitis in 4 patients receiving 54 Gy, 3 receiving 58 Gy and 1 receiving
62 Gy and grade 2 pneumonitis in 1 patient receiving 54 Gy. Four patients
have been hospitalized (3 febrile neutropenia and 1 ruptured duodenal ulcer).
Six of 7 patients re-staged have attained complete responses. Six patients
have received PCI. One patient died of neutropenic sepsis after receiving 20
RT fractions and another of pneumonia 38 days after completing RT. One
patient has had an out-of-field mediastinal failure.
Conclusions: The maximal tolerated hypofractionated chest RT dose has not
yet been determined on this protocol.
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Development of an Interdisciplinary Supportive Care Plan for
Patients with Lung Cancer
T. R. Borneman, M. Koczywas, B. R. Ferrell, M. Cristea, K. L. Reckamp,
City of Hope, Duarte, CA
Significance: Quality of Life (QOL) and symptom concerns are common in
lung cancer. The impact of lung cancer demands guidelines to support these
patients through the disease trajectory.
Purpose: Phase I of this research consisted of a retrospective chart review of
100 patients over a 12 month period, evaluating usual care. This paper
reports findings from the second phase in a NCI Comprehensive Cancer
Center using an interdisciplinary approach to pilot improved care of patients
with lung cancer.
Framework: A QOL model was applied to lung cancer across the physical,
psychological, social and spiritual domains.
Methods: Ten patients completed the Demographic Tool, FACT-Lung Tool,
Psychological Distress Thermometer, IADL Scale, and participated in a QOL
interview. The Research Nurse presented a summary of the QOL data and
interview to an interdisciplinary case conference. Recommendations were doc-
umented in the care plan. At one and three months after the case conference, the
nurse contacted the patient by phone to gain input on the care received.
Results: Mean age was 67 and 30% were ethnic minorities. Sixty percent
(60%) were recently diagnosed and undergoing initial treatments. Scores for
overall QOL using the FACT-L were moderate (x87.8). For QOL domains,
emotional well-being scores were the lowest (X18.4), followed by func-
tional (X21.1), social/family (X23.8), and physical (X24.5). Mean
score for IADL was 1.4. Qualitative data revealed several common QOL
concerns, including disease and treatment-related symptoms, psychological
concerns, social concerns, and spiritual concerns. Recommendations from
the case conferences focused on pain, cachexia, depression, dyspnea and
support services for family caregivers. On a scale of 0 not helpful to 10 
extremely helpful, the physicians rated the interdisciplinary care planning
conference at 8.9 in terms of “helpfulness to you as a physician” and at 8.7
in terms of “helpfulness to your patient.”
The research is now being applied to a future trial of a QOL intervention in
lung cancer.
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Evaluation of Nutritional Status in Lung Cancer Patients
Treated by Stereotactic Radiotherapy - The Role of a Dietician
L. van Miert, J. Vogel, L. Wisman, M. van de Pol, Dr Bernard
Verbeeten Instituut, Tilburg 5042SB, Netherlands
Purpose: The majority of cancer patients develop clinical malnutrition,
which negatively affects response to therapy, increases the incidence of
treatment-related side effects and decreases survival. The purpose of the
present study was to evaluate the nutritional status of stage I lung cancer
patients referred for stereotactic radiotherapy (SRT). These patients are
presumed to be at risk being malnourished, because of the presence of
various risk factors such as higher age and COPD.
Methods: Prospectively, 31 patients referred for lung-SRT were included.
Nutritional status was evaluated using the short nutritional assessment
questionnaire (SNAQ) and by an in-depth nutritional assessment by a
dietician. The assessment includes extensive dietary history and anthropom-
etry. Patients were considered to be malnourished if their diet does not
provide adequate calories and protein for growth and maintenance.
Results: The median age of patients referred for SRT was 72 years (range 51
90). The vast majority (91%) was medically inoperable, mainly due to
COPD. GOLD stage III or IV was seen in 19 of the 26 patients with COPD.
At the onset of SRT, malnutrition was present in two out of 31 patients, who
could successfully be treated by nutritional support. Only one of these two
patients was identified to be at risk for malnutrition by the SNAQ screening
tool. In both malnourished patients, the body mass index (BMI) was over 20,
suggesting no underweight. Two others, both with adequate intake and a
normal scoring at the SNAQ, were underweighted (BMI  20). One,
normally weighted patient was identified by the SNAQ to be at risk for
malnutrition. She had a sufficient nutritional intake.
Conclusion: This study showed that malnutrition in lung cancer patients
referred for stereotactic radiotherapy occurs infrequently. This is remarkable
since this specific patient population has various risk factors such as higher
age and COPD. Nevertheless, recognition and treatment of malnourished
patients remains important. Easily applicable screening tools, including the
SNAQ and the BMI, were not very accurate in identifying these patients.
Therefore, standard assessment by a dietician is recommended for this
patient group.
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